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ABSTRACT 
 
 
Cancer is a leading cause of mortality throughout the world and new treatments are 
urgently needed.  Recent studies suggest that bone marrow-derived mesenchymal 
stem cells (MSCs) home to and incorporate within tumour tissue.  This property can 
be  utilised  to  deliver  targeted  anticancer  therapies.    This  thesis  describes  the 
production of MSCs engineered to express TNF-related apoptosis-inducing ligand 
(TRAIL), a transmembrane protein that causes selective apoptosis of tumour cells.  
 
Human MSCs were transduced with TRAIL and the IRES-GFP reporter gene using a 
lentiviral  vector,  under  the  control  of  a  tetracycline  promoter.    Transduced  and 
activated MSCs caused lung, breast, squamous, and cervical cancer cell apoptosis in 
vitro.    In  vivo,  the  cells  were  able  to  specifically  home  to  tumours  and  both 
significantly reduce tumour growth, and eliminate metastatic disease. 
 
The data included in this thesis demonstrates for the first time a significant reduction 
in metastatic tumour burden with frequent eradication of metastases using inducible 
TRAIL-expressing MSCs.  This has a wide potential therapeutic role, which includes 
the treatment of both primary tumours and their metastases, possibly as an adjuvant 
therapy in clearing micrometastatic disease following primary tumour resection.      
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CHAPTER 1.  INTRODUCTION 
 
 
 
1.1  Background 
 
Cancer remains one of the leading causes of mortality and morbidity throughout the 
world (Jemal et al., 2007).  Present therapy focuses on the combination of surgery, 
chemotherapy  and  radiation  treatment.    Despite  healthcare  improvements  and 
treatment advances, many tumours are unresponsive to conventional therapy and a 
new modality of treatment is urgently needed. 
 
Cancer cells acquire the ability for unlimited cell proliferation, with self-sufficiency 
of growth signals and insensitivity to anti-growth signals.  They also gain angiogenic, 
metastatic  and  invasion  abilities  and  are  able  to  successfully  avoid  apoptosis 
(Hanahan & Weinberg, 2000).  These hallmarks of cancer cells, which set them apart 
from normal human cells, must be reversed for successful treatment of many cancers.   
 
 
1.2  Apoptosis   
 
Apoptosis is the process of programmed cell death.  It is a tightly regulated process 
important  both  in  normal  development  and  cell  homeostasis  in  addition  to  the 
removal of damaged cells.  Apoptosis is achieved by activation of either the intrinsic 
or extrinsic apoptotic pathway (Figure 1.1).  Both pathways lead to the activation of 
a  number  of  caspases.    The  caspases  are  cysteine-aspartate-proteases  that  are 
synthesized as inactive precursors.  The initiator caspases (2,8,9) are activated by 
proximity-induced  dimerisation,  and  they  are  then  able  to  activate  the  effector 
caspases (3,6,7) by proteolytic cleavage.  These effector caspases cleave DNA and 
intracellular structures, leading to successful apoptosis characterised by condensation 
of chromatin, fragmentation of DNA, and cell shrinkage (Motadi et al., 2007). Chapter 1.  Introduction     
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Figure 1.1  The extrinsic and intrinsic apoptosis pathways. 
The extrinsic apoptosis pathway is instigated by the binding of a death ligand to a specific 
receptor.  This leads to recruitment of Fas associated death domain (FADD) and caspase 8 
and a resulting caspase cascade.  Traditional cancer therapeutics work via the intrinsic 
apoptosis  pathway,  which  centres  on  DNA  damage,  the  activation  of  the  proapoptotic 
members  of  the  Bcl-2  family,  Bax  and  Bak,  and  the  release  of  cytochrome  c  from  the 
mitochodria.  Cytochrome c forms an apoptosome with caspase 9 and apoptotic protease-
activating factor 1 (Apaf 1), leading to activation of the effector caspases and apoptosis.  
The  pathways  are  interlinked  as  demonstrated  and  are  heavily  regulated  with  multiple 
activators (represented by arrows) including Smac/DIABLO and inhibitors (represented by 
headless arrows) such as inhibitors of apoptosis (IAPs), and cellular FLICE-like inhibitory 
protein (cFLIP).  
 Chapter 1.  Introduction     
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One  of  the  main  aims  of  cancer  therapy  is  to  cause  increased  apoptosis  of  the 
transformed  cells.  Most  chemotherapeutic  agents  and  radiotherapy  treatments 
attempt  to  produce  apoptosis  of  cancer  cells  by  causing  DNA  damage  and  the 
activation  of  the  intrinsic  apoptotic  pathway.    This  mechanism  is  reliant  on  the 
function of the p53 tumour suppressor gene, which causes the activation of the Bcl-2 
family member Bax, causing mitochondrial instability and release of cytochrome c 
into the cytosol (Levine, 1997).  This then forms a complex with apoptotic protease-
activating factor 1 (Apaf 1), ATP and procaspase 9 to form an apoptosome, leading 
to caspase 9 activation, and in turn the activation of the effector caspases.  The 
mitochondria  also  release  second  mitochondrial  activator  of  caspases/direct  IAP 
binding  protein  with  low  PI  (Smac/DIABLO),  which  are  also  proapoptotic, 
neutralising  the  caspase-inhibiting  activity  of  the  inhibitor  of  apoptosis  proteins 
(IAPs).  However, the majority of human tumours acquire mutations of p53, leading 
to the development of resistance to the intrinsic apoptosis pathway and conventional 
oncological therapies (Ashkenazi et al., 1999).   
 
Death  inducing  ligands  are  able  to  cause  apoptosis  of  cells  by  an  independent 
mechanism,  activating  the  extrinsic  apoptotic  pathway,  and  are  thus  attractive  as 
anti-tumour agents.  The death ligands are members of the tumour necrosis factor 
(TNF) superfamily.  These include TNF, Fas-ligand (Fas-L), and Tumour necrosis 
factor related apoptosis inducing ligand (TRAIL).  On binding the corresponding 
death ligand, the receptors trimerise and form death inducing signalling complexes 
(DISC) with Fas-associated death domain (FADD) and the initiator caspases 8 and 
10.  The initiator caspases are activated, leading to activation of the effector caspases 
(3,6,7)  and  the  cleavage  of  a  large  number  of  cellular  targets  and  apoptosis.  
Activation  of  the  initiator  caspases  at  the  DISC  can  be  inhibited  by  the  cellular 
FLICE-like  inhibitory  protein  (cFLIP),  which  has  homology  to  caspase  8  and 
prevents its activation.   
 
There is some crosstalk between the extrinsic and intrinsic pathways by death ligand-
induced activation of Bid, another Bcl family member.  Bid is cleaved by caspase 8 
and translocates to the mitochondria, interacting with the proapoptotic Bcl proteins, 
Bax and Bak, to cause outer mitochondrial membrane pores and release cytochrome 
c causing apoptosis via the intrinsic pathway.  In some cells (Type II), this cross-talk Chapter 1.  Introduction     
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and  concurrent  activation  of  the  intrinsic  pathway  is  necessary  for  death  ligand-
induced apoptosis.  However activation of only the extrinsic pathway is sufficient in 
other  cells  (Type  I),  which  are  thought  to  produce  larger  amounts  of  activated 
caspase 8 in the DISC (Ozoren & El-Deiry, 2002; Scaffidi et al., 1998).  Conversely, 
the  activation  of  the  intrinsic  death  pathway  has  also  been  shown  to  lead  to  a 
sensitisation of cells to death ligands.  Specifically, chemotherapeutic drugs, and 
irradiation have been shown to cause an upregulation of TRAIL receptors via p53 
dependent (Burns et al., 2001; Nimmanapalli et al., 2001; Wen et al., 2000; Wu et al., 
2003b) and independent mechanisms (Wen et al., 2000).  
 
Within the TNF family of death ligands, the expression of TNF and Fas-L ligands 
are extremely tightly controlled, being transiently expressed on some activated cells, 
and these molecules have been shown to damage normal tissues in addition to their 
proapoptotic effect on transformed cells (Ashkenazi & Dixit, 1998).  This translates 
to the limited clinical use of overexpression of these ligands in cancer therapy.  TNF 
has many actions in addition to the induction of apoptosis.  It primarily activates the 
proinflammatory and prosurvival nuclear factor  B (NF B), and this action causes a 
large inflammatory response and hypotension if TNF is used clinically.  Fas–L also 
has limited clinical use as it causes apoptosis in hepatocytes (Ashkenazi et al., 1999; 
Ogasawara et al., 1993).  Conversely, TRAIL is able to selectively induce apoptosis 
in transformed cells, but not in most normal cells (Ashkenazi et al., 1999; Walczak et 
al., 1999; Wiley et al., 1995), making it a promising candidate for tumour therapy. 
 
 
1.3  TRAIL 
 
TRAIL was originally described in 1995 having been cloned based on its homology 
to other members of the TNF family (Pitti et al., 1996; Wiley et al., 1995).  TRAIL is 
a  type  2  transmembrane  protein,  which  can  be  proteolytically  cleaved  from  the 
membrane to produce a soluble molecule.  This novel ligand was found to cause 
apoptosis on binding to specific receptors in a similar way to TNF and Fas-L.   
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To date, five receptors have been described for TRAIL (Figure 1.2).  Two of these 
receptors are found on the cell surface and contain active cytoplasmic death domains, 
leading to apoptosis on binding by the ligand; death receptor 4 (DR4) and death 
receptor 5 (DR5).  These receptors are type 1 transmembrane proteins consisting of 
cysteine rich domains.  DR5 has 58% overall homology to DR4, with particular 
similarity in the intracellular death domain region.  They are expressed on activated 
lymphocytes, in addition to a wide range of tissues (Kimberley & Screaton, 2004).  
Two further receptors are also located on the cell surface, but are unable to form 
cytoplasmic death domains; decoy receptor 1 (DcR1) and decoy receptor 2 (DcR2).  
DcR1  lacks  an  intracellular  region  and  is  attached  to  the  cell  membrane  by  a 
glycophospholipid.  It is expressed on peripheral blood lymphocytes, but is generally 
expressed much less widely than the other TRAIL receptors (Kimberley & Screaton, 
2004).  DcR2 has a shortened and inactive cytosolic portion but 58-70% homology 
with the other TRAIL receptors.  It is also widely expressed (Kimberley & Screaton, 
2004).  The fifth receptor, osteoprotegerin (OPG), is a soluble receptor of the TNF 
receptor family.  It is heavily glycosylated and exists primarily as a disulphide linked 
dimer.  The importance of osteoprotegerin as a decoy receptor in TRAIL has not 
been fully established.  Osteoprotegerin is primarily involved in the regulation of 
bone turnover and particularly the maturation and activity of osteoclasts by binding 
to the receptor activator of nuclear kappa beta ligand (RANKL) inhibiting its ability 
to bind to the RANK receptor and stimulate osteoclastogenesis (Holen & Shipman, 
2006).  Furthermore, studies have demonstrated a poor binding of TRAIL to OPG at 
body  temperatures  (Truneh  et  al.,  2000).  In  the  mouse  only  one  death-inducing 
receptor  with  homology  to  DR5  has  been  discovered,  in  addition  to  two  decoy 
receptors (mDcTrailr1, msDcTrailr2) (Lawrence et al., 2001).     
 Chapter 1.  Introduction     
  24 
 
 
 
 
 
Figure 1.2  The TRAIL receptors 
TRAIL has 5 receptors. DR4 and DR5 contain active cytoplasmic death domains, leading to 
apoptosis.  The decoy receptors DcR1 and DcR2 lack active death domains; DcR1 lacks an 
intracellular region and is attached to the cell membrane by a glycophospholipid, DcR2 has 
a shortened and inactive cytosolic portion.  Osteoprotegerin (OPG) is a soluble receptor, its 
role as a decoy receptor in TRAIL has not been fully established. 
 
 
 
 
1.3.1  Cellular Effects of TRAIL 
The primary cellular effect of TRAIL is the initiation of apoptosis.  Apoptosis is 
signalled  after  TRAIL  binds  as  a  homotrimer  to  DR4  or  DR5.    This  results  in 
trimerisation of the receptors and activation of the extrinsic apoptosis pathway, as 
described above.   
 
In addition to apoptosis, TRAIL has also been shown to act via other signalling 
pathways  including  NF B,  mitogen  activated  protein  kinases  (MAPKs), 
phosphoinositide 3-kinase (PIK3) and Akt (Figure 1.3).  This stimulation is much 
less potent and rapid than with TNF (Varfolomeev et al., 2005).  The molecular Chapter 1.  Introduction     
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determinants  of  the  activation  of  these  kinases  have  been  investigated  with  co-
immunoprecipitation  experiments.    These  have  suggested  the  involvement  of 
complexes  of  secondary  signalling  molecules  in  addition  to  the  formation  of  the 
apoptosis-inducing  DISC  (Varfolomeev  et  al.,  2005).    Suggested  components  of 
these secondary signalling complexes include receptor interacting protein 1 (RIP1), 
TNF receptor associated factor 2 (TRAF2), NF B essential modulator/I B kinase   
(NEMO/IKK ),  FADD/TNF  receptor  associated  death  domain  (TRADD),  and 
caspase 8.  RIP1 and TRAF2 are thought to lead to JUN N-terminal kinase (JNK) 
activation and the expression of cell proliferation genes, whereas NF B activation is 
stimulated  by  the  recruitment  of  NEMO  and  I B  kinase   /   (IKK   / ),  which 
phosphorylate  inhibitors  of   B  (I B),  leading  to  I B  degradation  and  NF B 
activation (Falschlehner et al., 2007).  However, the mechanisms underlying kinase 
pathway  stimulation  by  TRAIL  remain  poorly  understood,  with  studies 
demonstrating both a caspase-dependent (Varfolomeev et al., 2005) and a caspase-
independent  (Ehrhardt  et  al.,  2003)  mechanism.    In  addition,  the  exact  role  and 
importance  of  TRAIL  activation  of  these  kinase  pathways  is  uncertain.    Many 
studies suggest a predominantly anti-apoptotic or proliferative effect (Ehrhardt et al., 
2003; Romagnoli et al., 2007; Weldon et al., 2004), and it has been demonstrated 
that inhibition of the NF B (Romagnoli et al., 2007), and p38 MAPK (Weldon et al., 
2004) signalling pathways can lead to sensitisation of cancer cells to TRAIL-induced 
apoptosis.  The importance of these kinase signalling pathways may be increased in 
apoptosis resistant cells, where TRAIL has been shown to lead to an NF B-mediated 
increase  in  proliferation  and  invasion  of  tumours  in  vitro  (Ehrhardt  et  al.,  2003; 
Ishimura et al., 2006).  In addition, some studies have demonstrated the activation of 
NF B by the decoy receptor DcR2 (Degli-Esposti et al., 1997a), but this was not a 
universal finding (Meng et al., 2000).   
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Figure 1.3  The cellular effects of TRAIL  
The predominant effect of TRAIL receptor activation is apoptosis via the extrinsic apoptotic 
pathway. TRAIL has also been shown to activate additional signalling pathways such as 
nuclear factor  B (NF B), mitogen activated protein kinases (MAPKs); extracellular signal-
regulated kinase (ERK), JUN N-terminal kinase (JNK), and p38 and phosphoinositide 3-
kinase (PIK3) and Akt.  The signalling events downstream of receptor activation have not 
been determined but are thought to involve molecules such as receptor interacting protein 1 
(RIP1), TNF receptor associated factor 2 (TRAF2), NF B essential modulator/I B kinase   
(NEMO/IKK ),  and  FADD/TNF  receptor  associated  death  domain  (TRADD).    The 
functional significance of these pathways is also unknown with studies demonstrating both a 
prosurvival and apoptotic effect. 
 
 
However,  these  signalling  pathways  are  complex,  and,  depending  on  the  subunit 
composition of NF B, either a proapoptotic or antiapoptotic outcome may result 
(Johnstone et al., 2008).  Similarly, activation of extracellular signal-regulated kinase 
(ERK) (Frese et al., 2003), JNK (Sah et al., 2003), and p38 (Ohtsuka et al., 2003) 
have also been shown to sensitise cancer cells to TRAIL-mediated apoptosis, and 
other groups have suggested a supporting role of these kinase pathways in apoptosis 
with the increase of cytokines interleukin-8 (IL-8) and CCL2 leading to macrophage 
attraction  and  the  engulfment  of  apoptotic  cells  (Varfolomeev  et  al.,  2005).    At 
present, the studies investigating the role and importance of these kinase signalling 
pathways are rather contradictory, and the effects may be cell-specific.   Chapter 1.  Introduction     
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1.3.2  Tumour sensitivity 
TRAIL appears to be able to induce apoptosis selectively in tumour cells, sparing 
normal cells.  The mechanism underlying this selectivity is not fully understood, 
although  it  is  likely  to  be  multifactorial  (Figure  1.4).    The  presence  of  decoy 
receptors  was  initially  thought  to  explain  the  difference  in  sensitivity  between 
tumour cells and normal cells to TRAIL-induced apoptosis.  The decoy receptors 
have been shown to afford some protection to cells against the activities of TRAIL.  
Transient  transfection  experiments  using  DcR1  and  DcR2  have  demonstrated  its 
ability  to  inhibit  TRAIL-induced  apoptosis  (Degli-Esposti  et  al.,  1997a;  Degli-
Esposti et al., 1997b).  The mechanism of this effect has yet to be fully elucidated 
with suggested theories including simple competitive inhibition and the formation of 
ineffective mixed receptor complexes (Kimberley & Screaton, 2004).  Interestingly, 
DcR2 receptors lacking their intracellular domain do not protect cells from apoptosis 
suggesting  that  some  intracellular  mechanism  is  necessary  for  the  decoy  effect 
(Meng et al., 2000).  Despite the initial hypothesis that TRAIL sensitivity of a cell 
was directly related to its balance of TRAIL receptors and TRAIL decoy receptors, 
most  studies  have  failed  to  show  a  correlation  between  the  expression  of  these 
receptors and susceptibility to TRAIL-induced apoptosis (Kimberley & Screaton, 
2004)  and  experiments  with  receptor  specific  monoclonal  antibodies  have  also 
suggested that decoy receptor expression does not explain the relative sensitivity of a 
cell (Griffith et al., 1999).  Indeed, even the relative importance of DR4 and DR5 to 
the apoptosis of individual cells appears to differ between cell types and cannot be 
determined by the receptor expression.  B chronic lymphocytic leukaemia cells rely 
predominantly on DR4 to transmit the apoptotic signal, however have DR5 more 
abundantly expressed (MacFarlane et al., 2005). 
 
The  regulation  of  sensitivity  appears  to  be  far  more  complicated  than  receptor 
number and type.  Recent data suggest that post-translational modification of DR4 
and  DR5  may  be  important  in  determining  the  sensitivity  of  a  cell  to  TRAIL-
mediated apoptosis.  Tumours may over-express O-glycosyltransferase which leads 
to  O-glycosylation  of  TRAIL  receptors,  enhancing  ligand-mediated  receptor 
clustering, DISC formation and caspase 8 activation (Wagner et al., 2007).  Cells 
sensitive  to  TRAIL-mediated  apoptosis  have  O-glycosylation  of  DR4  and  DR5, Chapter 1.  Introduction     
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whereas  inhibition  of  this  post-translational  modification  suppressed  apoptosis 
(Wagner et al., 2007).  The association of TRAIL receptors with lipid rafts may also 
be  important.    Lipid  rafts  are  cholesterol  and  sphingolipid  rich  areas  in  the  cell 
membranes that concentrate signalling molecules and provide specific and distinct 
signalling, which may be different to the actions of the same proteins in different 
subcellular locations.  It has recently been demonstrated that TRAIL receptors not 
associated with lipid rafts may preferentially activate the non-apoptotic signalling 
pathways in response to TRAIL, such as NF B and ERK (Song et al., 2007). 
    
The relative activation of these alternative non-apoptotic TRAIL signalling pathways 
may also offer some explanation for the differential sensitivity of cells.  Inhibition of 
NF B activity has been shown to sensitise some cells to TRAIL-induced apoptosis 
(Romagnoli  et  al.,  2007),  and  cancer  cells  with  activating  PI3K  mutations  are 
relatively resistant to apoptosis by TRAIL (Samuels et al., 2005).  
 
Whatever the actual mechanism responsible for the selectivity of tumour cells to 
TRAIL, it is clear that cancer cells contain multiple molecular abnormalities, which 
normally lead to their death by apoptosis.  The cells that evade these normal safety 
mechanisms are nevertheless primed for apoptosis and hence may be more sensitive 
to death ligand targeting. Chapter 1.  Introduction     
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Figure 1.4  Cancer cells are specifically sensitive to TRAIL-induced apoptosis. 
Possible mechanisms to explain the selective apoptosis of cancer cell to TRAIL include 1) 
increase  in  decoy  receptors  in  normal  cells  which  may  activate  anti-apoptotic  kinase 
signalling  pathways,  2)  O-glycosylation  of  receptors  and  3)  their  location  in  lipid  rafts 
enhancing death inducing signalling complex (DISC) formation.  
 
 
 
1.3.3  Physiological functions of TRAIL  
Although TRAIL mRNA is found in a variety of cells and tissues in the body, the 
protein is mainly detected in cells of the immune system giving a hint as to the 
physiological role of this molecule.  TRAIL has been proposed to have a role in the 
regulation  of  haematopoiesis  (Secchiero  &  Zauli,  2008)  and  as  an  important 
mediator for the development of the immune system and particularly the negative 
selection of immature thymocytes (Lamhamedi-Cherradi et al., 2003).  However, this 
hypothesis has been questioned by in vitro data demonstrating a lack of effect of 
soluble TRAIL receptors in negative selection (Simon et al., 2001), and no lymphoid Chapter 1.  Introduction     
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or myeloid abnormalities in TRAIL-deficient mice (Cretney et al., 2003; Sedger et 
al., 2002).  TRAIL does however appear to have a role in immunoregulation with the 
modulation  of  T-cell  activation,  survival,  and  the  production  of  memory  T-cells 
(Janssen et al., 2005).  TRAIL-knockout mice have been shown to have a failure to 
induce apoptosis of activated T-cells and an increased autoimmunity (Lamhamedi-
Cherradi et al., 2003).  
 
The  predominant  effect  of  TRAIL  is  thought  to  be  its  physiological  role  in  the 
immune surveillance against tumours.  Natural killer (NK) cells, T-cells, monocytes, 
neutrophils,  and  dendritic  cells  have  all  been  shown  to  express  TRAIL 
physiologically and have TRAIL dependent anti-tumour effects (Cassatella, 2006; 
Kayagaki et al., 1999a; Kayagaki et al., 1999b).  TRAIL (in addition to perforin 1 
and FasL) is known to partly mediate the NK cell-induced cytotoxicity of TRAIL-
sensitive tumour lines in vitro and the anti-metastatic NK function in vivo in a mouse 
liver metastatic model (Takeda et al., 2001).  These responses were found to be 
dependent on interferon   (IFN ).  In a murine, allogenic bone marrow transplant 
(BMT), TRAIL expression on donor T-cells was also shown to be necessary for 
optimal graft-versus-tumour effects, but had no effects on graft-versus-host, again 
highlighting the tumour specificity of TRAIL (Schmaltz et al., 2002).  
 
Administration of a neutralising anti-TRAIL antibody or the use of TRAIL-knockout 
mice demonstrated the increased susceptibility of TRAIL-deficient mice to TRAIL-
sensitive  tumours  following  subcutaneous  application  of  the  carcinogen 
methylcholanthrene (MCA) (Cretney et al., 2002; Takeda et al., 2002).  Furthermore, 
p53
+/- mice  that  were  treated  with  the  same  neutralising  antibody  developed  an 
increased incidence of spontaneous, TRAIL-sensitive tumours (Takeda et al., 2002).  
The incidence of spontaneous haematological malignancies has also been shown to 
be increased in TRAIL-deficient mice (Zerafa et al., 2005). 
 
The physiological importance of TRAIL in tumour surveillance is also suggested by 
genetic lesions in some human cancers.  The TRAIL receptor genes can be mapped 
to  8p21-22  on  the  human  chromosome,  a  site  of  frequent  allelic  loss  in  cancers 
(Johnstone et al., 2008). DR5 mutations have been identified in up to 20% of human Chapter 1.  Introduction     
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cancers, including breast (Shin et al., 2001) and lung (Lee et al., 1999) cancer and a 
rare  DR4  allele  has  been  found  more  frequently  in  leukaemias  and  urogenital 
malignancies  (Wolf  et  al.,  2006).    There  are  also  defined  mutations  in  human 
malignancies  in  the  genes  downstream  from  TRAIL,  in  the  extrinsic  apoptotic 
pathway, such as caspase 8 and cFLIP, however these are part of a common pathway 
and do not define a specific role for TRAIL (Johnstone et al., 2008). 
 
In addition to a role in tumour surveillance, TRAIL is also thought to be involved in 
the  elimination  of  virus-infected  cells.    Normal  colonic  epithelial  cells  and 
fibroblasts were shown to be resistant to TRAIL-induced apoptosis.  Infection of 
these cells with cytomegalovirus or adenovirus led to an upregulation of TRAIL 
receptors and sensitised the cells to TRAIL (Sedger et al., 1999; Strater et al., 2002).  
A separate study demonstrated an upregulation of TRAIL expression in the lungs 
and on NK and T cells in influenza virus-infected mice, suggesting a role of TRAIL 
in the innate immunity against viral infection (Ishikawa et al., 2005).   
 
 
1.3.4  Uses of TRAIL as an antitumour therapy 
1.3.4.1 In vitro studies 
The selective sensitivity of cancer cells to recombinant TRAIL has been shown in a 
number of studies in vitro.  39 different cell lines from tumours of the lung, breast, 
colon, central nervous system, kidney and skin were tested with recombinant soluble 
TRAIL,  with  evidence  of  cytostatic  or  cytotoxic  effects  on  cell  growth  assays 
evident in 32 of the tested lines.  Conversely, similar tests on normal human cell 
types  including  lung  fibroblasts,  breast,  renal  and  prostate  epithelial  cells,  colon 
smooth muscle cells, and astrocytes showed no evidence of cytotoxicity (Ashkenazi 
et al., 1999).  These results have been repeated in several similar assays with both 
multiple cell lines and primary human cell cultures (Mitsiades et al., 2001) and a 
dose dependent effect of recombinant TRAIL has also been demonstrated in viability 
assays with glioma cells (Kock et al., 2007).  In addition to the use of recombinant 
TRAIL, monoclonal agonist antibodies against the active TRAIL receptors (DR4, 
DR5) have also been produced and shown to cause apoptosis in a variety of cancer Chapter 1.  Introduction     
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cell lines (Motoki et al., 2005; Pukac et al., 2005).  Cell lines have also been directly 
transduced to express both membrane-bound and soluble forms of TRAIL to cause 
apoptosis of cancer cells.  An increase in apoptosis, measured by flow cytometry and 
cell  viability  assays,  was  demonstrated  in  lung  cancer  (A549,  H460)  and  colon 
cancer (DLD-1, Lovo) cell lines transduced with adenoviruses expressing TRAIL 
(Lin et al., 2002).  Cancer cells transduced to express TRAIL were shown not only to 
become apoptotic themselves but also to cause death of neighbouring cancer cells by 
a ‘bystander effect’ (Kagawa et al., 2001).    
 
 
1.3.4.2 In vivo studies  
There have been some concerns as to the toxicity of recombinant soluble TRAIL 
preparations with some studies demonstrating in vitro sensitivity of normal human 
hepatocytes, brain tissues, neutrophils, and some epithelial cells (Jo et al., 2000; 
Nitsch et al., 2000; Renshaw et al., 2003).  Such toxicity had limited earlier trials on 
other  death  ligands.  Injection  of  Fas-L  led  to  massive  hepatic  necrosis  and 
haemorrhage and death of mice, whereas use of TRAIL was without systemic effects 
(Walczak et al., 1999).  This pattern was repeated in cynomolgus monkeys, where 
TNF caused severe toxicities but TRAIL was well tolerated (Ashkenazi et al., 1999).  
In addition to the apparent lack of toxicity, the repeated intravenous injections of 
recombinant  TRAIL  led  to  an  increase  in  tumour  cell  apoptosis,  a  reduction  in 
tumour  growth,  and  an  increase  in  survival  in  colon  (Ashkenazi  et  al.,  1999), 
pancreatic (Hylander et al., 2005), lung (Jin et al., 2004), myeloma (Mitsiades et al., 
2001),  glioma  (Pollack  et  al.,  2001),  and  breast  (Walczak  et  al.,  1999)  cancer 
xenograft models.  It is now thought that much of the in vitro toxicity was related to 
the  tagged  histidine  or  leucine  segments  of  the  recombinant  TRAIL  formations 
(Ganten et al., 2006; Lawrence et al., 2001; Meurette et al., 2006). 
 
TRAIL monoclonal antibodies with agonist activity have also shown the ability to 
destroy cancer cells in vivo.  An intravenous monoclonal antibody directed against 
DR4 caused a reduction in tumour growth in colonic, non small cell lung and renal 
tumours implanted subcutaneously (Pukac et al., 2005).  Similar results were also 
obtained with intraperitoneal treatment of a subcutaneous colon cancer model with a Chapter 1.  Introduction     
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monoclonal  antibody  to  DR5  (Motoki  et  al.,  2005).    An  added  advantage  of 
monoclonal  antibody  therapy  is  that  in  addition  to  binding  to  the  death  ligand 
receptor, the antibodies may also provoke immunological anti-tumour effects via the 
Fc fragment of the antibody. This was suggested by a study which demonstrated the 
antibody isotype was important in the efficacy of a DR4 antibody treatment in a 
mouse colon cancer model (Chuntharapai et al., 2001).  The Fc fragment can cause 
the recruitment of Fc receptor-expressing innate immune cells and cause antibody-
dependent cell-mediated cytotoxicity, or complement-dependent cytotoxicity.    
 
Other  TRAIL-delivery  systems,  such  as  gene  therapy,  have  also  been  used.  
Adenoviruses  have  been  used  to  express  TRAIL.    Such  adenoviruses  have  been 
directly injected into tumours, causing a reduction in tumour growth in several in 
vivo  xenograft  models  including  subcutaneous  prostate  (Griffith  &  Broghammer, 
2001) and colon (Lin et al., 2002) cancer models, a breast peritoneal carcinomatosis 
model (Lee et al., 2002), and an orthotopic glioblastoma model (Lee et al., 2002).  
Adenovirus vectors can cause tissue damage secondary to the innate and cellular 
immune responses to the virus and as such, less immunogenic recombinant adeno-
associated viruses have also been used in similar models (Mohr et al., 2004).  In 
addition to the direct injection of TRAIL-expressing adenoviruses into tumours, cells 
resistant to the effects of TRAIL have been transduced to express the death ligand 
and  then  used  for  injection  into  tumours  to  cause  apoptosis  with  their  bystander 
effects (Ucur et al., 2003).  
 
The  transduction  of  cells  to  express  TRAIL  in  the  in  vitro  and  in  vivo  systems 
described  above  produced  predominantly  membrane-bound  TRAIL.    Most 
investigators  could  find  no  evidence  of  soluble  TRAIL  in  the  supernatant  of 
transduced cells by ELISA, and the apoptosis of cancer cells was not reproduced by 
the use of the supernatant (Kagawa et al., 2001; Ucur et al., 2003), although this was 
not a universal finding (Wei et al., 2001).  Some authors have specifically attempted 
to produce soluble TRAIL by virally transducing cells with just the extracellular 
portion of TRAIL (Kim et al., 2006; Kim et al., 2004; Ma et al., 2005; Shi et al., 
2005; Wu et al., 2001; Wu & Hui, 2004).  There is some evidence that this leads to 
an increased apoptotic effect in some in vivo systems (Kim et al., 2006).  Conversely, 
there is also evidence to suggest that whereas DR4 will be activated by soluble or Chapter 1.  Introduction     
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membrane-bound TRAIL, DR5 requires membrane-bound or cross-linked TRAIL 
for activation, and that some cells which are not sensitive to soluble TRAIL apoptose 
when  the  TRAIL  is  tethered  to  a  cell  membrane  (Carlo-Stella  et  al.,  2006; 
Muhlenbeck et al., 2000; Wajant et al., 2001).  
 
 
1.3.4.3 Combinations of TRAIL with other agents 
To increase cancer cell killing, TRAIL can be used in combination with other agents.  
Logically, the use of standard anticancer therapies, which cause cancer cell death by 
the intrinsic apoptosis pathway, would combine well with TRAIL therapy, which 
utilises the extrinsic pathway.  There is however an increased synergism of such a 
combined approach, greater than the sum of its parts, due to the cross-talk between 
the  intrinsic  and  extrinsic  pathways,  such  that  chemotherapeutic  agents  and 
radiotherapy are able to increase the apoptotic effects of TRAIL, even in cancer cells 
previously resistant.  This synergism has been demonstrated with both in vitro and in 
vivo xenograft studies. There are a variety of possible mechanisms postulated for the 
synergism of the standard anti-cancer therapies including the upregulation of TRAIL 
receptors  (shown  in  prostate  and  bladder  cancer  cells  with  ionising  radiation 
(Shankar  et  al.,  2004)  and  a  range  chemotherapy  drugs  including  paclitaxel, 
vincristine,  vinblastine,  etoposide,  and  doxorubicin  (Shankar  et  al.,  2005)),  the 
clustering  of  the  receptors  into  lipid  rafts  (shown  in  leukaemic  B-cells  with 
doxorubicin  (Dumitru  et  al.,  2007)),  the  downregulation  of  apoptotic  pathway 
inhibitors  (c-FLIP  down  regulation  demonstrated  in  prostate  cancer  cells  with 
doxorubicin  (El-Zawahry  et  al.,  2005)),  or  the  enhanced  cleavage  of  caspases 
(demonstrated  in  mesothelioma  with  cisplatin  (Belyanskaya  et  al.,  2007)  and 
etoposide (Broaddus et al., 2005)).  
 
In addition to the combination with chemo- and radiotherapy, as the mechanism of 
TRAIL-induced apoptosis has become elucidated, this has also led to the rational 
combination of TRAIL therapy with other agents to specifically sensitise tumour 
cells  to  TRAIL-induced  apoptosis.    These  include  blocking  inhibitors  of  the 
apoptosis cascades such as c-FLIP, Bcl-2 (Kock et al., 2007), and IAP inhibitors (Li 
et al., 2004) and blocking the pro-survival pathways with PI3K (Martelli et al., 2003) Chapter 1.  Introduction     
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and NF B inhibitors (Khanbolooki et al., 2006), the latter of which was shown to 
overcome TRAIL resistance in pancreatic cancer cells both in vitro and in vivo.  
Histone  deacetlylase  (HDAC)  inhibitors  have  been  shown  to  increase  TRAIL 
receptor  expression  and  localisation  to  lipid  rafts  (Vanoosten  et  al.,  2005),  and 
proapoptotic  genes,  while  reducing  the  apoptotic  inhibitors  c-FLIP  and  the  IAPs 
(Bolden et al., 2006) making it a promising candidate for combination therapy, and 
this was demonstrated in vivo with the eradication of murine breast tumours (Frew et 
al., 2008). 
 
As described above, a potential advantage of TRAIL monoclonal antibodies is the 
immunological  recruitment.    Some  authors  have  investigated  the  prospect  of 
augmenting this further to enhance the production of tumour-specific cytotoxic T 
lymphocytes.  One approach was the combination of the DR5 agonist monoclonal 
antibody with agonists to CD40 and CD137, to stimulate antigen presenting cells or 
costimulating T-cells respectively.  This combination treatment was able to cause 
regression of tumours comprising 90% breast cells engineered to be TRAIL-resistant 
(Uno et al., 2006). 
 
It is important to bear in mind that the increased sensitivity of cancer cells to TRAIL 
with combination therapies may also increase the sensitivity of normal cells to this 
therapy.  There is some evidence of chemotherapy (Meurette et al., 2006) and HDAC 
inhibitors sensitising normal hepatocytes to TRAIL, and hence it would be important 
to consider the possible increased toxicity of combination therapy. 
 
 
1.3.4.4 Translational studies 
The promise of TRAIL as an oncological treatment from in vitro and in vivo work 
has led to its development for translational work.  Recombinant TRAIL (AMG951, 
Amgen, CA, US) has been used in Phase 1 studies for advanced solid tumours or 
non-Hodgkin’s lymphoma (NHL).  No drug related dose limiting toxicities were 
reported.  Consistent with preclinical work (Ashkenazi et al., 1999), the half-life of 
the  recombinant  TRAIL  was  36  minutes.    Out  of  the  51  trial  patients,  1  partial 
response (PR - defined by Response Evaluation Criteria in Solid Tumours (RECIST)) Chapter 1.  Introduction     
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and 13 with stable disease (SD) were reported.  Further Phase 1b studies of AMG951 
in combination with other agents have been performed in relapsed, low-grade NHL 
and non small cell lung cancer (NSCLC) with good tolerability and tumour response 
rates (NHL- 11 patients, 3 complete responses (CR), 3PR; NSCLC- 18 patients 1CR, 
9PRs).  These studies are now in Phase 2 clinical trials (Ashkenazi, 2008; Johnstone 
et al., 2008). 
 
There  has  also  been  the  development  of  human  monoclonal  antibodies  to  DR5 
(HGS-ETR2  (mapatumumab,  Human  Genome  Sciences,  MD,  USA))  and  DR4 
(HGS-ETR1 (lexatumumab, Human Genome Sciences)).  Two Phase 1 trials using 
intravenous  humanised  mapatumumab  as  a  monotherapy  for  advanced  solid 
malignancies have been performed.  Stable disease was reported in 19/49 and 12/41 
patients in these trails, with the agent being well tolerated (Hotte et al., 2008).  This 
product was also used in combination with chemotherapy agents yielding PRs in 
4/28 patients.  Phase 2 trials have also been reported with mapatumumab in NHL 
and NSCLC (NHL- 40 patients, 1CR, 2PR, 12SD; NSCLC- 32 patients, 9SD) (Greco 
et al., 2008).  Clinical trials with lexatumumab for solid malignancies demonstrated 
stable disease in 22/68 cumulative patients from two Phase 1 trials, with 1 patient 
reported to have asymptomatic liver enzyme derangement.  Further DR5 monoclonal 
antibodies  (HGS-TR2J  (Human  Genome  Sciences),  AMG655  (Amgen),  Apomab 
(Genentech, CA, US), LBY-135 (Novartis, NJ, US), CS1008 (Daiichi Sankyo Co., 
Tokyo, Japan)) have also recently begun clinical testing (Ashkenazi, 2008; Johnstone 
et al., 2008). 
 
 
1.3.5  The need for a better TRAIL vector 
The use of intravenous recombinant TRAIL or monoclonal antibodies, and the direct 
injection  of  TRAIL  expressing  cells  into  tumours  have  both  shown  promise  as 
possible  treatments  for  cancer.  The  intravenous  use  of  recombinant  TRAIL  has 
several problems.  The nature of its delivery means that there is no specific targeting 
of the active compound.  In addition, the pharmacokinetic half-life of recombinant 
TRAIL  was  shown  to  be  32  minutes  in  the  plasma  of  the  experimental  monkey 
(Ashkenazi et al., 1999) and 36 minutes in the recent human Phase 1 clinical trial, Chapter 1.  Introduction     
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necessitating frequent and high doses to produce the desired effect.   Monoclonal 
antibodies against TRAIL receptors have the advantages of specific and high affinity 
binding  with  a  prolonged  half-life  in  comparison  to  the  recombinant  TRAIL.  
However,  with  the  uncertainty  surrounding  the  biological  importance  of  decoy 
receptors, there is a possibility that this specific binding to active receptors may 
cause increased toxicity to normal cells.  In addition, not all cells express both DR4 
and DR5 and even when both receptors are present on the cell surface, they may not 
activate  the  apoptosis  cascade  equally.    This  is  exemplified  by  colon  and  breast 
cancer cell lines, which express both types of TRAIL receptor, but only transduce 
the apoptotic signal with DR5 ligand binding (Kelley et al., 2005).  Conversely, only 
binding to DR4 promotes apoptosis in chronic lymphocytic leukaemia cells, despite 
the expression of both DR4 and DR5 on the cell surface (MacFarlane et al., 2005).  
The majority of monoclonal antibodies being produced at present for clinical trials 
are agonists to DR5 (see above), however this is likely to be a reflection of the 
relatively increased expression of DR5 on tumour cells rather than on functional 
studies (Johnstone et al., 2008).  
 
An improved treatment will involve the direct targeting of tumour cells and their 
micrometastases by cells expressing TRAIL in a long term, controllable manner.  For 
this delivery, adult stem cells and especially mesenchymal stem cells from the adult 
bone marrow are a promising source of vectors to realise the full potential of TRAIL 
therapy. 
 
     
1.4  Stem Cells 
 
Stem cells are cells that have unlimited self-renewal properties with the ability to 
divide asymmetrically, both renewing themselves and producing more differentiated 
progenitors (Table 1.1).  Stem cells are characteristically divided into embryonic and 
adult stem cells.  Embryonic stem cells are derived from the inner cell mass of the 
blastocyst  of  a  developing  embryo  and  are  able  to  produce  progeny  of  all  cell 
lineages  (ectoderm,  mesoderm,  endoderm).    In  contrast  to  the  pluripotency  of 
embryonic stem cells, the progeny of adult stem cells are classically thought to be Chapter 1.  Introduction     
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lineage restricted.  Adult stem cells are found in discrete niches within adult tissues 
and are thought to divide infrequently in the steady state, but have the potential to 
repair  damaged  tissues  by  replacing  specific,  specialised  cells.    The  best 
characterised and most accessible adult stem cells are bone marrow derived stem 
cells (BMSCs).  Bone marrow derived stem cells consist of haematopoietic stem 
cells  (HSCs)  which  produce  progenitors  for  all  types  of  mature  blood  cells  and 
mesenchymal stem cells (MSCs) which differentiate into mature cells of the stromal 
tissue including fat, bone, and cartilage (Bonnet, 2003). 
 
Many adult organs have limited regenerative capacity, and the initial research with 
stem  cells  focused  on  attempts  to  harness  the  potential  for  the  reparative  and 
unlimited  survival  properties  of  stem  cells  to  mediate  epithelial  repair  in  injured 
organs.    The  primitive  nature  and  pluripotent  potential  of  embryonic  stem  cells 
would appear to make them the best candidate for such reparative therapies with the 
potential to produce any differentiated cell necessary.  The limited potency of adult 
stem cells would seem to restrict them to repair of cells of a specific lineage, for 
example the restoration of the immune system after bone marrow transplantation. 
Interestingly, several studies over the last decade have pointed towards the potential 
of adult stem cells, and bone marrow stem cells in particular, to be able to produce 
differentiated  cells  not  restricted  to  their  lineage,  with  cells  from  the  adult  bone 
marrow producing a variety of non-haematopoietic cells both in vitro and in vivo 
(Anjos-Afonso et al., 2004; Ishizawa et al., 2004; Kotton et al., 2001; Krause et al., 
2001; Yamada et al., 2004).  This ability of adult cells to produce progeny crossing 
lineage barriers, adopting the phenotypes of other tissues, is defined as ‘plasticity’.  
Initial experiments suggested that following transplantation, a single bone marrow 
stem cell had the potential to engraft as epithelial cells in many organs, including 
20%  of  type  2  pneumocytes  in  the  lung  (Krause  et  al.,  2001).    Further  studies 
demonstrated a reduction in injury following bone marrow stem cell administration 
(Ortiz et al., 2003; Rojas et al., 2005).  However the last few years has seen a re-
evaluation,  and  there  is  an  appreciation  that  the  significant  contribution  of  bone 
marrow cells to epithelial repair is probably a function of methodological flaws and 
artefacts (Loebinger et al., 2008; Loebinger & Janes, 2007). 
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The ability of the stem cell to differentiate in multiple lineages is not the primary 
consideration for this thesis.  The aim is the utilisation of the ability of these cells to 
migrate  to  tumours,  and  for  this  adult  bone  marrow  derived  cells  have  several 
advantages.  The use of embryonic cells is likely to involve the destruction of an 
embryo and research in this field has met with moral, ethical and political objections. 
Embryonic stem cells have a greater tumorigenic potential than adult stem cells and 
there are inherent risks associated with the immune rejection of these cells (Orkin & 
Morrison, 2002).  Conversely, adult stem cells can be manipulated ex-vivo and the 
cells used can be autologous, thus reducing the risk of immune rejection.  Many of 
the ethical objections with embryonic cells are also not valid with the use of these 
cells.  
 
 
1.4.1  Contribution of bone marrow stem cells to extracellular matrix 
1.4.1.1 Tissue stroma 
Despite  the  reassessment  of  the  contribution  of  bone  marrow  derived  cells  to 
epithelial  repair  in  damage  models,  there  remains  strong  evidence  for  their 
participation  in  areas  of  both  physiological  and  pathological  extracellular  matrix 
deposition,  including  wound  healing,  tissue  stroma,  and  organ  fibrosis.    The 
fibroblasts that enter and proliferate within fibrotic lesions were classically thought 
to be of resident tissue origin.  Models describing the pathophysiology of fibrosis 
have developed to include other contributions to the fibroblast and myofibroblast 
communities within these fibrotic lesions.  These include the possibility of epithelial 
to mesenchymal transition (EMT) and the significant contribution of fibroblasts and 
myofibroblasts  from  the  bone  marrow  (McAnulty,  2007).    Circulating  fibrocytes 
originating from the bone marrow were described and shown to be important in both 
physiological and pathological repair (Abe et al., 2001; Bucala et al., 1994; Phillips 
et al., 2004; Schmidt et al., 2003).  Chimeric mice with transplanted, labelled bone 
marrow were used to demonstrate greater than 30% bone marrow contribution to the 
fibroblasts in a skin wound healing model (Direkze et al., 2003; Ishii et al., 2005).  In 
a  bleomycin  mouse  model  of  lung  fibrosis,  80%  of  type  1  collagen-expressing 
fibroblasts at the sites of lung fibrosis were shown to be of bone marrow origin Chapter 1.  Introduction     
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(Hashimoto  et  al.,  2004;  Ishii  et  al.,  2005),  and  similar  results  were  found  with 
paracetamol induced lung injury (Direkze et al., 2003).  MSCs have been shown to 
be preferentially attracted to and retained in infarcted myocardium (Barbash et al., 
2003), cerebral ischaemia (Chen et al., 2001), areas of allograft rejection (Wu et al., 
2003a), and lung fibrosis (Epperly et al., 2003; Ortiz et al., 2003). 
 
 
 
Cell type  Definition 
 
 
Stem cell  Cells with unlimited self renewal, dividing asymmetrically 
to  produce  an  identical  daughter  cells  and  a  more 
differentiated progenitor. 
 
Bone marrow stem cell    Comprises haematopoietic and mesenchymal stem cells. 
 
Haematopoietic stem cell  Stem cell able to form all cells of the blood lineage. 
 
Mesenchymal stem cell  Stromal stem cell able to produce supporting cells including 
bone, fat, and cartilage. 
 
Fibroblast  Main  mature  cell  type  involved  in  the  production  of  the 
extracellular matrix and collagen of tissues. 
 
Myofibroblast  Fibroblasts can be activated (e.g. by transforming growth 
factor     (TGF )  to  form  these  cells,  which  produce 
extracellular matrix but also have the ability to contract.   
 
Fibrocytes   Circulating peripheral cells of bone marrow origin.  Often 
described  as  blood-derived  fibroblasts.    Express  a 
characteristic  pattern  of  markers  including  the  leukocyte 
common antigen CD45, the haematopoietic marker CD34, 
and collagen 1.   
 
 
 
Table 1.1  Definitions of cell types 
 
 
1.4.1.2 Tumour stroma 
The tumour stroma is very important in determining cancer spread and growth.  The 
tumour  stroma  is  composed  of  fibroblasts  and  myofibroblasts  which  produce 
extracellular matrix and the ‘desmoplastic reaction’, endothelial cells involved in 
angiogenesis, and inflammatory cells (De Wever & Mareel, 2003; Desmouliere et al., Chapter 1.  Introduction     
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2004; Direkze & Alison, 2006).  Contrary to acting solely as a supporting structure, 
the tumour stroma is integral to the behaviour of the tumour (Bhowmick et al., 2004).  
Tumours  have  been  compared  to  unresolved  wounds  that  produce  a  continuous 
source of inflammatory mediators (Dvorak, 1986).  Myofibroblasts in the tumour 
stroma  can  secrete  growth  factors  and  proteolytic  enzymes  that  influence  the 
invasion and progression of tumours (Orimo et al., 2005). In some situations the 
presence of a tumour capsule has been shown to be protective, leading to a increased 
prognosis  in  human  hepatocellular  carcinoma  (Ng  et  al.,  1992).    Conversely, 
increased stroma and myofibroblast numbers were associated with a worse prognosis 
in other cancers (Barth et al., 2002a; Barth et al., 2002b; Barth et al., 2002c; Cardone 
et  al.,  1997),  and  the  proliferative  activity  of  stromal  fibroblasts  was  shown  to 
correlate  to  breast  cancer  metastasis (Hasebe  et  al.,  2000).    Tumour-stromal  cell 
contact  has  been  shown  to  upregulate  the  expression  of  stromal  matrix 
metalloproteinases and promote the invasion of human cervical cancer cells (Sato et 
al., 2004).  Furthermore, myofibroblasts and fibroblasts, activated by irradiation, led 
to  an  increased  invasiveness  of  pancreatic  cancer  cells  in  coculture  experiments 
(Ohuchida et al., 2004).       
 
As with repair and fibrosis, in addition to the tissue origin of stromal cells, bone 
marrow derived stem cells contribute to this desmoplastic response in the form of 
myofibroblasts and fibroblasts, as well as participating in tumour neovasculogenesis.    
Experiments tracking the fate of labelled, bone marrow-derived cells following bone 
marrow transplant have shown myofibroblasts and endothelial cells originating from 
the bone marrow in a murine xenograft pancreatic tumour model (Ishii et al., 2003), 
and  an  endogenous  murine  pancreatic  cancer  model  where  up  to  25%  of  the 
myofibroblasts were bone marrow derived (Direkze et al., 2004).  These results have 
been repeated in a range of xenograft tumour models, with the amount of tumour 
stroma and bone marrow-derived cell contribution related to both the tumour cell and 
the  site  of  implantation  (Sangai  et  al.,  2005).    Furthermore,  these  bone  marrow 
derived cells appear to be functional with the demonstration of collagen production 
(Direkze et al., 2006).  
 
Tumour neovasculogenesis is one of the hallmarks of cancer, and a contribution of 
bone  marrow  derived  stem  cells  to  the  angiogenesis  of  tumours  has  also  been Chapter 1.  Introduction     
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demonstrated (Lyden et al., 2001).  Bone marrow cells (Sca
1+) labelled and injected 
intravenously were shown to incorporate as endothelial like cells into the periphery 
of  a  glioma  (Anderson  et  al.,  2005).    The  importance  of  this  contribution  was 
illustrated by a decrease in tumour size and an increase in apoptosis when these bone 
marrow cells were transduced with the suicide gene (HSV-tk) (Ferrari et al., 2003).  
In contrast, other studies have only shown a minimal contribution of bone marrow 
cells to the newly formed tumour endothelium (Dwenger et al., 2004).   
 
Sex  mismatched  bone  marrow  transplants  in  humans  have  also  been  utilised  to 
determine the contribution of bone marrow derived cells to tumours.  Colorectal 
adenomas  diagnosed  2  months  after  bone  marrow  transplantation  were  found  to 
consist of 1-4% bone marrow derived cells which displayed features of neoplastic 
colonic adenoma cells.  A similar pattern, with up to 20% of the neoplastic cells of 
bone marrow origin was found in a patient who developed lung cancer four years 
post bone marrow transplant (Cogle et al., 2007).  A contribution to the tumour 
vasculature has also been demonstrated (Peters et al., 2005). 
 
In addition to the incorporation of bone marrow-derived cells following whole bone 
marrow transplantation, mesenchymal stem cells have also been shown to have an 
ability  to  specifically  target  tumour  tissue.    In  vitro  migration  studies  have 
demonstrated  a  enhanced  migration  of  MSCs  towards  tumour  cells  and  the 
conditioned medium from tumour cells (Menon et al., 2007; Nakamizo et al., 2005; 
Xin et al., 2007), in addition to platelet-derived growth factor (PDGF), epidermal 
growth factor (EGF), and CXCL12 (SDF1  ) (Nakamizo et al., 2005).  A variety of 
tumour  models  have  also  shown  the  ability  of  MSCs  to  incorporate  into  and 
proliferate within tumour stroma in vivo.  Kaposi’s sarcoma (Khakoo et al., 2006), 
colorectal  cancer  (Menon  et  al.,  2007),  glioma  (Nakamizo  et  al.,  2005),  breast 
metastases (Studeny et al., 2004)  and melanoma metastases (Studeny et al., 2002; 
Studeny et al., 2004; Xin et al., 2007) have all been used and showed consistent 
MSC incorporation when MSCs were delivered systemically.  MSCs have also been 
shown to migrate to tumours when delivered intraperitoneally in an ovarian cancer 
model (Komarova et al., 2006), and cerebrally in a glioma model (Nakamizo et al., 
2005).    The incorporation of MSCs has been shown both into established tumours 
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some  authors  have  suggested  that  established  tumours  are  necessary  for  the 
development of the neovascularisation and the stromal-derived cytokines and growth 
factors that are essential to attract the circulating MSCs (Djouad et al., 2003). 
  
 
1.5  Mesenchymal Stem Cells 
 
MSCs are a subgroup of the adult bone marrow stem cells, which play an important 
role in supporting haematopoiesis and supplying differentiated stromal tissue.  They 
can be isolated by their ability to adhere to plastic in culture, and expanded easily.  
There are no specific cell markers that can be used to categorically define an MSC 
and present identification relies upon a combination of their ability to differentiate in 
vitro into fat, bone, and cartilage, the expression of CD73, CD90, and CD105, and 
the lack of expression of haematopoietic cell markers (CD11b, CD14, CD19, CD34, 
CD45, CD79 , HLA-DR) on the cell surface (Dominici et al., 2006).   MSCs have 
several properties in addition to their tumour homing capabilities, which lend them 
towards  a  role  as  a  vector  for  cancer  therapy.    MSCs  can  be  relatively  easily 
transduced and expanded in culture for many passages, whilst retaining their growth 
and multi-lineage potential (Giordano et al., 2007; Lee et al., 2001; Marx et al., 
1999).  They also seem to be relatively immunoprivileged due to their expression of 
major  histocompatibility  complex  (MHC)1,  but  lack  of  MHC2,  and  the 
costimulatory molecules CD80, CD86, CD40 (Javazon et al., 2004).  This property 
may  allow  the  delivery  of  allogenic  MSCs  without  prior  immunomodulation, 
opening up the possibility of their clinical use as a cell therapy. 
 
 
1.5.1  Homing mediators 
It is likely that the mechanism responsible for the homing of adult bone marrow stem 
cells to tumours involves chemokine ligands and receptors in a similar fashion to the 
recruitment  of  leukocytes  to  areas  of  inflammation.    The  importance  of  the 
chemokine  CXCL12  and  its  receptor  CXCR4  has  been  well  established  for 
haematopoietic  stem  cells  (Chute,  2006;  Peled  et  al.,  1999).    The  chemokines Chapter 1.  Introduction     
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responsible for homing and migration of mesenchymal stem cells are however less 
well characterised.  Chemokines are a family of small glycoproteins that regulate 
chemotaxis  in  addition  to  effects  on  proliferation  and  differentiation.    There  are 
approximately 50 human chemokines that are divided in XC, CC, CXC, and CX3C 
families, based on the position of the cysteine residues within the primary amino acid 
sequence.    They  bind  to  seven-transmembrane,  G-protein  coupled  receptors.  
Multiple authors have attempted to describe a definitive account of the functional 
chemokine  receptors  that  are  present  on  human  MSCs  and  the  cytokines  and 
chemokines that have the greatest influence on MSC migration (Honczarenko et al., 
2006; Ponte et al., 2007; Ringe et al., 2007; Sordi et al., 2005; Von Luttichau et al., 
2005).  One study demonstrated that MSCs expressed three CC chemokine receptors 
(CCR1,7,9) and CXC chemokine receptors (CXCR4,5,6), and one CX3C chemokine 
receptor (CX3CL1) by RTPCR and flow cytometry.  The use of chemokine ligands 
for  these  receptors  stimulated  signalling  pathways,  with  the  phosphorylation  of 
MAPKs,  activation  of  signal  transducer  and  activator  of  transcription  (STATs; 
CXCL12 activating STAT-5, CCL5 activating STAT-1), and focal adhesion kinase 
signalling pathways (FAKs).  The chemokine ligands also stimulated chemotaxis in 
vitro, and CXCL12 induced F-actin polymerisation (Honczarenko et al., 2006).  A 
slightly  different  panel  of  chemokine  receptors  (CCR2,3,4,5;  CXCR4,5)  was 
suggested  in  a  further  study  by  flow  cytometry  and  Western  blot.    This  study 
demonstrated, by functional migration experiments, that the growth factors PDGF 
and insulin-like growth factor-1 (IGF-1) were the most potent chemotaxis agents to 
MSCs, with only three (CCL5, CXCL12, CCL22) of nine tested chemokines having 
a significant effect on migration.  The stimulation of MSCs with tumour necrosis 
factor   (TNF ) however, significantly increased the chemokine-induced migration, 
suggesting that both the systemic and local inflammatory state may be important in 
MSC homing (Ponte et al., 2007).  Growth factors were also deemed important in 
MSC migration in a further study in which basic fibroblast growth factor (bFGF) had 
the most potent effect (Schmidt et al., 2006).  MSCs isolated from multiple donors 
were  used  to  demonstrate  the  mRNA  expression  of  a  large  panel  of  chemokine 
receptors,  however  immunochemistry  only  confirmed  protein  expression  in  a 
subgroup  of  these.    Furthermore,  the  expression  of  some  chemokine  receptors 
(particularly  the  CC  group)  varied  between  donors,  whereas  other  chemokine Chapter 1.  Introduction     
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receptors were expressed universally (CXCRs, CCR8,9) (Ringe et al., 2007).   Other 
multiple  reports  have  suggested  alternative  expression  patterns  and  functional 
importance of different chemokines and their receptors in MSC migration including 
CCR1,4,7,10,  CXCR5  (Von  Luttichau  et  al.,  2005),  and  CCR1,7,  CXCR4,6, 
CX3CR1 (Sordi et al., 2005). 
 
Of the chemokines, the contribution of CXCL12 to the recruitment of MSCs is of 
particular interest.  This chemokine is critical for haematopoietic stem cell migration, 
and knockouts of either the ligand or receptor CXCR4 are universally fatal in utero, 
with the chemokine involved in the migration of HSCs from the liver to the bone 
marrow.  Similarly, the migration of bone marrow-derived stem cells to fibrotic lung 
is reduced with CXCL12 neutralisation (Phillips et al., 2004; Xu et al., 2007a).  The 
importance  of  this  chemokine  in  MSC  migration  is  suggested  by  studies 
demonstrating an increased migration of MSCs, tranduced to overexpress CXCR4, to 
the infarcted myocardium (Cheng et al., 2008), and the in vivo migration of MSCs to 
the brain after exogenous CXCL12 injection (Ji et al., 2004).  CXCL12 may also be 
an important mediator of MSC recruitment to tumours.  The stroma surrounding 
breast cancer was shown to be a rich source of this chemokine (Orimo et al., 2005) 
and whole tumour explants were also shown to secrete this cytokine (Dwyer et al., 
2007).  A further in vitro study examined the differences in gene expression profiles 
between  MSCs  exposed  to  conditioned  medium  from  tumours  cells  and  bone 
marrow cells.  The authors concluded that the CXCL12/CXCR4 axis was important, 
but that the MSCs produced the chemokine which then acted in an autocrine manner 
(Menon et al., 2007).  Other studies however have failed to confirm the importance 
of CXCR4 for MSC migration.  Blockade of CXCR4 did not affect MSC migration 
in a myocardial infarct model (Ip et al., 2007) and some groups have not shown 
expression of this receptor on MSCs (Von Luttichau et al., 2005).   
 
Based on the established literature for leukocyte migration, other possible important 
candidates  for  MSC  chemotaxis  include  the  receptors  CXCR1,2  and  CCR3, 
neutralisation of which has been shown to decrease leukocyte migration (Luster et al., 
2005; Spaeth et al., 2008), and CCR2 important in macrophage trafficking (Sekido et 
al., 1993).  Indeed, CCL2 was shown to be secreted by breast cancer cells in vivo 
and the use of a neutralising antibody reduced the homing of MSCs (Dwyer et al., Chapter 1.  Introduction     
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2007).  The same study also demonstrated an increased serum level of CCL2 in post-
menopausal breast cancer patients compared to controls.   
 
MSCs  are  also  believed  to  use  adhesion  molecules  and  integrins  to  enable 
extravasation in a similar fashion to leukocytes (Ruster et al., 2006).  P-selectin is 
important in the initial endothelial contact and rolling of leukocytes, and neutralising 
antibodies  against  the  endothelially  expressed  P-selectin  also  resulted  in  fewer 
endothelial cell-bound MSCs in vitro (Ruster et al., 2006).  The very late antigen-4 
(VLA-4) and its counterpart adhesion molecule vascular cell adhesion molecule-1 
(VCAM-1) are critical for leukocyte arrest on activated endothelium, and antibodies 
to either resulted in a decreased MSC adherence to the endothelium (Ruster et al., 
2006).  Furthermore, the migration of MSCs to ischaemic myocardium was reduced 
by blocking MSC  1-integrin, a component of VLA-4 (Ip et al., 2007).  Despite the 
similarities, there are however likely to be differences between leukocyte and MSC 
extravasation, for example platelet/endothelial cell adhesion molecule-1 (PECAM-1), 
which is involved in leukocyte transmigration, is not expressed on MSCs (Karp & 
Leng Teo, 2009). 
 
The large variability between the reports of the chemokines and cytokines relevant to 
MSC migration may be partly explained by the heterogeneity of the cell population. 
This includes the extraction and identification of the cells, the culture conditions and 
the possibility of cell activation either in vivo or ex vivo.  The ability of MSCs to 
home and migrate appears to decrease during in vitro expansion in relation to their 
loss  of  surface  expression  of  chemokine  receptors  (Honczarenko  et  al.,  2006; 
Rombouts & Ploemacher, 2003).  Culture confluence has also been shown to impact 
on MSC homing with increased confluency increasing the production of the tissue 
inhibitor  of  matrix  metalloproteinase-3  (TIMP-3)  and  inhibiting  transendothelial 
migration (De Becker et al., 2007).  Conversely, hypoxic culture conditions increase 
matrix  metalloproteinases  (MMPs)  and  MSC  migration  (Annabi  et  al.,  2003).   
Despite the variability, the general consensus is that MSCs do express a number of 
chemokine receptors which are likely to be involved in their homing capabilities 
(Chamberlain et al., 2007), often with combination of cytokines and chemokines 
necessary for the maximal effect (Ozaki et al., 2007).  Chapter 1.  Introduction     
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1.5.2  Use of MSCs as delivery vectors  
1.5.2.1 Cancer 
The ability of MSCs to specifically home to a wide range of tumours has led several 
groups to investigate these cells in delivering anticancer agents (Figure 1.5).  Human 
MSCs, engineered to express IFN  by transduction with adenovirus, have been used 
to provide targeted delivery of this potent antiproliferative and proapoptotic agent to 
gliomas  (Nakamizo  et  al.,  2005)  and  metastatic  breast  (Studeny  et  al.,  2004), 
melanoma  (Studeny  et  al.,  2002;  Studeny  et  al.,  2004),  and  prostate  (Ren  et  al., 
2008b) cancer models.  The use of MSC-delivered IFN , which suppresses tumour 
cell  growth  by  induction  of  differentiation,  S-phase  accumulation  and  apoptosis, 
resulted in an increased survival and/or reduced tumour burden in all these models.  
IFN -expressing MSCs have also been used for the immunostimulatory, apoptosis-
inducing, and anti-angiogenic effects of IFN  with similar results in a metastatic 
melanoma model (Ren et al., 2008a).  MSCs have also been adenovirus-transduced 
to  express  IL-12,  with  the  rationale  of  improving  the  anti-cancer  immune 
surveillance by activating cytotoxic lymphocytes, natural killer cells, and producing 
IFN .  In this model, the intravenously delivered IL-12-expressing MSCs reduced 
metastases from subcutaneous tumours (Chen et al., 2008).  In addition, if delivered 
intraperitonealy,  one-week  prior  to  tumour  inoculation,  the  MSCs  were  able  to 
prevent the development of the subcutaneous tumours (Chen et al., 2006).  A similar 
approach  of  immunostimulation  with  tumour-targeted  chemokines  was  used  to 
deliver the chemokine CX3CL1 (fractalkine), which is able to activate T-cells and 
NK  cells.    This  therapy  reduced  the  metastastic  load  caused  by  the  intravenous 
delivery of melanoma and colon cancer cell lines (Xin et al., 2007).  MSCs have also 
been produced to deliver IFN  which stimulated apoptosis and inhibited leukaemic 
cell proliferation in vitro (Li et al., 2006), and the immunomodulatory cytokine IL-2 
with a reduction in tumour growth and improved survival when directly injected into 
murine gliomas (Nakamura et al., 2004). 
 
In addition to the delivery of growth factors, cytokines, and chemokines, MSCs have 
also  been  engineered  to  deliver  conditional  replicative  adenoviruses  (CRAds)  to 
reduce tumour growth and spread in vivo.  These viruses are able to destroy tumour 
cells by viral replication, and following oncolysis, further newly produced virus is Chapter 1.  Introduction     
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then released to the surrounding tumour tissue.  This therapy improved survival in a 
murine ovarian cancer model (Komarova et al., 2006), orthotopic breast and lung 
tumour  models  (Hakkarainen  et  al.,  2007),  and  a  lung  metastasis  model  (Stoff-
Khalili et al., 2007).   
 
MSCs have also been used to serve as vehicles for targeted chemotherapy with an 
enzyme prodrug conversion approach.  One study combined MSCs that produced 
herpes simplex virus-thymidine kinase (HSV-tk) retroviral vectors in the proximity 
of tumours, with the prodrug ganciclovir, leading to glioma cell death in vitro and in 
vivo  (Uchibori  et  al.,  2009).    In  different  studies,  MSCs  expressed  the  cytosine 
deaminase  enzyme,  which  converts  the  substrate  5-fluorocytosine  (5-FC)  to  the 
highly toxic 5-fluorouracil (5-FU), which they delivered to the tumour cells resulting 
in a reduction of melanoma (Kucerova et al., 2008) and colon cancer (Kucerova et 
al., 2007) subcutaneous tumours.   However, these approaches are limited by the 
toxicity of the treatment to the delivery MSC.  
 
 
1.5.2.2 Non-cancer 
In addition to homing to tumours, MSCs also home to areas of damage and repair.   
As  a  result,  studies  have  also  investigated  their  use  as  delivery  vectors  in  other 
pathologies.    Endotoxin-mediated  acute  lung  injury  was  reduced  with  the  use  of 
MSCs expressing angiopoietin-1, a critical factor for endothelial survival (Mei et al., 
2007).  Mesenchymal stem cells transduced with endothelial nitric oxide synthase 
(eNOS) could also improve monocrotaline-induced pulmonary arterial hypertension 
in rats (Kanki-Horimoto et al., 2006).   Vascular endothelial growth factor (VEGF) 
expressing  MSCs  were  also  shown  to  improve  cardiac  function  in  a  myocardial 
infarction  model  (Matsumoto  et  al.,  2005).    Significant  improvements  were  also 
recorded in an experimental autoimmune encephalomyelitis model with the use of 
intravenous MSCs transduced to express human ciliary neurotrophic factor (CNTF), 
a factor known to promote myelogenesis and reduce inflammation (Lu et al., 2009), 
and a collagen induced arthritis model with IL-10 overexpressing MSCs, suppressing 
the  immune  response  and  regulating  cytokine  production  (Choi  et  al.,  2008).Chapter 1.  Introduction     
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Figure 1.5  MSCs migrate towards tumours 
A)  Intravenously  injected  MSC  are  able  to  specifically  migrate  towards  multiple  lung 
metastases.  B) The tumour produces a chemotactic gradient attracting MSCs, which are 
able to incorporate into the tumour architecture. Chapter 1.  Introduction     
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MSCs  can  also  be  used  to  deliver  genes  to  ‘replace’  mutant  genes  in  genetic 
deficiencies.  Animal and small clinical studies have shown potential in osteogenesis 
imperfecta  (Horwitz  et  al.,  1999;  Horwitz  et  al.,  2001)  and  lysosomal  storage 
diseases (Koc et al., 2002). 
 
Other  bone  marrow  derived  progenitor  cells  have  also  been  used  as  vectors. 
Endothelial  progenitor  cells  transduced  with  eNOS  have  been  used  in  a  similar 
pulmonary  hypertension  model  (Zhao  et  al.,  2005)  and  this  has  led  to  the 
development of the PHACeT clinical trial in humans, which is currently enrolling 
patients.  
 
 
1.5.3  Effects of MSCs themselves 
1.5.3.1 Non-cancer 
It is important not to regard MSCs simply as inert vectors but as active cells with 
possible effects on both physiological and pathological processes.  In particular, it is 
known that MSCs have profound immunosuppressive effects.  T-cells cultured with 
MSCs do not proliferate with antigenic or mitogenic stimuli.  This may be due to the 
arrest of the T-cell in the G0/G1 phase with consequent prevention of S phase entry 
and  inhibition  of  cell  division  (Glennie  et  al.,  2005).    Similar  effects  have  been 
demonstrated on B-cells (Corcione et al., 2006) and dendritic cells (Ramasamy et al., 
2007a), leading to a reduction in plasma cell maturation and antibody production, 
and antigen presentation respectively.  In addition to direct T-cell inhibition, MSCs 
also induce CD4
+CD25
+FoxP3
+ regulatory T-cells (Treg), which further limit the 
activation of CD4 and CD8 subsets, B-cells, and NK cells (Wolf & Wolf, 2008).  
MSCs affect immune cells by several mechanisms including direct cell contact and 
the release of many soluble factors, including nitric oxide (Sato et al., 2007). 
 
The immunosuppressive effects of MSCs have been harnessed in the treatment of 
graft  versus  host  disease  (GvHD)  following  bone  marrow  transplantation.    A 
multicentre,  Phase  2  clinical  trial  for  MSCs  in  severe,  steroid-resistant  GvHD, 
demonstrated a complete response in 30 patients and partial response in a further 9 Chapter 1.  Introduction     
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out  of  55  treated  patients.    Interestingly,  there  was  no  difference  in  response  or 
adverse effects between patients receiving cells from matched or unmatched donors 
(Le Blanc et al., 2008).  A Phase 2 study utilising the immunosuppressive effects of 
the MSCs is also ongoing in Crohn’s disease (Weiss et al., 2008), and there is also 
encouraging in vivo data for experimental collagen-induced arthritis (Augello et al., 
2007) and autoimmune encephalomyelitis (Zappia et al., 2005), suggesting further 
potential clinical applications in other autoimmune diseases. 
 
In addition, MSCs are thought to be able to reduce damage in several injury systems 
by both stimulating repair and exerting anti-inflammatory effects.  This has been 
utilised in clinical trials in cardiology (Assmus et al., 2006; Hare & Chaparro, 2008; 
Lunde et al., 2006; Schachinger et al., 2006), whereby MSCs have been infused 
acutely following myocardial infarction and in chronic ischaemic heart failure, with 
an improvement in cardiac function, infarct size, and remodelling (Hare & Chaparro, 
2008).      In  the  lung,  systemic  MSC  administration  following  bleomycin-induced 
pulmonary fibrosis led to decreased inflammation, and reduced fibrosis and collagen 
deposition in murine models (Ortiz et al., 2003; Rojas et al., 2005).  Expression of 
IL-1  receptor  antagonist  by  MSCs  and  the  subsequent  reduction  of  the 
proinflammatory cytokines TNF  and IL-1 have been postulated as central to this 
effect.  Similarly, MSCs were shown to regulate the inflammatory signals from lung 
cells injured by either intratracheal (Gupta et al., 2007) or intraperitoneal (Xu et al., 
2007b)  endotoxin,  with  a  reduction  in  lung  injury.      Phase  2  clinical  trials  are 
presently  being  performed  to  investigate  whether  the  anti-inflammatory  and 
reparative function of MSCs may benefit patients with moderate to severe chronic 
obstructive lung disease.  The paracrine effects of MSCs on tissue protection and 
repair,  with  the  secretion  of  trophic  factors,  have  also  been  proposed  for  the 
improvements  in  other  organ  damage  models  including  fulminant  hepatic  failure 
(Parekkadan et al., 2007), stroke (Li et al., 2002), and acute kidney injury (Togel et 
al.,  2007).    MSCs  have  also  been  shown  to  produce  proangiogenic  cytokines 
including VEGF and bFGF, and this property has been used to enhance blood vessel 
growth in chronic limb ischaemia (Kinnaird et al., 2004). 
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1.5.3.2 Cancer 
It is especially important to consider the role of the MSC in cancer in the context of 
these  immunosuppressive,  reparative,  and  angiogenic  properties.    Subcutaneously 
delivered, allogenic, melanoma cells only produced tumours in mice with the co-
administration of MSCs, and immunosuppression was thought to be a pivotal factor 
for this observation (Djouad et al., 2003).  The same group also demonstrated an 
earlier  development  of  tumours  when  syngeneic  Renca  kidney  cancer  cells  were 
implanted with MSCs.  MSCs however did not alter the cancer cell growth in vitro, 
supporting an immunosuppressive role for the in vivo differences.   The kinetics of 
tumour growth and metastases were not affected in these experiments (Djouad et al., 
2006).  
 
The production of trophic factors by MSCs has also been implicated in enhancing 
tumour  growth  and  spread.    MSCs  enhanced  the  in  vivo  growth  of  Burkitt’s 
lymphoma cells by a mechanism dependent on the VEGF pathway (Kyriakou et al., 
2006).    MSCs  have  also  been  shown  to  secrete  the  chemokine  CCL5,  which 
promoted an increase in the motility, invasion, and metastasis of  breast cancer cells 
in a mouse subcutaneous xenograft model (Karnoub et al., 2007).  The production of 
IL-6 by MSCs was also implicated in the increased growth of breast cancer cells by 
STAT-3 phosphorylation and signalling (Sasser et al., 2007).      
 
Further  tumour-enhancing  effects  of  MSCs  have  also  been  demonstrated  with 
colonic cancer (Zhu et al., 2006) and chronic myeloid leukaemia cell lines.  In the 
latter experiment the MSCs increased in vivo tumour proliferation, but reduced the 
cancer cell proliferation in vitro.  In order to resolve the discrepancy, the authors 
suggested  MSCs  were  able  to  downregulate  cyclin  D2  and  arrest  cancer  cells  at 
G0/G1, preserving their proliferative capacity and reducing apoptosis (Ramasamy et 
al., 2007b).  
 
In contrast, MSCs have also been shown to have intrinsic antineoplastic properties.  
MSCs  were  also  shown  to  arrest  hepatoma,  lymphoma,  and  insulinoma  cells  at 
G0/G1, but this reduced proliferation was accompanied by an increase in cancer cell 
apoptosis and a reduction in malignant ascites when hepatoma cells were injected Chapter 1.  Introduction     
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intraperitoneally (Lu et al., 2008).   An improvement in other cancer models has also 
been demonstrated with the use of MSCs.  Intratumoural injection of MSCs led to 
the  inhibition  of  tumour  growth  and  increased  survival  of  rats  with  glioma 
(Nakamura et al., 2004), and both intratumoural or intravenous injection of MSCs 
led to the reduction in growth and metastases of a breast cancer model, with the 
increase of apoptotic markers (Sun et al., 2009).   
 
Furthermore,  intravenously  delivered  MSCs  were  able  to  inhibit  the  growth  of 
Kaposi’s  sarcoma  (KS)  in  a  mouse  model,  in  a  dose  dependent  manner.    The 
mechanism was due to the inhibition of Akt activity within KS cells, and cell-cell 
contact was necessary (Khakoo et al., 2006).  The release of soluble factors by MSCs 
has also been shown to reduce tumour growth and progression in glioma (Nakamura 
et al., 2004), melanoma and lung carcinoma models (Maestroni et al., 1999).  The 
MSC-induced cancer cell inhibition was preserved with the separation of the cells 
across a transwell membrane.  The nature of the soluble factor was not determined, 
however  the  effect  was  not  neutralised  by  IFN / ,  TNF ,  or  TGF   antibodies 
(Maestroni et al., 1999).  Conditioned media from MSCs has however also been 
shown to lead to the downregulation of NF B and the phosphorylation of inhibitor 
 B  (p-I B ) in hepatoma and breast cancer cells, leading to a decrease in their in 
vitro proliferation (Qiao et al., 2008b).  The same group also delineated a further 
mechanism in a separate study, with the secretion of dickkopf proteins (DKK-1) by 
MSCs leading to the downregulation of the Wnt signalling pathway in breast cancer 
cells and a reduction in their proliferation (Qiao et al., 2008a).   
 
In addition to affecting the behaviour of cancer cells, there is some concern that the 
stem  cells  may  themselves  become  malignant.    Stem  cells  have  the  capacity  for 
unlimited proliferation, making them attractive candidates for malignant change.  In 
vitro passaging of human MSCs has demonstrated the potential for the development 
of karyotype abnormalities (Rubio et al., 2005; Wang et al., 2005), and systemically 
delivered  murine  MSCs  have  produced  sarcomas  (Tolar  et  al.,  2007)  and 
osteosarcomas (Aguilar et al., 2007).  Malignant change of bone marrow-derived 
cells has also been implicated in a murine gastric carcinoma model.  Helicobacter 
felis was used to create a chronic gastric injury, within which a carcinoma developed Chapter 1.  Introduction     
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from bone marrow-derived cells (Houghton et al., 2004).  However, a recent study 
performed  to  assess  the  potential  susceptibility  of  human  bone  marrow-derived 
MSCs to malignant transformation demonstrated no features consistent with this, 
with stable karyotypes and shortening teleomeres over the 44-week culture period, 
and concluded that MSCs remained suitable for cell therapies after in vitro expansion 
(Bernardo et al., 2007).  
 
Despite the concerns, Phase 1 and 2 clinical trials have now been performed, or are 
ongoing, with exogenous MSCs for the promotion of haematopoietic recovery (Koc 
et  al.,  2000),  and  GvHD  (Le  Blanc  et  al.,  2008)  following  BMT,  osteogenesis 
imperfecta  (Horwitz  et  al.,  2002),  ischaemic  cardiac  disease  (Hare  &  Chaparro, 
2008),  Crohn’s  disease  (Weiss  et  al.,  2008),  and  chronic  obstructive  pulmonary 
disease (COPD) (Iyer et al., 2009), and so far neither acute nor long term adverse 
effects have been reported following their infusion. 
 
 
1.6  The combination of TRAIL and MSCs 
 
The  use  of  MSCs  to  deliver  TRAIL  combines  cells  with  the  ability  to  seek  out 
tumours with a protein that is able to specifically kill them.  This combination is 
particularly attractive.  TRAIL has advantages over some of the other anti-cancer 
MSC delivery systems described above, as there appear to be very limited effects on 
non-cancerous tissues.  Furthermore, the targeted delivery of TRAIL with MSCs 
overcomes some of the problems encountered with recombinant TRAIL or TRAIL 
monoclonal  antibodies.    MSC-targeted  TRAIL  is  more  physiological  than  the 
monoclonal antibodies, which rely on the effects of a specific active receptor, and 
has a much better half life and increased delivery across the blood-brain barrier than 
recombinant TRAIL.  In addition the MSCs deliver TRAIL directly to the tumours.   
 
Such  is  the  promise  of  this  technique,  recent  studies  have  now  investigated  the 
combination  of  TRAIL  with  bone  marrow  derived  cells.    In  one  study,  mice 
underwent  a  bone  marrow  transplant  with  constitutively  TRAIL-overexpressing 
donor marrow.  The aim of this study was not specific tumour targeting of TRAIL, Chapter 1.  Introduction     
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however it did show a lack of toxicity of normal cells and a reduction of syngeneic 
tumour growth in vivo (Song et al., 2006).  Another group used adenoviruses to 
produce transient expression of TRAIL in CD34
+ bone marrow cells.  These cells 
were  selected  because  of  their  ability  to  interact  with  endothelial  cells  and 
demonstrated an improved survival in lympho-haematopoietic tumours (Carlo-Stella 
et al., 2006).  Some very recent work has also looked at combining MSCs with 
TRAIL.    These  studies  demonstrated  a  decreased  tumour  growth  following 
administration of TRAIL-expressing MSCs in glioma (Kim et al., 2008; Sasportas et 
al., 2009) and subcutaneous tumour models (Mohr et al., 2008), however all of these 
studies used direct intratumoural MSC administration to demonstrate the effect.  The 
ideal  goal  would  be  to  use  systemic  MSC  therapy  for  multiple  tumours  to  fully 
utilise the homing ability of the MSC.  The one study looking at systemic TRAIL-
expressing  MSCs  showed  no  effect  on  a  subcutaneous  colon  cancer  model 
(Luetzkendorf et al., 2009).   
 
 
1.7  Summary 
 
The  possible  use  of  mesenchymal  stem  cells  as  a  cellular  therapy  in  cancer  is 
exciting.  TRAIL is a new molecule with the potential to become a mainstay of 
cancer  therapy.    This  thesis  combines  two  exciting  and  developing  fields  by 
engineering mesenchymal stem cells to express TRAIL in a controlled manner, and 
utilises their ability to incorporate into different tumour models. 
 
 
1.8  Hypothesis 
 
Mesenchymal stem cells will home to cancer.  These cells can be engineered to 
produce  TRAIL,  under  the  control  of  doxycycline,  which  will  cause  cancer  cell 
apoptosis.  This will allow control of tumour growth and metastasis in vivo. 
 
 Chapter 1.  Introduction     
  56 
1.9  Aims 
 
1.  Engineer MSCs to express doxycycline-inducible TRAIL.  
2.  Produce suitable tumour models and establish MSC incorporation into tumours. 
3.  Reduce cancer growth and metastasis with the use of MSC expression of TRAIL.Chapter 2.  Materials and Methods      
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CHAPTER 2.  MATERIALS AND METHODS 
 
 
 
2.1  General chemicals, solvents and plastic ware  
 
All  chemicals  were  of  analytical  grade  or  above  and  were  obtained  from  Sigma 
Aldrich (Poole, UK) unless otherwise stated. All water used for the preparation of 
buffers  was  distilled  and  deionised  (dH2O),  using  a  Millipore  water  purification 
system  (Milipore  R010  followed  by  Millipore  Q  plus;  Millipore  Ltd.,  MA,  US). 
Polypropylene centrifuge tubes and pipettes were obtained from Becton Dickenson 
(Oxford, UK).   
 
 
2.2   Cell Culture 
 
All  sterile  tissue  culture  media,  sterile  tissue  culture  grade  trypsin/EDTA,  tissue 
culture antibiotics and fetal bovine serum (FBS) were purchased from Invitrogen 
(Paisley, UK) unless otherwise stated.  Sterile tissue culture flasks and plates were 
obtained from Nunc (Roskilde, Denmark) unless otherwise stated.  
 
All cells were cultured in Dulbecco’s modified Eagle’s medium (DMEM) with 4mM 
L-Glutamine,  50U/ml  penicillin  and  50µg/ml  streptomycin  and  10%  (v/v)  fetal 
bovine serum (FBS) and incubated at 37°C in a humidified, 5% CO2 atmosphere, 
unless otherwise stated. The serum for all cells transduced with the Tet-on plasmids 
was replaced by Tet-system approved FBS (Clontech, Paris, France).   
 
Hela,  A549,  293T  H357  and  MDAMB231  cells  were  obtained  from  Cancer 
Research UK, London Research Institute (CRUK, London, UK).  Normal primary 
human adult lung fibroblasts were a kind gift from Dr. Robin McAnulty in the host 
laboratory and were cultured in a 10% CO2 atmosphere.  Human adult mesenchymal Chapter 2.  Materials and Methods      
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stem cells were provided through the Tulane Centre for Gene Therapy, MSC cell 
distribution center (LA, US) and cultured in  MEM with 4mM L-Glutamine, 50 
U/ml penicillin and 50µg/ml streptomycin, and 16% (v/v) fetal bovine serum (FBS).  
H357  cells  were  cultured  in  a  1:3  mix  of  Hams  F12  medium  and  DMEM.    In 
addition to FBS, L-Glutamine, and antibiotics, this medium was supplemented with 
10
-10M  cholera  enterotoxin  (ICN  Pharmaceuticals  Ltd.,  Oxon,  UK),  0.5g/ml 
hydrocortisone, 10ng/ml epidermal growth factor, and 5µg/ml insulin.  
 
Media  was  changed  every  3  days.    Cells  were  grown  until  approximately  80% 
confluent and then mobilised by washing with autoclaved phosphate-buffered saline 
(PBS) followed by 18µl/cm
2 of 0.05% trypsin in EDTA.  The H357 cells would not 
detach  efficiently  using  this  technique  and  hence  they  were  washed  and  then 
incubated in Versene for 5 minutes at 37°C before trypsinisation as above.  After 
detachment, cells were passaged into 175 cm
2 tissue culture flasks at ratios of 1:3 to 
1:8 every 3 – 10 days depending on rate of proliferation.  Human adult mesenchymal 
stem cells were plated at 50-100 cells/cm
2 following passage.  All cells were stored 
in liquid nitrogen, in 50% (v/v) medium, 40% (v/v) FBS and 10% (v/v) DMSO, 
except human adult mesenchymal stem cells, which were stored in 65% medium, 
30% FBS, and 5% DMSO.  
 
 
2.3  Mesenchymal stem cells 
 
The human adult mesenchymal stem cells provided from the Tulane Centre for Gene 
Therapy were fully characterised at source.  Nevertheless, key MSC properties were 
reassessed. 
  
 
2.3.1  Differentiation  
Human adult mesenchymal stem cells were differentiated according to previously 
described methods (Pittenger et al., 1999).  The cells were plated in 6-well plates 
until they reached 100% confluency.  The cell culture medium was then removed, Chapter 2.  Materials and Methods      
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the  cells  washed  with  PBS,  and  bone  (cell  culture  medium  containing  10nM 
dexamethasone, 20mM  -glycerolphosphate, 50µM L-Ascorbic acid 2-phosphate) or 
fat  (cell  culture  medium  containing  0.5µM  dexamethasone,  0.5µM 
isobutylmethylxanthine, 50µM indomethacin) differentiation media was added to the 
wells as required.  The cells were washed with PBS and the medium changed every 3 
days for 21 days.  At the end of 21 days, the cells were washed in PBS and fixed in 
neutral buffered formalin.  The bone differentiation plates were then washed in dH2O 
and stained with 1% (w/v) Alizarin Red S, whereas the fat differentiation plates were 
washed with PBS and stained with 0.3% (w/v) Oil-Red-O (both BDH Laboratory, 
Poole, UK).  
  
 
2.3.2  Colony forming ability 
MSC colony forming assays were performed according to the methods described by 
the Tulane Centre for Gene Therapy.  One hundred MSCs were plated on a 10cm 
diameter culture dish and cultured for 14 days.  After this time period, the cells were 
washed with PBS and stained with 3% (w/v) Crystal Violet in 100% methanol for 10 
minutes.    The  number  of  colonies  2mm  or  larger  in  diameter  were  counted  and 
expressed as a percentage of the original 100 cells plated to give the percentage 
colony forming unit. 
 
 
2.4   Side population cells 
 
Hoechst 33342 is a nuclear binding dye that stains all cells.  The side population (SP) 
defines  a  subgroup  of  cells  with  the  ability  to  efflux  this  dye  with  a  multi-drug 
transporter.  
 
 
2.4.1  Side population identification and sorting 
To  identify  the  side  population,  previously  described  protocols  were  followed Chapter 2.  Materials and Methods      
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(Goodell et al., 1996).  H357, MDAMB231, and A549 cells were harvested at full 
confluence,  resuspended  at  1x10
6  cells/ml in  medium,  and  incubated  at  37°C  for 
10 minutes.  Cells were then labelled with 2.5, 5, or 7.5µg/ml Hoechst 33342 for 45, 
60, or 90 minutes at 37°C to determine the required incubation time.  The labelling 
was also repeated in the presence of the multi-drug transporter inhibitor reserpine at 
concentrations of 5µM and 50µM.  The cells were counterstained with 2.5µg/ml 
propidium iodide (PI) to label dead cells, which were excluded from the analysis, 
and  then  placed  on  ice.    They  were  analysed  by  flow  cytometry  on  either  a 
FACSCalibur or LR2 machine (both Becton Dickenson).    Hoechst red and blue 
fluorescence was detected using the UV excitation laser with the 620 long pass and 
440/40 bandpass filters respectively.  PI was detected with excitation by the blue 
(488nm) laser and 610/20 nm filter.  For SP analysis, at least 1 x10
5 total events were 
collected, and all subsequent analysis was performed using FlowJo software (Tree 
Star Inc., OR, US).  The SP was a small subgroup of cells that stained poorly with 
Hoechst and appeared to locate off the side of the main population of cells.  This 
population was lost with the use of reserpine. The optimal staining conditions were 
5µg/ml Hoechst 33342 for 45 minutes and 7.5µg/ml Hoechst 33342 for 60 minutes 
for  the  H357  and  A549  cells  respectively.  Fluorescence-activated  cell  sorting 
(FACS) of the SP and non-SP cells was performed using a MoFlo High-Performance 
Cell Sorter (Dako, Glostrup, Denmark).  
 
 
2.4.2  Colony-forming assays 
Two hundred SP or non-SP H357 cells were seeded per 6-well plate and cultured for 
14 days. Colonies were washed, fixed using 3% (w/v) paraformaldehyde (PFA), and 
stained with Rhodanile Blue overnight.  Colonies were counted using an Olympus 
CK2  inverted  phase-contrast  light  microscope  (Olympus,  Essex,  UK).    A  large 
colony was defined as greater than 32 cells per colony, and abortive colonies were 
defined as colonies that contained fewer than 32 cells according to the previously 
described  system  (Jones  &  Watt,  1993).  In  mitoxantrone  dihydrochloride  dose–
response assays, 200 H357 cells were plated per well of a 6-well plate and cultured 
in the presence of 0, 1, or 10ng/ml of mitoxantrone for 3 days.  The wells were then Chapter 2.  Materials and Methods      
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washed 3 times with PBS and the normal medium replaced. After a further 14 days, 
the cultures were fixed, stained, and counted.  
 
 
2.5  Production of plasmid constructs 
 
2.5.1  Production of TRAIL DNA for plasmid 
E.  coli  bacteria  containing  the  plasmid  (PCMVsport6)  with  full  length  human 
TRAIL  (clone:  IRATp970G0G0955D6)  were  obtained  from  RZPD  (Berlin, 
Germany).  These bacteria were streaked onto an LB agar selection plate containing 
50 g/ml ampicillin, and incubated overnight at 37ºC.  A single colony was picked 
from this freshly streaked selection plate and used to inoculate a 5ml starter culture 
of LB broth (Fisher Scientific, Loughborough, UK) containing 50 g/ml ampicillin.  
This was incubated for 6 hours at 37ºC on an orbital shaker at 220 rpm.  2ml of the 
starter  culture  were  then  transferred  to  200mls  of  LB  broth  containing  50 g/ml 
ampicillin for overnight incubation on the orbital shaker at the same conditions.  The 
plasmid DNA contained within the bacteria in the LB broth was purified using the 
Purelink HiPure Plasmid DNA Maxiprep Kit (Invitrogen) as follows.  Bacteria were 
harvested by centrifugation of the LB broth at 4000g for 10 minutes.  The pellet was 
resuspended in 10mls of resuspension buffer (50 mM Tris-HCl pH8, 10mM EDTA) 
with 20mg/ml RNase A, before mixing with 10mls lysis buffer (0.2M NaOH, 1% 
(w/v) SDS) to release the plasmid from the bacteria.  The cell debris and genomic 
DNA were then precipitated out of solution with 10mls precipitation buffer (3.1M 
potassium  acetate  pH5.5)  and  centrifugation  at  12000g  for  10  minutes.      The 
supernatant  containing  the  plasmid  was  then  passed  through  a  pre-packed, 
equilibrated anion exchange column and the negatively charged phosphates on the 
DNA  backbone  interacted  with  the  positive  charges  on  the  surface  of  the  resin, 
allowing the removal of RNA, proteins, carbohydrates and other impurities with the 
wash buffer (0.1M sodium acetate pH5, 825mM NaCl).  The plasmid DNA was 
eluted from the column under high salt conditions, with the elution buffer (100mM 
Tris-HCl pH8.5, 1.25M NaCl) and precipitated by centrifuging at 15000g for 30 
minutes at 4ºC in 10.5mls isopropanol.  The plasmid DNA was then washed with Chapter 2.  Materials and Methods      
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70% (v/v) ethanol, recentrifuged at 15000g for 5 minutes and resuspended in 200  l 
of TE buffer (10mM Tris-HCl pH8, 0.1mM EDTA).  
 
The  purified  DNA  was  diluted  and  quantified  by  using  an  Ultrospec  3000 
spectrophotometer (GE Healthcare, Amersham, UK) to measure the UV absorbance 
at 260nm (A260).  The yield of DNA ( g/ml) was calculated by A260 x 50 x dilution 
factor, which is based on the assumption that A260 = 1 for a 50 g/ml solution.  
 
This DNA was then used as a template for PCR reactions. 
 
 
2.5.1.1 PCR conditions 
PCR conditions were optimised using a range of magnesium concentrations (2.5-
4mM) and annealing temperatures (56-60ºC).  The optimal conditions for the TRAIL 
DNA were 20ng of plasmid DNA in a total of 25 l of PCR reaction mix (final 
concentrations 3mM MgCl2, 0.4 M each of forward and reverse primers, 1 U/ml 
Taq  DNA  polymerase,  200 M  deoxyribonucleotide  triphosphate  (dNTP),  1x 
NH4SO4 buffer in distilled and deionised water (ddH20); all reagents from Bioline, 
London, UK). The PCR microtubes were covered and placed in a pre-programmed 
tetrad thermocycler (MJ Research, CA, USA). The thermocycling conditions used 
were an initial denaturing cycle (94°C, 2mins) followed by 30 cycles of denaturing, 
annealing and extension (94°C, 45 secs; 56°C, 45 secs; 72°C, 1 min) and a final 
cycle of extension (72°C, 2 mins).  The primers were designed to ensure that the 
DNA sequence encoding the full length TRAIL ((flTRAIL); amino acids 1-281) and 
the extracellular portion of TRAIL (‘soluble TRAIL’; sTRAIL) (amino acids 114-
281) were flanked by the restriction enzymes Mlu1 and BstB1 at the 5’ and 3’ ends 
respectively (Table 2.1, Figure 2.1). 
 
 Chapter 2.  Materials and Methods      
  63 
Primer  Nucleotide sequence 
 
 
5’ flTRAIL  5’-GTACGCGTGCCACCATGGCTATGATGGAGGTCCAGG-3’ 
 
3’ flTRAIL  5’-GTCGTTCGAATTAGCCAACTAAAAAGGCC-3’  
 
5’ sTRAIL  5’-GTACGCGTGCCACCATGGTGAGAGAAAGAGGTCCTCAG-3’ 
 
3’ sTRAIL    5’-GTCGTTCGAATTAGCCAACTAAAAAGGCC-3’ 
 
 
 
Table 2.1  Primers used to flank full length (fl) and soluble (s) TRAIL with Mlu1 and 
BstB1 restriction enzymes. 
 
 
Gel separation electrophoresis was used to confirm the products were of the expected 
size  (flTRAIL  864  base  pairs  (bp),  sTRAIL  528  bp).    The  gel  was  prepared  by 
dissolving 1.5% agarose (w/v) in 100mls 1 x TBE (0.045 M Tris-Borate, 0.001M 
EDTA, pH8). Ethidium bromide was added to the gel at a final concentration of 
0.5µg/ml). The gel, once solidified, was placed in a gel tank filled with 1 x TBE 
running buffer.  2µl of 5 x loading buffer (5% Orange G (w/v) in glycerol) was 
mixed with 8µl of each PCR product and run on a lane of the gel. A DNA molecular 
marker (Marker VIII, 0.25µg/ml, Boehringer, Mannheim, Germany) was also used. 
The gel was run for 35 minutes at 80 volts. The DNA bands were then visualised 
using  a  UV  transilluminator  (FLA-3000,  Fuji,  Bedford,  UK)  and  Syngene  Gene 
Genius Bio-imaging system (Synoptics, MD, US). 
 
After confirmation that the products were of the correct size, the DNA from the PCR 
was purified using the QIAquick PCR Purification Kit (Qiagen, Crawley, UK).  The 
PCR mix was diluted 1:6 into Buffer PBI, which has a high salt content and allows 
the DNA to absorb to the silica membrane of the spin columns.  These were then 
centrifuged at 16200g for 1 minute, washed with 750  l of buffer PE and centrifuged 
twice more for 1 minute to remove the other impurities such as primers and enzymes 
from the mix.  The DNA was then eluted with 10 l ddH20, and the yield reassessed 
by measuring the absorbance at 260nm as above. Chapter 2.  Materials and Methods      
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Figure 2.1  The sequence of full length TRAIL containing the restriction enzymes Mlu1 
and BstB1 
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2.5.2  Production of lentiviral backbone for plasmid 
The  lentiviral  plasmid  vector  carrying  the  Tetracycline  (Tet)-inducible  system 
(Figure 2.2A, a kind gift from A. Thrasher, London, UK) was used as a backbone for 
the incorporation of TRAIL DNA.  This plasmid had been produced from a pRRL-
derived self inactivating backbone into which the Tet-on system elements had been 
introduced,  and  had  shown  to  have  low  background  activity  and  high  levels  of 
induction over months in vitro and in vivo (Barde et al., 2006).   
 
The TRAIL gene that had been cloned as above could have been directly inserted 
into  this  lentiviral  backbone.    However,  Dr.  Susana  Aguilar  had  also  used  this 
lentiviral plasmid vector for the addition of a different insert, the human dickoff 
(DKK) gene.  With this gene, internal ribosome entry site-green fluorescent protein 
(IRES-GFP) had also been added to the lentiviral plasmid vector, which would be a 
useful addition to my plasmid, allowing readout of the TRAIL transgene expression.  
In order to insert DKK and IRES-GFP into the lentiviral plasmid backbone, the DKK 
gene  had  first  been  cloned  into  the  pENTR1A  vector  tool  containing  IRES-GFP 
(Figure  2.2B).    This  had  been  done  by  flanking  the  DKK  with  the  restriction 
enzymes Sal1 (at the 5’ end) and BamH1 (at the 3’ end) by PCR amplification of 
DKK, using the primers in Table 2.2.   
 
 
Primer  Nucleotide sequence 
 
 
5’ DKK  5’-ACGCGTCGACATGATGGCTCTGGGCGCAGC-3’ 
 
3’ DKK  5’- ACGCGGATCCTTACGTAGAATCGAGACCGA -3’   
 
 
 
Table 2.2  Primers used to flank DKK with Sal1 and BamH1 restriction enzymes to allow 
entry into the pENTR1A plasmid adjacent to IRES-GFP . 
 
 
The DKK gene was then inserted into the pENTR1A vector adjacent to the IRES-
GFP with the Sal1 and BamH1 restriction enzymes. The DKK-IRES-GFP section 
was  then  flanked  by  Mlu1  and  EcoRV  restriction  enzymes  by  further  PCR Chapter 2.  Materials and Methods      
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amplification, using the primers in Table 2.3, in order to position it into the Tet-
inducible lentiviral plasmid  
 
 
Primer    Nucleotide sequence 
 
 
5’ DKK-IRES-GFP  5’-ACGCACGCGTATGATGGCTCTGGGCGC-3’ 
 
3’ DKK-IRES-GFP  5’-ACGCGATATCTCGAGTGCGGCCGCTTTA -3’   
 
 
 
Table  2.3    Primers  used  to  flank  DKK-IRES-GFP  with  Mlu1  and  EcoRV  restriction 
enzymes to allow entry into the Tet-inducible lentiviral plasmid. 
 
 
This section was then cut out of this vector and positioned into the lentiviral plasmid 
using  the  Mlu1  and  Eco  RV  restriction  sites,  which  also  removed  the  alkaline 
phosphatase section from the original lentiviral plasmid vector (Figure 2.2C).  This 
produced an intermediate plasmid, lentivirus plasmid DKK, which I directly worked 
with. 
 
Unique restriction enzyme cutting sites (Mlu1, BstB1) that flanked the DKK gene 
were  found  on  this  intermediate  plasmid  using  NEBcutter  v2.0 
(http://tools.neb.com/NEBcutter2/index.php) allowing the DKK gene to be removed 
and the TRAIL gene to be inserted whilst retaining the useful IRES-GFP readout 
construct (Figure 2.2D,E). 
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Figure 2.2  Production of plasmid constructs.  
A) Original tetracycline (Tet)-inducible lentivirus, B) pENTR1A vector containing IRES-
GFP,  used  for  cloning  Dickoff  (DKK)  next  to  IRES-GFP.    C-E)  simplified  plasmid 
manipulation, C) alkaline phosphatase (ALP) section cut out of Tet-inducible lentivirus with 
Mlu1/EcoRV and replaced with DKK-IRES-GFP.  D) DKK section cut out of Tet-inducible 
lentivirus with Mlu1/BstB1 and replaced with TRAIL (soluble or full length).  E) Final Tet-
inducible TRAIL lentivirus plasmid with GFP readout. WPRE: Woodchuck hepatitis virus 
responsive  element,  cPPTcts:  central  polypurine  tract  with  termination  sequence,  CMV: 
cytomegalovirus, IRES: internal ribosome entry site, GFP: green fluorescent protein, HIV: 
human immunodeficiency virus. Chapter 2.  Materials and Methods      
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2.5.2.1 Restriction enzyme digestion 
All restriction digests were performed with enzymes and buffers supplied by New 
England  Biolabs  ((NEB),  Hitchin,  UK),  unless  otherwise  stated.    The  purified 
flTRAIL  and  sTRAIL  DNA  flanked  by  Mlu1  and  BstB1  products  produced  in 
section 2.2.1.1 were digested sequentially with the restriction enzymes BstB1 (1x 
Buffer 4, 1000 U/ml BstB1 in 100µl ddH20 for 1 hour at 65ºC) and Mlu1 (1x Buffer 
3,  500  U/ml  Mlu1  in  100µl  ddH20  for  1  hour  at  37ºC)  with  DNA  purification 
between the 2 reactions using the QIAquick PCR Purification Kit as described above. 
 
The intermediate lentivirus plasmid DKK was also digested sequentially with BstB1 
and Mlu1.  To stop religation of single cut vectors, dephosphorylation of the 5’ ends 
was  performed  using  260U/ml  alkaline  phosphatase,  calf  intestinal  (CIP)  and  1x 
buffer 3 (both from NEB) in ddH20 for 90 minutes at 37ºC.  The product from the 
digest and dephosphorylation reactions was then run on a 1% (w/v) agarose gel using 
the  HyperLadder1  molecular  weight  marker  (Bioline).    A  1%  (instead  of  1.5%) 
agarose gel was used to allow the larger products to run efficiently.   An ultraviolet 
lamp  was  used  to  demonstrate  the  823bp  DKK  gene  and  the  separate  9350bp 
lentiviral plasmid.  The lentiviral plasmid was cut out of the gel and a QIAquick Gel 
Extraction  Kit  (Qiagen)  was  used  to  isolate  and  purify  the  DNA  for  the  Tet-on 
lentiviral plasmid backbone, which was cut at Mlu1 and BstB1 restriction sites.  The 
gel segment containing this lentivirus plasmid backbone was weighed and dissolved 
in Buffer QG (300 l of added for each 100mg of gel) at 50ºC.  Isopropanol (100 l of 
added for each 100mg of gel) was then added and the solution placed in a spin 
column, where the DNA adsorbed to the silica membrane.  These columns were then 
centrifuged  at  16200g  for  1  minute,  washed  with  500   l  of  buffer  QG  and 
recentrifuged.  750  l of buffer PE was then added to the column and centrifuged 
twice more for 1 minute to ensure removal of the impurities.  The DNA was then 
eluted with 10 l ddH20 and the yield reassessed by measuring the absorbance at 
260nm as above.  This construct was then used for the incorporation of the TRAIL 
DNA. 
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2.5.3  Production of the flTRAIL, sTRAIL, and empty Tet-inducible plasmid.  
The soluble and full length TRAIL inserts were separately ligated with the lentiviral 
plasmid vector at room temperature for 1 hour using 20000U/ml T4 DNA Ligase and 
2 l DNA T4 Ligase Reaction Buffer (both from NEB) made up to a reaction volume 
of 20 l with ddH20. Molar ratios of 0:1, 1:1, 5:1,and 10:1 (insert:vector) were used 
in separate reactions with 50ng (10 l) of the vector in each reaction.  The ligation 
mixtures  were  transformed  into  library  efficient  E.  coli  DH5   competent  cells 
(Invitrogen) by mixing 50 l of the competent cells with 4 l (10ng plasmid) of the 
ligation mix.  This mixture was incubated on ice for 30 minutes, followed by 42ºC 
for 45 seconds and ice for 2 minutes.  It was then added to 900 l S.O.C. medium 
(Invitrogen) and incubated at 37ºC, 220rpm for 1 hour in an orbital shaker.  The 
solution  was  then  centrifuged  at  800g  for  3  minutes  and  the  pelleted  bacteria 
resuspended in 200 l S.O.C. medium before being plated on ampicillin (50 g/ml) 
impregnated LB agar plates and incubated at 37ºC overnight.  Individual colonies 
were apparent following incubation from all the ligation mixtures apart from the 
negative control (0:1; insert:vector).   
 
Before using these colonies to produce large quantities of sTRAIL and flTRAIL 
lentivirus plasmid with a maxiprep procedure as in 2.5.1, several of the individual 
bacterial colonies were tested for the presence of the TRAIL containing plasmids by 
colony PCR and a faster miniprep procedure.  Colony PCR involved the same PCR 
conditions as in section 2.5.1.1, with a loop used to transfer a small amount of an 
individually marked bacterial colony to a total of 25 l of PCR reaction mix (final 
concentrations 3mM MgCl2, 0.4 M each of forward and reverse primers, 1 U/ml 
Taq  DNA  polymerase,  200 M  deoxyribonucleotide  triphosphate  (dNTP),  1x 
NH4SO4 buffer in ddH20).  The majority of colonies produced TRAIL products on 
this PCR suggesting the incorporation of the TRAIL lentiviral plasmid.  Selections 
of  these  colonies  were  then  used  to  inoculate  5ml  starter  cultures  of  LB  broth 
containing 50 g/ml ampicillin.  These were incubated for 6 hours at 37ºC on an 
orbital  shaker  at  220  rpm,  before  1.5mls  were  used  for  a  miniprep  using  the 
FastPlasmid  mini  kit  (Eppendorf,  Cambridge,  UK).    The  1.5  ml  culture  was 
centrifuged at 16200g to pellet the bacteria, which was resuspended in 400 l of an 
ice cold lysis solution containing a mixture of enzymes and detergents that serves to Chapter 2.  Materials and Methods      
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resuspend the bacterial pellet and lyse bacteria, denature and solubilise the cellular 
components,  degrade  RNA,  and  trap  DNA.    The  lysate  was  then  added  to  spin 
columns  and  centrifuged  at  16200g  for  1  minute  prior  to  the  addition  of  400 l 
alcohol based-wash buffer and 2 further centrifuges.  The DNA was then eluted in 
50 l of TE buffer (10mM Tris-HCl pH8.5, 0.1mM EDTA).  The purified plasmid 
DNA  was  quantified  by  measuring  the  UV  absorbance  at  260nm.    A  miniprep 
produces significantly less purified plasmid than the maxiprep, however it is a much 
quicker procedure and was used to test the accuracy of the plasmid DNA before the 
maxiprep was performed.   
 
To confirm that the DNA product from the minprep was correct, the plasmid DNA 
was cut with restriction enzymes, run on a 1% agarose gel and the bands visualised 
using  a  UV  transilluminator,  as  previously.    In  order  to  distinguish  between  the 
planned TRAIL lentivirus plasmid and the original intermediate plasmid with DKK 
inserted,  restriction  enzyme  cutting  sites  that  cut  the  lentivirus  plasmid  TRAIL 
differently from the original intermediate lentivirus plasmid DKK were found on 
using NEBcutter v2.0.  The restriction enzyme Xba1 (Fermentas, Ontario, Canada) 
was able to cut the TRAIL lentivirus plasmid twice leaving 2 products of 808 base 
pairs (bp) and either 9401bp (flTRAIL) or 9288bp (sTRAIL), whereas the enzyme 
cut the intermediate lentivirus plasmid DKK three times producing 7405bp, 808bp, 
1960bp  fragments  (Figure  2.3A,B).    This  enzyme  (1x  Buffer  Y
+/Tango/BSA, 
75U/ml Xba1) was added to 0.5 g DNA from the miniprep, made up to 20µl in 
ddH20, and incubated overnight at 37ºC before running on the agarose gel (Figure 
2.3C).  
 
The remainder of the 5ml LB starter cultures that had produced the correct flTRAIL 
and sTRAIL lentiviral plasmid products on miniprep were then used to inoculate 
200mls of LB broth containing 50 g/ml ampicillin for overnight incubation on the 
orbital  shaker  prior  to  purification  using  the  Purelink  HiPure  Plasmid  DNA 
Maxiprep  Kit  as  described  earlier  (2.5.1).    After  production,  purification  and 
quantification of the sTRAIL and flTRAIL lentivirus plasmids, the validity of the 
constructs were confirmed by DNA sequence analysis (Cogenics, Essex, UK).   Chapter 2.  Materials and Methods      
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Figure  2.3    Xba1  digestion  distinguishes  the  TRAIL  lentivirus  plasmid  from  the 
intermediate DKK lentivirus plasmid. 
A-B)  Xba1  restriction  enzyme  cutting  sites  on  A)  Intermediate  DKK  inducible  lentivirus 
plasmid  and  B)  full  length  TRAIL  (flTRAIL)  inducible  lentivirus  plasmid.    C)  UV 
visualisation of Xba1 cut plasmid on a 1% agarose gel. The DKK lentivirus plasmid is cut 3 
times  with  Xba1  and  produces  10173bp  (uncut),  9365bp,  1960bp,  and  808bp  segments, 
whereas the flTRAIL lentivirus plasmid can be distinguished from this by being cut only 
twice  and  producing  9401bp  and  808  bp  segments.    The  uncut  flTRAIL  vector  (uncut) 
(10209bp) is also shown as a negative control.  DNA molecular weight marker VIII (VIII) 
and hyperladder I (HLI) molecular weight markers were used. Chapter 2.  Materials and Methods      
  72 
An  empty  vector  lentivirus  plasmid  containing  IRES-GFP,  but  neither  DKK  nor 
TRAIL had been produced and sequenced by Dr. Susana Aguilar.  Briefly, IRES-
GFP flanked by the restriction enzymes Mlu1 and EcoRV was produced by PCR of 
the pENTR1A plasmid, using the primers in Table 2.4.  The PCR product was then 
ligated into the lentiviral plasmid using the Mlu1 and EcoRV restriction sites in the 
same way as the DKK had been introduced (section 2.5.2).   
 
 
Primer  Nucleotide sequence 
 
 
5’ IRES-GFP  5’-ACGCACGCGTGCCCCTCTCCCTCCC-3’ 
 
3’ IRES-GFP  5’-ACGCGATATCTCGAGTGCGGCCGCTTTA-3’   
 
 
 
Table 2.4  Primers used to flank IRES-GFP with Mlu1 and EcoRV restriction enzymes to 
allow entry into the Tet-inducible lentiviral plasmid. 
 
 
In  order  to  amplify  the  amount  of  this  empty  vector  lentivirus  plasmid,  it  was 
transformed  into  DH5   E. coli,  streaked  onto  LB  agar  plates  overnight  and  the 
colonies  used  to  inoculate  LB  broth  as  a  substrate  for  maxiprep  production  and 
purification, as with flTRAIL and sTRAIL lentivirus plasmids.  The plasmid product 
(0.5 g)  was  then  checked  by  cutting  out  the  IRES-GFP  section  (1331bp)  with 
EcoRV  and  Mlu1  restriction  enzymes  (1x  buffer  3,  500  U/ml  Mlu1,  1000U/ml 
EcoRV, 100µg/ml BSA, made up to 20µl in dH2O and incubated at 37°C for 1 hour) 
and demonstrating the correct product sizes (1331bp and 7969bp) after running on a 
1% agarose gel. 
 
At the end of the maxipreps, between 1.5 and 2mg of validated flTRAIL, sTRAIL, 
and empty lentivirus plasmid were produced and stored at -20°C for further use. 
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2.6  Plasmid introduction into cells 
 
2.6.1   Transient transfection 
Transient transfection was used to assess the function of the flTRAIL, sTRAIL and 
empty  lentivirus  plasmids  within  cells  using  a  simple  and  rapid  technique.  
Transfection  describes  the  introduction  of  nucleic  acids  into  cells  by  non-viral 
methods.  It typically involves the opening of transient pores in the cell membranes 
to allow the uptake of the plasmid.  The cationic polymer polyethylenimine (PEI), 
which  binds  to  the  negatively  charged  DNA  and  is  taken  up  in  the  cell  by 
endocytosis, and Fugene (Roche Diagnostics Ltd, Burgess Hill, UK), a blend of non-
liposomal lipids, were used for transfection    
 
For PEI-based transfection, 1x10
6 293T cells were seeded in a 6-well plate. The 
following  day,  at  80-90%  cell  confluence  75µl  Optimem  plus  3-15µl  of  10mM 
polyethylenimine  (PEI)  was  added  to  a  mixture  of  75µl  Optimem  and  3µg  of 
plasmid.  After 20 minutes the solution was added to the 6-well plate and they were 
incubated at 37°C for 4 hours.  The medium was then replaced with normal medium 
and 10µg/ml doxycycline.  The success of the transient transfection procedure was 
then assessed by the proportion of GFP-positive cells on flow cytometry.  Using this 
assessment, 9µl of PEI in the above reaction was found to be optimal. 
 
For Fugene-based transfection, 3x10
5 293T cells were seeded in a 6-well plate. The 
following day, 2µg of plasmid was added to 150µl Optimem plus 6µl of Fugene and 
after 20 minutes, the solution was added to the 50-60% confluent 293T cells. The 
cells were incubated at 37°C for 4 hours and the medium was then replaced with 
normal medium and 10µg/ml doxycycline.  The success of the transient transfection 
procedure  with  this  technique  was  similarly  assessed  by  GFP  expression.    This 
technique was found to be less successful than the PEI-based transfection, which was 
therefore used for further experiments and lentivirus production.  
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2.6.2   Stable transduction   
The advantage of transient transfection is the ability to assess the function of the 
plasmid within cells using a simple and rapid technique.  However, the DNA is not 
inserted into the nuclear genome and is hence lost after cell division.  For this project, 
the  stable  and  long-term  expression  of  the  transgene  was  necessary.    The 
transduction of cells generally describes the introduction of nucleic acids into cells 
by viral methods and the use of a lentivirus enables incorporation of the DNA into 
the host cell’s genome with stable transgene expression.   
 
 
2.6.2.1 Production of lentivirus 
Lentiviral vectors, pseudotyped with the vesicular stomatitis G protein (VSV-G), 
were produced by transfecting 293T cells with the plasmids, as follows.  Twelve 
million 293T cells were seeded in a 175 cm
2 flask.  The following day, at 80-90% 
cell confluence, the medium was exchanged for 15mls of Optimem plus 10mls of a 
solution made by mixing 3.6ml PEI and 56.4ml Optimem, to 600µg TRAIL plasmid, 
450µg of the packaging construct pCMV-dR8.74, 150µg of a plasmid producing the 
VSV-G envelope (pMD.G2) and 60mls Optimem (both pCMV-dR8.74 and pMD.G2 
were a kind gift from A. Thrasher, UCL, London, UK).  
 
The cells were incubated at 37ºC for 4 hours and the medium was then exchanged 
for the normal cellular medium. The following day, the medium was exchanged for 
17ml  of  normal  medium  into  which  the  lentivirus  was  secreted.    This  medium 
containing the virus was collected and purified by centrifugation at 2500rpm at 4ºC 
to remove cell debris, and then filtered through a 0.45µm membrane.  The virus was 
subsequently concentrated by ultracentrifugation at 18000 rpm at 4ºC (SW28 rotor, 
Optima LE80K Ultracentrifuge, Beckman, High Wycombe, UK).  The viral pellet 
was  resuspended  in  50µl  PBS,  centrifuged  at  4000rpm  4ºC  and  the  supernatant 
containing the virus stored at -80ºC before use.      
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2.6.2.2 Titration of lentivirus 
The amount of collected virus generated by the above method was quantified by 
titrating different dilutions of the virus with 293T and Hela cells.  Fifty thousand 
cells were seeded onto each well of a 12-well plate.  The following day at 30-40% 
cell confluency, the medium was exchanged for medium containing virus dilutions 
of  1/100,  1/1000,  1/10000,  and  1/100000  and  4µg/ml  of  polybrene,  which  is  a 
cationic polymer enabling efficient cellular uptake of the virus.  The following day, 
the medium was replaced with normal medium and 10µg/ml doxycycline.  After a 
further 48 hours, the cells were trypsinised and the percentage of GFP-positive cells 
at each viral dilution assessed by flow cytometry.  The viral titre was calculated in 
virus particles/ml as below: 
 
 
Viral titre =% of GFP cells x dilution of virus x number of cells infected (i.e. 50000) 
               100 
 
 
2.6.2.3 Stable transduction of MSCs 
Human mesenchymal stem cells were transduced with the lentivirus when 30-40% 
confluent in a similar manner to the 293T and Hela cells above.  The amount of virus 
used was expressed as the number of virus particles per MSC.  This is defined as the 
multiplicity  of  infection  (MOI).    For  MSC  transduction,  an  MOI  of  10  (in 
accordance with previous reports (Aguilar et al., 2007; Chan et al., 2005)) and 20 
was used.  The transduced MSCs were then cultured with 10µg/ml doxycycline and 
the success of the transduction quantified by the percentage of GFP-positive MSCs 
on flow cytometry assessment. 
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2.7  In vitro TRAIL transgene expression 
 
2.7.1  Antibodies 
The primary antibodies used for flow cytometry were a rabbit polyclonal antibody to 
TRAIL (H257, sc-7877, 1µg/ml), and a mouse monoclonal antibody to TRAIL (2E5, 
sc-51709, 2.5µg/ml), both from Santa Cruz Biotechnology (CA, US).  
 
The primary antibodies used for western blotting were a rabbit polyclonal antibody 
to TRAIL (H257, sc-7877, 1µg/ml) and a mouse monoclonal antibody to  -actin (sc-
130300, 0.2µg/ml), both from Santa Cruz Biotechnology.  
 
 
2.7.2  Flow cytometry 
Flow cytometric analysis was performed on either a FACSCalibur or LR2 machine.  
Electronic  compensation  of  the  recording  was  performed  to  minimise  overlap  of 
emission spectra. Samples were gated according to forward scatter and side scatter 
characteristics to exclude cell debris and cell doublets. A minimum of 1x10
5 gated 
events was collected for each sample analysed. Sample analysis and quantitation was 
performed using FlowJo Software. 
 
GFP fluorescence was detected using a blue excitation laser (488nm) and 530/30 nm 
band pass filter.  The secondary antibody AlexaFluor 647 binding was detected using 
a red excitation laser (635nm) and 660/20 nm band pass filter.  Dead cells were 
detected with 2.5µg/ml PI or 1µg/ml 4',6-diamidino-2-phenylindole (DAPI).  PI was 
detected with the blue laser and 610/20 nm filter, whereas DAPI detection utilised 
the ultraviolet laser (355nm) for excitation and a band pass filter at 440/40 nm.  DiI-
labelling  (Invitrogen)  of  cells  was  detected  using  the  blue  excitation  laser  and 
575/26nm band pass filter.   TRAIL surface antibody detection was performed by 
washing  cells  with  PBS  followed  by  mobilisation  with  300µl  0.05%  trypsin  in 
EDTA.  Cells were pelleted by centrifugation (300g, 5 mins) and then resuspended 
in 100 l of PBS with the primary antibody for 30 minutes at room temperature.  The Chapter 2.  Materials and Methods      
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cells were washed and resuspended in 100 l of PBS with a AlexaFluor 647 goat 
anti-mouse  or  goat  anti-rabbit  secondary  antibody  for  30  minutes  at  room 
temperature, before washing and resuspending in 500 l of PBS. 
 
 
2.7.3  Western blots 
2.7.3.1 Sample collection and preparation 
Cells were grown in 12-well plates.  Supernatants were collected and centrifuged 
(300g,  5mins)  to  remove  cells  and  cell  debris  and  then  stored  prior  to  western 
blotting at -80°C.  Cell lysates were obtained by lysing the cells with 100 l RIPA 
buffer  (1%  (v/v)  Igepal  Ca-630,  0.5%  (w/v)  Sodium  deoxycholate,  0.1%  (w/v) 
sodium  dodecyl  sulphate  (SDS))  supplemented  with  complete  protease  inhibitor 
cocktail (Complete-mini; Roche Diagnostics Ltd.) and left to stand for 5 minutes. 
The cell layer was subsequently scraped with a pipette tip and the lysate centrifuged 
(16200g,  10  mins,  4°C)  to  remove  insoluble  cell  debris.    The  supernatant  was 
collected and the DNA sheered by passing the sample 15 times through a 25G needle.  
Samples were stored at -80 °C. 
 
 
2.7.3.2 BCA protein assay 
To  ensure  equivalent  amounts  of  protein  were  loaded  for  the  different  samples, 
protein  concentration  of  cell  lysates  or  supernatants  was  assessed  using  the 
bicinchoninic acid (BCA) protein assay (Thermo Fisher Scientific, IL, US).  20µl of 
each sample or standard (bovine serum albumin (BSA)) was added to 200µl of BCA 
working reagent in a 96-well plate. The plate was agitated on a plate shaker for 30 
seconds, and then incubated at 37°C for 30 minutes prior to reading the absorbance 
at  550nm  on  a  Titertek  Multiscan  MCC/340  plate  reader  (Labsystems,  Turku, 
Finland).  The absorbance of the samples was compared to the standards (of known 
protein concentration) to ascertain the sample protein concentration.  
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2.7.3.3 Western blotting procedures 
Samples were diluted in dH2O to equivalent protein concentrations and mixed with 
5x Laemmli Buffer (3.125mM Tris-base pH 6.8, 10% (w/v) SDS, 20% (v/v) glycerol, 
50mM Dithiothreitol (DTT), in dH2O with bromophenol blue).  The samples were 
then incubated on a heat block for 10 min at 110°C and placed on ice prior to loading 
on  the  western  blot  gel.    A  10%  SDS-polyacrylamide  resolving  gel  (10%  (v/v) 
acryamide mix (0.27% bis-acrylamide)) (Geneflow Ltd., Fradley, UK), 0.04% (v/v) 
tetramethylethylenediamine (TEMED), 0.1% (w/v) ammonium persulphate (APS), 
0.1% (w/v) SDS, 0.3M Tris-base (pH8.8), in dH2O) with a 2.5% stacking gel (2.5% 
acrylamide mix, 0.05% TEMED, 0.05% APS, 0.05% SDS, 0.06M Tris (pH6.8), in 
dH2O) was prepared and 25µl samples added to the wells. 5µl of SeeBlue® Plus 2 
protein  ladder  (Invitrogen)  was  also  loaded.  The  gel  was  run  at  100V  in 
Tris/Glycine/SDS  running  buffer  (0.25M  Tris-base,  1.92M  Glycine,  1%  SDS,  in 
dH2O). 
 
Following  separation,  the  gel  was  removed  from  the  cassette  and  proteins  were 
transferred onto a Hybond-ECL nitrocellulose membrane (GE Healthcare), using a 
horizontal semi-dry transfer method (NovaBlot; Pharmacia LKB, Uppsala, Sweden) 
with  transfer  buffer  (25mM  Tris-base,  0.2M  glycine,  1%  (w/v)  SDS,  20%  (v/v) 
methanol in dH2O) at a current of 0.8mA per cm
2 of gel, for 1 hour. The quality of 
protein  transfer  was  assessed  by  briefly  staining  the  membrane  with  0.1%  (w/v) 
PonceauS solution and then the blot was placed in Tris-buffered saline (TBS)(20mM 
Tris-base, 150mM NaCl, pH7.4) containing 0.1% (v/v) Tween20 (TBST).  
 
Blots were incubated with blocking buffer containing 5% (w/v) non-fat dry milk in 
TBST for 1 hour.  Blots were then incubated with primary antibodies in 5% (w/v) 
BSA in TBST overnight at 4°C. All blots were then washed 3 x 5 mins in TBST and 
incubated for 1 hour at room temperature with HRP-conjugated secondary antibody. 
After further washing in TBST, 2ml of ECL reagent (GE Healthcare) was applied to 
the  membrane  and  incubated  for  1  minute.  Excess  reagent  was  drained  off  and 
immunoreactive  bands  were  visualized  by  exposing  the  membrane  to 
autoradiography film (Hyperfilm, GE Healthcare), for between 30 seconds and 5 
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2.7.4  ELISA assay 
ELISAs  were  performed  using  the  human  TRAIL  Quantikine  ELISA  kit  (R&D 
systems, Abingdon, UK).  Cell supernatants were prepared by removing particulates 
by centrifugation (300g, 5 mins).  Cell lysates were prepared by suspending cells in 
the supplied cell lysis buffer at 37 °C for 30 minutes at 1 x 10
7 cells/ml, followed by 
centrifugation (500g, 15 mins).  Samples (50µl) containing equal amounts of protein 
(assessed  by  the  BCA  assay)  were  added  to  100µl  of  assay  diluent  RD1S  and  
incubated at room temperature onto preprepared ELISA plates for two hours on a 
horizontal orbital microplate shaker set at 500rpm.  The plates were washed 4 times 
with wash buffer and 200µl TRAIL conjugate added to the wells for 2 hours at room 
temperature on the orbital shaker.  The plates were then rewashed 4 times and 400µl 
of a colour substrate solution added before they were incubated in the dark.  The 
reaction was stopped after 30 minutes with the addition of 50µl stop solution.  The 
absorbance at 450nm was determined on a Titertek Multiscan MCC/340 plate reader 
and  compared  to  known  concentrations  of  recombinant  TRAIL  (R&D  systems), 
which  were  used  to  produce  a  standard  curve,  to  ascertain  the  TRAIL  protein 
concentration  in  the  samples.  The  readings  at  540nm  were  subtracted  from  the 
450nm values to correct for optical imperfections in the plate.  
 
 
2.8  In vitro TRAIL transgene functional assessment 
 
2.8.1  Agonists and antibodies 
For experiments assessing the pharmacological modulation of coculture experiments, 
the following compounds were used; the pan-caspase inhibitor zVADfmk at 1µg/ml, 
a soluble recombinant TRAIL at 200ng/ml and a neutralising TRAIL antibody at 
250ng/ml (the latter two from R & D Systems).   
 
2.8.2   Coculture experiments 
Human  MSCs  transduced  with  the  full  length  TRAIL  plasmid  (MSCFLT)  were 
plated  at  different  ratios  with  cancer  cells.    A  total  of  1x10
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together in 2ml of the normal MSC medium in each 6-well plate.  The following day, 
10µg/ml doxycycline, or other active agents, were added to the cocultures and left 
for 48 hours.  
 
In  order  to  differentiate  between  cancer  cells  and  MSCFLT,  cancer  cells  were 
stained  with  DiI  before  coculture.    The  cells  to  be  stained  were  collected  at  a 
concentration of 1x10
6/ml in medium without serum and 5µl/ml of DiI was added 
and incubated for 20 minutes at 37ºC.  Following this the cells were washed twice in 
PBS before use.  For the coculture of SP cancer cells and MSCFLTs, the cancer cells 
were stained with DiI as above and then sorted into SP and non-SP populations by 
FACS as previously described.  The freshly sorted SP and non-SP cells were then 
immediately cocultured with the MSCFLT cells. 
 
 
2.8.2.1 Apoptosis assessment  
The apoptosis and death of the cells in coculture were assessed by Annexin V-based 
flow  cytometry.  Media,  including  floating  cells,  was  collected  from  each  well. 
Adherent cells were washed with PBS and mobilised with 300µl 0.05% trypsin in 
EDTA.  All  cells  were  collected  into  centrifuge  tubes  containing  the  previously 
removed  media  and  were  pelleted  by  centrifugation  (300g,  5  mins).  Cells  were 
washed in medium, centrifuged (300g, 5 mins) and then resuspended in 500 l of 
Annexin V binding buffer with 5µl of Annexin V-647 antibody (Invitrogen) for 40 
minutes on ice.  2µg/ml DAPI or 5µg/ml PI was then added to each sample before 
flow  cytometry  analysis.    Annexin  V  is  a  35–36  kDa  calcium-dependent 
phospholipid  binding  protein  that  has  a  high  affinity  for  phosphatidlserine. 
Phosphatidlserine  is  located  on  the  cytoplasmic  side  of  the  cell  membrane, 
inaccessible to cell surface binding proteins, in normal viable cells.   In apoptotic 
cells, it is translocated to the outer plasma membrane, thus exposing it to the external 
cellular environment and allowing binding of Annexin V.   The Annexin V is also 
able  to  pass  through  the  membrane  of  dead  cells  that  have  lost  their  membrane 
integrity and bind to phosphatidlserine in the interior of the cell.  These dead cells 
however  will  also  stain  with  the  cell  impermeant  dead  cell  stains  PI  or  DAPI.  
Consequently, Annexin V
-/DAPI
-  (or PI
-) cells were judged to be viable, Annexin Chapter 2.  Materials and Methods      
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V
+/DAPI
- cells were considered to be undergoing apoptosis, and Annexin V
+/DAPI
+ 
cells were considered late apoptotic or necrotic, and recorded as dead. 
 
 
2.8.2.2 Production of dominant negative FADD cancer cells 
The mechanism of TRAIL induced apoptosis is via the extrinsic apoptotic pathway.  
On  binding  the  ligand,  activation  of  the  TRAIL  receptor  leads  to  recruitment  of 
FADD and caspase 8; the start of the caspase cascade.  In order to demonstrate the 
apoptosis and death caused by the MSCFLT cells was similarly by this mechanism, 
defective FADD constructs were transduced into Hela cancer cells to disrupt the first 
part of the extrinsic apoptosis pathway. 
 
AM12s transduced with dominant negative FADD/GFP (dnFADD) or GFP (empty 
vector)  constructs  were  obtained  as  a  kind  gift  from  Dr.  Sam  Janes  in  the  host 
laboratory.  In brief, the AM12s were produced as follows.  Phoenix packaging cells 
were transduced with a retroviral vector containing dnFADD/GFP or GFP alone, and 
5µg/ml of polybrene.  The confluent Phoenix cells released virus into the culture 
medium.  2.5ml of this medium was collected, filtered through a 0.45µm membrane, 
and added to AM12 cells with 5µg/ml of polybrene.  The AM12 cells had been 
plated at a density of 2x10
5 cells per 100mm
2 dish the previous day.  After culture 
for 12 hours, the medium was replaced with normal medium and the transduced 
AM12 cells were selected in 2.5µg/ml puromycin. 
 
The dnFADD and empty AM12s were grown to 80% confluence.  The medium 
containing the virus was then collected, filtered through a 0.45µm membrane, and 
added to Hela cells (30% confluence) with 5µg/ml polybrene.  After 24 hours, the 
medium was changed to normal Hela medium, the cells were then selected with 
1µg/ml puromycin, and the expression of GFP checked with an inverted-fluorescent 
Axiovert S100 microscope (Carl Zeiss Ltd., Herts., UK).    
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2.8.3  Colony forming ability in coculture 
Two hundred freshly FACS-sorted SP or non-SP H357 cells were seeded per six-
well plate.  MSCFLT cells were separately cultured and their continued proliferation 
prevented by the addition of 4µg/ml mitomycin C for 2 hours before being washed 
with PBS.  Mitomycin C is an inhibitor of DNA synthesis and nuclear division and is 
commonly used to metabolically inactivate feeder cells in the culturing of specific 
cells.  The day after the SP and non-SP cells had been seeded, 5x10
4 mitomycin C-
treated MSCFLT cells were added, with or without 10µg/ml of doxycycline.  The 
use of mitomycin C would prevent the continued growth of the MSCFLT and permit 
SP  and  non-SP  colony  formation.      After  14  days  of  coculture,  colonies  were 
washed, fixed using 3% PFA, and stained with Rhodanile Blue overnight.  Colonies 
were counted as previously described.  
 
 
2.9   In vitro assessment of MSC homing to tumours 
 
2.9.1  Antagonists 
The  neutralising  antibodies  used  for  the  cell  migration  assays  were  a  rabbit  IgG 
antiserum fraction against IL-6 (Sigma, 1- 100 µg/ml), and a goat affinity isolated 
antibody against IL-8 (Sigma, 0.1-10 µg/ml).  
 
 
2.9.2  Cell migration assay 
Migration of MSCs across a transwell was performed to assess in vitro migration, as 
described previously (Nakamizo et al., 2005; Schmidt et al., 2006; Xin et al., 2007).  
1.5x10
5  cancer  cells  or  293T  cells  were  plated  in  800µl  of  normal  medium 
containing either 0% or 10% FBS on the bottom well of a transwell plate (8µm pore 
membrane; Becton Dickenson, Oxford, UK).  After 24 hours, neutralising antibodies 
were  added  to  the  bottom  well  and  4x10
4  MSCs  in  300µl  of  the  same  medium 
(without antibodies) were added to the upper well.  The MSCs were allowed to 
migrate across the membrane for 6-24 hours at 37°C.  The cells attached to the upper Chapter 2.  Materials and Methods      
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side of the membrane were then wiped away with a cotton bud, before the cells that 
had migrated to the lower side of the membrane were fixed and stained using a 
Rapid  Romanowsky  staining  kit  (Raymond  Lamb,  Eastbourne,  UK).    The 
membranes were removed from the transwells and mounted on slides.  The number 
of cells that had migrated to the lower side of the membrane was counted by taking 
an average of five fields of view at x10 magnification (Olympus BX40).  
 
 
2.9.3  Human cytokine array kit 
A human cytokine array kit (R&D Systems) was used to assess multiple chemokines 
and  cytokines  produced  by  cancer  cells  in  parallel.    The  nitrocellulose  array 
membranes contained selected capture antibodies spotted in duplicate.  
 
Cells were grown in 12-well plates.  Supernatants were collected and centrifuged 
(300g, 5mins) to remove cells and cell debris and then stored at -80°C.  1ml of each 
sample was added to 0.5mls of array buffer and 15µl of detection antibody cocktail 
and incubated at room temperature for 1 hour.   The membranes were blocked prior 
to use with 2mls array buffer for one hour on a rocking platform at room temperature 
and following this, the sample mixture was added and the membranes incubated 
overnight at 4°C. The following day, the membranes were washed 3 times in wash 
buffer,  prior  to  the  addition  of  1.5ml  Streptavidin-HRP  for  30  minutes  at  room 
temperature.      The  membranes  were  rewashed  3  times  and  protein  binding  was 
detected  using  the  ECL-chemiluminescense  detection  system  (GE  Healthcare). 
Positive signals were detected by exposing the membrane to autoradiography film 
(GE  Healthcare)  for  1-10  minutes.    This  kit  was  also  used  to  investigate  the 
cytokines and chemokines produced in vivo.  For this, whole lungs, individual lobes, 
or  subcutaneous  tumours  were  removed  from  the  mouse  and  immediately  snap 
frozen in liquid nitrogen.  This tissue was then pulverised into a fine powder under 
liquid nitrogen and stored at -80°C before use.  The tissue powder was weighed and 
standardised before homogenisation in 600µl PBS containing 1% (v/v) Triton X-100 
and supplemented with complete protease inhibitor cocktail (Complete-mini; Roche 
Diagnostics Ltd.).  This sample was then centrifuged at 16200g for 5 minutes before 
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Semi-quantitative analysis of the cytokine array was performed using densitometery.  
Films were transformed into digital format by transmissive greyscale scanning at 
300dpi on a standard flat bed scanner (Epson, Herts., UK). The scanned images were 
transferred  to  the  public  domain  NIH  Image  J  program  (developed  at  the  US 
National Institutes of Health and available at http://rsbinfo.nih.gov/nih-image/) and 
the optical density of each signal was calculated with reference to a calibration curve 
(specifically generated by scanning a Kodak photographic step tablet (Kodak, Herts., 
UK) with known optical density gradient using the same settings as described above). 
The optical density of the target was then normalised against the optical density of 
the positive controls, thus allowing correction for protein loading and enabling a 
meaningful comparison between samples.  
 
 
2.10  In vivo models 
 
2.10.1  Animals  
Six-week old nude and NOD/SCID mice (Harlan, Bicester, UK) were kept in filter 
cages  at  the  central  biological  services  facility,  University  College  London.  The 
animals were kept on a 12 hour light/dark cycle at 25°C and were provided with 
filtered  air,  and  autoclaved  food  and  water  ad libitum.    All  animal  studies  were 
performed in accordance with British Home Office procedural and ethical guidelines 
   
 
2.10.2  Models 
2.10.2.1 Subcutaneous model 
Subcutaneous tumours were obtained by the injection of 2x10
6 MDAMB231, A549, 
or H357 cells subcutaneously into the left flank with a 29G needle.  The cells were 
prepared  and  then  suspended  in  200µl  PBS  and  kept  on  ice  before  injection.  
Tumours were measured every 3-5 days with callipers, and the volume calculated as 
4/3 r
3, where r denoted the measured radius.   Chapter 2.  Materials and Methods      
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2.10.2.2 Lung cancer model 
A direct injection, lung cancer model was developed with reference to previously 
described methodology (Doki et al., 1999; Yamaura et al., 1999; Yamaura et al., 
2000). A549 cells were prepared and resuspended in a 20µl mixture of PBS and 
1mg/ml Matrigel (Becton Dickenson) at a concentration of 1x10
6/ml.     Matrigel is a 
soluble  basement  membrane  preparation  and  was  used  to  prevent  the  cells  from 
leaking out of the lung.  Animals were anaesthetised with Halothane (3%) in 2 l/min 
Oxygen.    The  left  thoracic  wall  was  shaved  and  cleaned  with  alcohol.    A  5mm 
incision was made approximately 5mm distal to the angle of the scapula and tissue, 
fat  and  muscles  were  separated  by  blunt  dissection.    The  left  lung  motion  was 
observed through the pleura and a 29G needle was then used to inject the cells into 
the lung at a depth of approximately 3mm.  The incisions were sutured using 4.0 
prolene and the mice were returned to their cages following recovery. Mice were 
sacrificed and the lungs harvested at 10-day intervals to ascertain the progression and 
natural history of this model.   
  
 
2.10.2.3 Metastatic model  
Two million MDAMB231 or A549 cells were prepared and suspended in 200µl PBS 
and kept on ice before intravenous injection into the lateral tail vein.  Mice were 
sacrificed and the lungs harvested at 10-day intervals to ascertain the progression and 
natural history of this model.   
 
 
2.10.3  Use of TRAIL-transduced MSCs 
The MSCFLT cells were labelled with CM-DiI using the same protocol described 
earlier for DiI staining.   In the subcutaneous models, MSCFLT cells were either 
delivered coincidentally with the cancer cells; 2x10
6 MDAMB231 were mixed with 
0.75x10
6 MSCFLT cells in 200µl PBS and kept on ice before subcutaneous injection, 
or  after  tumours  had  become  established;  1x10
6  MSCFLTs  in  50µl  PBS  were 
injected into established subcutaneous tumours.  Chapter 2.  Materials and Methods      
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In  the  metastatic  models,  0.5  x10
6 -  0.75x10
6  MSCFLT  cells  were  suspended  in 
200µl PBS and kept on ice before intravenous injection into the lateral tail vein.  The 
MSCFLTs  were  injected  at  timepoints  varying  between  2  and  34  days  after  the 
cancer models had been set up and the exact timings and doses are described in the 
individual experiments in the results section.  
 
To  activate  the  TRAIL  constructs  in  the  MSCFLT  cells,  mice  were  fed  water 
containing 2mg/ml doxycycline and 3% (w/v) sucrose. 
 
 
2.11  Tissue preparation 
 
2.11.1  Histological processing 
Mice  were  sacrificed  by  CO2  asphyxiation,  followed  by  laparotomy  and 
exsanguination. Lungs were harvested as follows; the thoracic cavity was opened 
and the trachea exposed and intubated with a 22G venflon.  The lungs were then 
insufflated with 4% (w/v) PFA at a pressure of 20cm H2O before the trachea was 
ligated. The heart and lungs were then removed en block, weighed, and placed in 4% 
PFA at 4°C.  After 4 hours, samples were transferred to 15% (w/v) sucrose in PBS 
and stored overnight at 4°C. Samples were then washed in 30% (v/v) ethanol and 
transferred to 70% (v/v) ethanol.  Lung specimens were divided into separate lobes 
and along with the heart were processed in paraffin wax.  3µm sections were cut 
from  paraffin  embedded  specimens  and  mounted  on  polylysine  slides  (VWR, 
Leicestershire, UK) for staining. Subcutaneous tumours were excised, weighed, and 
processed in a similar fashion. 
 
 
2.11.2  Preparation of ex-vivo tumour cells 
The  tumours  were  excised  and  placed  in  ice  cold  PBS.    They  were  then  finely 
chopped, incubated with 0.1% (w/v) collagenase A (Roche Diagnostics Ltd.) in PBS 
and passed successively through a 70µm filter and a 40µm filter (Becton Dickenson) 
to remove tissue debris. The resulting cell suspension was centrifuged (300g, 5 mins), Chapter 2.  Materials and Methods      
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and  the  cell  pellet  re-suspended  in  normal  cell  culture  medium.  The  cells  were 
transferred to 75cm
2 tissue culture flasks and incubated at 37°C in a humidified, 5% 
CO2 atmosphere for continued cell growth. 
 
 
2.11.3  Tissue homogenisation 
For  real  time  RTPCR,  and  the  measurement  of  the  production  of  cytokines  and 
chemokines, whole lungs, individual lobes, or subcutaneous tumours were removed 
and immediately snap frozen in liquid nitrogen.  This tissue was then pulverised into 
a fine powder under liquid nitrogen and stored at -80°C before use.  
 
 
2.12  Immunohistochemistry    
 
2.12.1  Antibodies 
The primary antibodies used for immunohistochemical localization studies were a 
rabbit  polyclonal  antibody  to  GFP  (A6455,  1/1000)  from  Invitrogen,  a  rabbit 
monoclonal antibody to Ki67 (SP6, VP-RMO4, 1/200) from Vector Laboratories 
(Peterborough,  UK),  and  goat  polyclonal  antibodies  to  TRAIL  (K-18,  sc-6079, 
4µg/ml),  and  vimentin  (C-20,  sc-7557,  1µg/ml),  both  from  Santa  Cruz 
Biotechnology. 
 
 
2.12.2  Immunoperoxidase technique 
For immunohistochemical staining, 3µm sections were dewaxed and rehydrated by 
immersion in xylene followed by decreasing concentrations of ethanol through to 
water.    They  were  then  washed  twice  in  PBS.    To  unmask  antigenic  epitopes, 
sections  were  pre-treated  by  immersion  in  0.01M  sodium  citrate  and  microwave 
heating  at  high  power  for  two  consecutive  periods  of  ten  minutes.  Pre-treated 
sections were then washed twice in PBS. Endogenous peroxidise was blocked by 
immersing sections in 3% (v/v) H2O2 for 30 minutes at room temperature. Sections Chapter 2.  Materials and Methods      
  88 
were then washed twice in PBS and treated with a 1 in 6 solution of serum (matching 
that in which the secondary antibody was raised e.g. goat serum for a goat anti-rabbit 
secondary  antibody)  in  PBS  containing  4  drops/ml  of  Avidin  block  (Vector 
Laboratories) for 20 minutes at room temperature. Samples were then drained before 
addition of primary antibody in 1% (w/v) BSA in PBS with 4 drops/ml of Biotin 
block (Vector Laboratories) for 1-2 hours at room temperature.  Appropriate isotype 
controls were used for each experiment.   Samples were washed twice in PBS then 
treated with a 1:200 dilution of biotinylated secondary antibody (Dako) in PBS 1% 
(w/v) BSA for 1 hour at room temperature. Samples were rewashed in PBS before 
the  addition  of  1:200  Streptavadin  HRP  (Dako)  in  PBS  for  30  minutes  at  room 
temperature.    Sections  were  washed  in  PBS  again,  before  3,3-Diaminobenzidine 
(DAB) peroxidise substrate (Vector Laboratories) was added for 10 minutes at room 
temperature.    Samples  were  drained,  rinsed  in  dH2O,  counterstained  with  Gill’s 
Haematoxylin, dehydrated in Xylene and mounted on a coveraid system (Sakura 
Firetek,  CA,  US).    Microscopy  was  performed  with  an  Olympus  BX  40  light 
microscope. 
 
The  optimal  pre-treatment  regimen  and  primary  antibody  concentration  was 
determined by performing a titration with each antibody with suitable positive and 
negative controls.  This consisted of a range of antibody concentrations, including 
the  recommended  dilution,  and  different  antibody  unmasking  pre-treatments 
including no pre-treatment, 10µg/ml Proteinase K, or microwave heating in citrate 
buffer. These sections were then immunohistochemically stained and the optimal 
conditions  selected.    The  microwave  heating  in  citrate  buffer  was  used  for  pre-
treatment for all the primary antibodies, unless otherwise stated.  
 
 
2.12.3  Immunofluorescence 
For immunohistochemical staining, 3µm sections were dewaxed and washed 3 times 
in  PBS.    The  CM-DiI  retained  fluorescence,  despite  the  fixation  and  dewaxing 
procedures.  The slides were then counterstained with 1µg/ml DAPI and washed 
twice in distilled water before mounting with Immu-mount (Thermo Electron Corp., 
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For  staining  of  ex-vivo  cells,  the  cells  were  cultured  onto  tissue  culture  plastic 
microscope slides (Nunc).  They were fixed with 4% (w/v) PFA for 20 minutes at 
room temperature, washed 3 times in PBS, and permeabilised with 0.2% (v/v) Triton 
X-100 in PBS for 5 minutes.  The cells were then blocked with PBS containing 5% 
(v/v) goat serum, before application of the primary antibody diluted in the blocking 
solution for 1 hour.  After 3 washes, the fluorescent secondary antibody (Alexa 488, 
2µg/ml) was applied for a further hour.  The cells were then rewashed and 1µg/ml 
DAPI applied and mounted with Immu-mount.  Microscopy was performed with a 
Carl Zeiss Axioskop 2 fluorescent microscope or with Dr. Liwen Lu on a Bio-Rad 
MRC 1024 confocal microscope (both Carl Zeiss Ltd.). 
 
 
2.12.4  TUNEL staining 
Apoptosis was detected on histological sections with TUNEL  (TdT-mediated dUTP-
X nick end labelling) staining.  This relies on the enzymatic labelling of the double-
stranded  and  single-stranded  DNA  breaks  that  result  from  caspase-induced  DNA 
cleavage. The enzyme, terminal deoxynucleotidyl transferase (TdT), catalyzes the 
template-independent  polymerization  of  deoxyribonucleotides  to  the  3'-end  of 
single- and double-stranded DNA (Walker & Quirke, 2001). 
 
An in situ cell death detection kit (Roche Diagnostics Ltd.) was used for TUNEL 
staining.  3µm sections were dewaxed, and washed 3 times in PBS.  The tissues were 
then permeabilised with 10 g/ml Proteinase K for 10 minutes, washed in PBS, and 
incubated with 50µl of the TUNEL reaction mix at 37 °C, in the dark for 1 hour.  
The  slides  were  then  rinsed  in  PBS  3  times  and  analysed  with  a  fluorescent 
microscope.  
 
 
2.13   Real-time RT-PCR analysis  
 
In order to minimise degradation of RNA, all reagents were made with molecular 
biology grade DEPC-treated deionised water (Ambion, TX, USA).  All equipment Chapter 2.  Materials and Methods      
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was cleaned thoroughly using RNaseZap and nuclease free pipette tips (Continental 
Lab Products, CA, US) were used for all procedures involving RNA. 
 
 
2.13.1  RNA extraction 
RNA was isolated using TRIzol reagent.  TRIzol is a solution containing phenol and 
guanidine isothiocyanate.  This dissolves the cell components, while maintaining 
RNA integrity.  1ml of TRIzol was added to either each well of a 6-well plate, or to a 
micro-centrifuge tube containing homogenized, snap frozen, ex vivo tissue.  The 
cells in the 6-well plate were scraped with a pipette tip, while the ex vivo tissue was 
pipetted and vortexed to ensure lysis.  The solution was then transferred to a micro-
centrifuge tube, and 200µl chloroform added. The tubes were then vortexed and left 
at room temperature for 5 minutes, before centrifugation at 16200g (15 minutes at 
4°C) to separate the mixture into upper aqueous and lower organic phases. The upper 
aqueous phase containing the RNA was removed to a fresh micro-centrifuge tube 
and  the  RNA  precipitated  with  the  addition  of  0.5ml  isopropanol  followed  by 
incubation  at  room  temperature  for  10  minutes  and  centrifugation  (16200g,  15 
minutes, 4°C). The supernatants were discarded and the RNA pellets washed with 
500µl ice-cold 75% (v/v) ethanol followed by centrifugation (16200g, 15 minutes, 
4°C).  The washed pellets were then air dried, before resuspension in 17µl nuclease-
free water.  
 
Total RNA was DNase-treated to remove contaminating genomic DNA using an 
Ambion DNA-free kit.  This kit uses DNase I to nonspecifically cleave genomic 
DNA into 5’ phosphorylated oligonucleotides.  The 17µl isolated total RNA was 
added to 2µl DNase buffer, and 1µl DNase I reagent, vortexed, and incubated for 20 
minutes at 37°C.  The reaction mixtures were placed on ice, and 2µl inactivation 
resin, which binds DNase I, was then added. The tubes were vortexed and incubated 
at room temperature for 1 minute, before centrifugation at 2300g for 2.5 minutes at 
4°C  to  pellet  the  inactivation  resin.  The  supernatant  containing  the  RNA  was 
removed to fresh tubes without disturbing the DNase inactivation resin, which was 
then discarded. 
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The quantity of RNA was assessed using the Ultrospec 3000 spectrophotometer by 
measuring the A260, as described previously with DNA quantification. The yield of 
RNA ( g/ml) was calculated by A260 x 40 x dilution factor, which is based on the 
assumption that A260 = 1 for a 40 g/ml solution.  The quality of the RNA was then 
assessed by running samples on an agarose gel. Samples were prepared as 1µl total 
RNA  dissolved  in  11µl  DEPC-treated  water,  with  3µl  loading  buffer  (48%  (v/v) 
deionoised  formamide  (Invitrogen),  6%  (v/v)  formaldehyde  (BDH),  5%  (v/v) 
glycerol, 0.1% (v/v) ethidium bromide 20 mM MOPS, 5 mM sodium acetate and 1 
mM EDTA pH 8.0 made up in DEPC-treated water and dyed with bromophenol 
blue). Each RNA sample was heated to 65°C for 5 minutes and placed on ice prior to 
loading. The RNA was separated through a 1.5% agarose-formaldehyde gel (6% (v/v) 
formaldehyde,  1.5%  (w/v)  agarose,  20mM  MOPS,  5mM  sodium  acetate,  1mM 
EDTA, pH 8.0, made using DEPC–treated water) at 80mV for 45 minutes. RNA 
images were then visualised using a UV transilluminator as with the DNA previously.  
A ratio of approximately 2:1 of the intensities of the 28S rRNA to the 18S rRNA 
bands was taken as confirmation that the RNA was not significantly degraded. 
   
  
2.13.2  cDNA synthesis 
Complementary DNA (cDNA) was prepared by reverse transcription using an RT-
PCR kit from Applied Biosystems (Warrington, UK).  1µg total RNA of each sample 
was added to a reaction mix of 5mM MgCl2, 1x reverse transcriptase buffer, 2.5mM 
dNTP mix, 2.5µM random hexamers, 1U/µl RNase inhibitor, 2.5U/µl MuLv reverse 
transcriptase, in a 20µl reaction volume. The mix was incubated at room temperature 
for 10 minutes, 42°C for 15 minutes, 99°C for 5 minutes, and then 5°C for 5 minutes, 
using a pre-programmed tetrad thermocycler. 
 
 
2.13.3  Primer design 
Primers  were  designed  using  internet  based  software.  The  ENSEMBL  database 
(http://www.ensembl.org/index.html)  was  used  to  find  accession  numbers  for 
genomic  RNA  and  DNA.  These  were  then  inserted  into  Spidey Chapter 2.  Materials and Methods      
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(http://www.ncbi.nlm.nih.gov/spidey/), to align genomic and RNA sequences, and 
locate  intron/exon  boundaries.    Primers  were  designed  to  be  intron-spanning,  to 
minimize  the  risk  of  genomic  DNA  amplification.    The  primer-design  software, 
Primer  3  (http://fokker.wi.mit.edu/primer3/input.htm),  was  used  to  design  primer 
sequences according to the parameters:  product size 85-130bp, primer size 18-22bp, 
primer melting temperature 58-62°C, with an optimum of 60°C and a maximum 
temperature difference of 0.5°C, primer GC% 40-60%, and maximum poly-X set at 
3. 
 
  Primers were then selected from the list, and run in silico, using FastPCR software 
(http://www.biocenter.helsinki.fi/bi/Programs/fastpcr.htm),  and  checked  for  the 
formation  of  primer  dimers.  The  products  were  then  searched  through  BLAST 
(http://blast.ncbi.nlm.nih.gov/Blast.cgi?CMD=Web&PAGE_TYPE=BlastHome) 
nucleotide to check the specificity of each primer for the intended sequence. Primers 
were synthesized by Invitrogen, and reconstituted in ultrapure nuclease-free water. 
 
 
Primer  Nucleotide sequence 
 
 
5’ TRAIL  5’-TTCACAGTGCTCCTGCAGTC-3’ 
 
3’ TRAIL  5’-AAGCAATGCCACTTTTGGAG-3’   
 
5’ 18S  5’-TTGACGGAAGGGCACCACCAG-3’ 
 
3’ 18S    5’-GCACCACCACCCACGGAATCG-3’ 
 
 
 
Table 2.5  Primers used for real time RTPCR of TRAIL and the housekeeping gene 18S. 
 
 
2.13.4  Real time RTPCR 
Real time RTPCR was performed on a Roche LightCycler 1.5 Real-time Detection 
System and analysed using LightCycler Real-time PCR Detection System Software 
version 3.5 (Roche Diagnostics Ltd.).  Real time PCR using Lightcycler technology 
relies on the incorporation of a fluorescent dye into double stranded DNA. As copies Chapter 2.  Materials and Methods      
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of DNA increase with each PCR cycle so does fluorescence and this can be detected 
and  measured  by  the  Lightcycler  thus  allowing  quantification  of  copy  number.   
cDNA  (1µl)  was  added  to  19µl  of  a  mastermix  containing  Precision  Mastermix 
(SYBR Green) (PrimerDesign, Hampshire, UK), forward and reverse primers (final 
concentration  500nM),  and  MgCl2  in  nuclease-free  water,  and  placed  in  a  glass 
LightCycler capillary. Each capillary was centrifuged for 2 minutes at 2000rpm at 
4°C,  placed  in  the  LightCycler  carousel,  and  run  under  the  following  cycling 
conditions: one cycle of 50 °C for two minutes, and then 95 °C for two minutes 
followed by forty-five cycles of 95 °C for five seconds, 55 °C for five seconds and 
then 72 °C for fifteen seconds.  
 
For each primer pair, the optimum magnesium concentration was determined, by 
running a reaction mix of template cDNA known to express the gene of interest, with 
varying  magnesium  concentrations.  The  magnesium  concentration  giving  the 
steepest exponential section of the amplification curve, which usually also gave the 
lowest cycle number at which amplification was detectable, was selected. 
 
The efficiency of each primer pair was also verified. This was necessary because the   
2
-  CT analysis method assumes a primer efficiency of 2, so that the product will 
increase  exponentially  during  amplification.  In  order  to  determine  the  primer 
efficiency, half-logarithmic dilutions of template cDNA were used in a reaction mix 
with the optimum magnesium concentration.  Crossing threshold (Ct) values were 
defined as the earliest point of the linear region of the exponential section of the 
amplification  curve  to  reach  a  minimum  threshold  of  detection.  The  log 
concentrations of the template cDNA were then plotted against the Ct value and the 
slope of the resultant line determined. Efficiency was then calculated as: efficiency = 
10
(-1/slope).  Primers were only used if the reaction efficiency was greater than 95%. 
 
To quantify differences in mRNA target gene expression in each sample, Ct values 
were determined from the linear region of the logarithmic amplification plot. Each 
sample was also tested for expression of the housekeeping gene 18S and the Ct 
values were analysed by normalizing the target gene Ct to the housekeeping gene Ct. 
Fold change was calculated using the standard 2
-  Ct method (Livak & Schmittgen, 
2001). Statistical analysis was performed on   Ct values. The melting curve of each Chapter 2.  Materials and Methods      
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product was analysed to verify that a single product had been obtained for each 
primer pair, indicated by a single melting curve. 
 
 
2.14  Metastases Quantification 
 
The number and size of tumour nodules were assessed in haematoxylin and eosin 
(H&E) sections using similar methodology to that previously described (Zhang et al., 
2008).  Photomicrographs of representative sections of the entire lung were taken at 
x2 magnification.  This created a complete picture of all lobes of the lungs of the 
mice.  Image analysis software (SimplePCI High Performance Imaging Software, 
Hamamatsu  Photonics,  Herrsching,  Germany)  was  used  to  trace  around  the 
metastatic deposits and the lung sections and then calculate lung and metastasis area 
and number of metastases.  
 
 
2.15  Statistics 
 
Statistical analysis was performed using GraphPad Prism v4 (GraphPad Software, 
CA,  USA).    Multiple  groups  were  analysed  by  Anova  with  Tukey  (one-way)  or 
Bonferroni (two-way) post-hoc tests.  Single group data was assessed using Students 
t-test. Results were considered to be statistically significant for p   0.05.  All in vitro 
experiments  were  performed  in  triplicate,  unless  otherwise  specified.Chapter 3.  Results I      
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CHAPTER 3.  RESULTS I - MSCs engineered to 
express inducible TRAIL 
 
 
 
The first aim of this project was to be able to transduce MSCs to express TRAIL, 
under  the  control  of  doxycycline.    This  chapter  discusses  this  aim  with  the 
production of TRAIL-transduced MSCs and investigates the function and ability of 
these cells to destroy cancer cells in vitro. 
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3.1  Mesenchymal stem cell properties 
 
Stem  cells  need  to  be  able  to  self-renew  indefinitely  and  divide  asymmetrically 
producing a replicate cell and a more differentiated daughter.  Mesenchymal stem 
cells  should  be  able  to  differentiate  into  stromal  cells  including  bone,  fat,  and 
cartilage.  Fully characterised MSCs were purchased from Tulane University and 
rechecked and shown to have successful colony forming ability, producing a mean of 
48 ± 2.8 colonies from 100 cells, demonstrating their self renewal properties, and 
were also stimulated to produce bone and fat cells, demonstrating their multipotency 
(Figure 3.1). 
 
 
 
 
 
 
Figure 3.1  Characterisation of MSCs. 
A) MSCs cultured on a 6-well plate.  B) Differentiation to adipocytes, Oil-Red-O staining.  C) 
Differentiation  to  osteoblasts,  Alizarin  Red  S  staining.    D)  Colony  forming  ability 
demonstrated by the growth of 50 colonies from 100 cells.  Scale bars represent 40 µm at x 5 
magnification and 5 µm at x 40 magnification. 
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3.2  Expression of TRAIL in transduced cells  
 
3.2.1  Transient transfection  
Human embryonic 293T kidney cells were transiently transfected with the full length 
TRAIL (flTRAIL), soluble TRAIL (sTRAIL), and empty vector (ev) constructs all 
containing IRES-GFP.  To optimise transient transfection conditions, Fugene and 
PEI transfection agents were used at different concentrations.  GFP expression was 
used as a marker of successful expression of the construct and assessed by flow 
cytometry.  There was very little GFP expression with Fugene as a transfection agent.  
PEI, used at between 1 and 5µl per µg of plasmid DNA, gave the optimal GFP 
expression with the three constructs at 3µl per µg of plasmid DNA.  Under these 
conditions, up to 60% of 293T cells transiently transfected with either the empty 
vector or the sTRAIL vector had GFP expression when exposed to doxycycline for 2 
days.  This percentage was lower for the flTRAIL construct (37%).  The Tet-on 
system was also very leaky with similar percentages of GFP-positive cells without 
doxycycline,  however  the  intensity  of  GFP  expression  was  lower  in  these  cells 
(Figure 3.2). 
 
In addition to flow cytometry for GFP expression, the cells were stained with an 
anti-TRAIL antibody to assess for surface expression of TRAIL.  There was some 
evidence of TRAIL expression on the cells transfected with the full length TRAIL 
and exposed to doxycycline (2.3%; Figure 3.2F).  As with GFP expression, a lower 
level of TRAIL expression was also evident without the use of doxycycline (0.7%; 
Figure 3.2E).   As expected, there was no evidence of surface expression of TRAIL 
on the cells transfected with either the empty vector or the extracellular portion of 
TRAIL ( 0.1%; Figure 3.2B,D).   
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Figure 3.2  Transient transfection of 293T cells 
Flow  cytometry  plots  (marked  with  cell  percentage)  assessing  the  success  of  transient 
transfection of 293T cells with empty (A,B), soluble TRAIL (sTRAIL, C,D), and full length 
TRAIL  (flTRAIL,  E,F)  constructs.    The  tetracycline-on  system  appears  leaky  with  the 
transient  transfection,  as  GFP  is  expressed  in  a  similar  percentage  of  cells  without 
doxycycline (nd) (A,C,E).  There is however an increased intensity of GFP fluorescence in 
the cells activated with doxycycline (dox) (B,D,F).  There is only a small amount of TRAIL 
protein expressed on the surface of the cells transfected with flTRAIL and activated with 
doxycycline (F).  Chapter 3.  Results I      
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In view of the relatively low expression of TRAIL, as assessed by flow cytometry, 
western blots of the cell lysates and supernatants were performed.  This confirmed 
the production of the 32kDa TRAIL protein in the cells transfected with flTRAIL.  
There was also evidence of the production of the extracellular portion of TRAIL 
(21kDa) in the cell lysates of those cells transfected with sTRAIL.  There was no 
TRAIL in either control cells or cells transfected with the empty vector (Figure 3.3).  
There was no TRAIL protein in the supernatant with any of the transfected or control 
cells.   
 
 
 
Figure 3.3  Transiently transduced 293T cells produce TRAIL. 
Western blot of 293T cells transiently transduced with full length TRAIL (flt), soluble TRAIL 
(st), empty vector (emp), or nothing (con).  Flt and st proteins should be 32kDa and 21 kDa 
respectively. 
 
 
3.2.2  Stable transduction  
With transient transfection, DNA is not usually inserted into the nuclear genome and 
hence is lost after cell division.  Stable viral transduction involves incorporation of 
foreign DNA into the genome allowing it to be passed to all progeny.    Lentivirus 
containing  flTRAIL  and  sTRAIL  was  produced  and  used  to  transduce  human 
embryonic  293T  kidney  cells  at  different  concentrations.    As  with  the  transient 
transfection,  flow  cytometry  analysis  of  GFP  expressing  cells  was  used  as  a 
surrogate for successful plasmid incorporation, and used to calculate the number of 
viral particles per ml.   
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3.2.2.1 Full length, membrane-bound TRAIL 
Full length TRAIL (flTRAIL) virus ratios of 1/100, 1/1000, 1/10000, and 1/100000 
were added to the 293T cells and achieved 69.6, 37.4, 3.8, 0.4 % of GFP positive 
cells respectively.  The lower viral ratios usually give more accurate results, as there 
is less likely to be multiple plasmids per cell.  With this in mind, and using the 
calculation below, there were around 2x10
7 virus particles/ml of virus solution. 
 
Viral titre =% of GFP cells x dilution of virus x number of cells infected (i.e. 50000) 
               100 
 
The Tet-on system was not leaky with the stable transduction and GFP was only 
expressed by the cells exposed to doxycycline (69.6% compared to 3.3% GFP +ve 
cells at 1/100 lentivirus dilution; Figure 3.4). 
 
Most lentivirus titrations are actually performed with Hela cells.  As these cells are 
cervical  cancer  cells,  there  was  concern  that  these  cells  would  be  killed  by  the 
TRAIL  activation,  and  hence  unsuitable  for  use  in  determining  the  virus 
concentration. Propidium iodide, a nuclear binding dye that fluorescently stains dead 
cells, was used to ascertain the number of cells killed by transduction and activation 
of the TRAIL transgene. With 293T cell titration, the number of dead cells did not 
significantly increase with the use of doxycycline and activation of the transgene 
(1/1000  virus;  3.1%  dead  cells  with  doxycycline,  5.7%  without;  Figure  3.5B), 
suggesting that these cells were resistant to TRAIL-induced apoptosis, as expected.  
Conversely,  when  Hela  cancer  cells  were  utilised  for  the  virus  titration,  a  large 
amount of cell death occurred with doxycycline activation (1/1000 virus 25.4% dead 
cells with doxycycline, 3.6% without doxycycline; Figure 3.5A).  This experiment 
justified  the  original  decision  to  use  293T  cells  for  the  virus  titration,  but  also 
suggested  the  functionality  of  the  TRAIL  transgene  at  specifically  killing  cancer 
cells.   
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Figure 3.4  Full length TRAIL lentivirus titrated with 293T cells. 
flTRAIL lentivirus was added to 5x10
4 293T cells at viral dilutions ranging from 1/100 to 
1/100000.  Flow cytometry was used to assess the percentage of cells expressing GFP to 
ascertain  the  number  of  viral  particle/ml.  This  stable  transduction  of  293T  cells 
demonstrated transgene activation (GFP expression) only on activation with doxycycline 
(dox) and not in the cells without doxycycline (nd).  Propidium iodide (PI) was used to 
assess the number of dead cells. Chapter 3.  Results I      
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Figure 3.5  Hela cells are killed by transduction with the full length TRAIL lentivirus and 
activation with doxycycline. 
A)  flTRAIL  lentivirus  was  added  to  5x10
4  Hela  cells  at  different  viral  dilutions.    Flow 
cytometry  assessed  the  percentage  of  cells  expressing  GFP,  as  a  marker  of  successful 
transduction, and the percentage of dead cells with propidium iodide (PI).  GFP was only 
expressed when the cells were activated with doxycycline (dox), and was associated with a 
large increase in cell death.  B) The dox-induced cell death was not seen with transduction 
of the 293T cells. Neither GFP expression nor death was seen in Hela cells without dox-
induced transgene activation (nd). Chapter 3.  Results I      
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Mesenchymal  stem  cells  were  next  stably  transduced  with  flTRAIL  at  different 
multiplicities of infection (MOI).  The MOI is the number of virus particles per MSC 
and can easily be defined with the knowledge of the number of cultured MSCs and 
the viral titre as above. An MOI of 10 was chosen for future experiments producing 
82.1 ± 0.4% successful transduction (GFP expression) at day seven, while limiting 
the number of dead cells to 4.8 ± 1.8% (Figure 3.6C).  As with the 293T cells, and 
again  as  expected,  the  low  MSC  death  rate  suggests  these  cells  are  resistant  to 
TRAIL-induced apoptosis.    
 
An ELISA for TRAIL protein expression was used to show that the stable TRAIL-
transduced MSCs (MSCFLT) were able to produce TRAIL protein.  TRAIL was 
only produced when the transgene was activated by doxycycline and there was more 
TRAIL production after 4 days of doxycycline compared to after 1 day exposure 
(15.0 ± 0.3 vs. 9.8 ± 1.4 pg TRAIL/µg total protein; p<0.05, Anova) (Figure 3.6D).  
In addition to the cell lysates, there was 502.9 ± 235.1 pg/ml TRAIL evident in the 
doxycycline-stimulated MSCFLT cell supernatants, compared to 12.3 ± 20.9 pg/ml 
in the  supernatants of MSCFLT cells without doxycycline (p=0.02, t-test).  The 
MSCFLT  cells  retained  their  MSC  characteristics  after  the  transduction  process, 
including the capacity to differentiate into fat and bone stromal tissues.    
 
 
3.2.2.2 Soluble TRAIL 
A soluble TRAIL (sTRAIL) lentivirus containing the extracellular portion (amino 
acids  114-281)  of  TRAIL  was  also  produced  and  virus  ratios  of  1/100,  1/1000, 
1/10000, and 1/100000 were added to the 293T cells and achieved 63.3, 16.7, 1.3, 
0.1 % of GFP positive cells respectively.  Using the same rationale and calculation as 
with flTRAIL, this produced an sTRAIL viral yield of 7x10
6 viral particles/ml.  As 
with the flTRAIL system, the Tet-on system was specific with stable transduction 
and GFP was only expressed by the cells exposed to doxycycline (63.3% compared 
to 0.6% GFP +ve cells at 1/100 lentivirus dilution; Figure 3.7A). 
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Figure 3.6  MSCs transduced with full length TRAIL lentivirus express GFP and TRAIL 
under doxycycline control. 
MSCs are transduced with flTRAIL and activation of the transgene with doxycycline leads to 
GFP expression.  A) light and (B) fluorescent microscopy.  Scale bars represent 20µm.  C) 
Flow cytometry demonstrates >80% GFP+ve cells.  D) ELISA demonstrates that TRAIL 
protein  is  also  produced  by  the  doxycycline-activated,  MSCFLT  lysates.    PI:  propidium 
iodide.  **p<0.01, *p<0.05.  
 
 
Unlike with the flTRAIL, the use of Hela cells for the sTRAIL virus titration did not 
produce an increase in cell death.  At 1/1000 virus, there were 6.5% and 7.7% dead 
Hela cells in the doxycycline and no doxycycline groups respectively.  This result 
suggested a lack of activity of the sTRAIL, despite activation of the transgene (as 
judged by GFP expression; Figure 3.7B).  MSCs were transduced with sTRAIL at an 
MOI of 10 (42.0 ± 25.5% GFP expression).  No TRAIL protein was detectable by 
ELISA with either cell lysate or supernatant. Chapter 3.  Results I      
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Figure 3.7  293T and Hela cells transduced with soluble TRAIL lentivirus express GFP 
but are not killed. 
A-B) sTRAIL lentivirus was added to 5x10
4 293T (A) or Hela (B) cells at different viral 
dilutions.  Flow cytometry demonstrated GFP expression only when the cells were activated 
with  doxycycline  (dox).    B)  Unlike  with  full  length  TRAIL  transduction,  there  was  no 
increase in death in the Hela cells when the sTRAIL transgene was activated with dox. nd: 
no doxycycline. Chapter 3.  Results I      
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The lack of sTRAIL expression on permanently transduced cells, coupled with the 
apparent lack of apoptotic functional effect on the Hela cell virus titration, focused 
the remainder of the project on flTRAIL.  The initial idea behind the use of sTRAIL 
was a possible paracrine apoptotic effect (Kim et al., 2006).  However, there is also 
evidence  to  suggest  that  membrane-bound  TRAIL  is  superior  in  activating  the 
receptor DR5, and that some cells which are not sensitive to soluble TRAIL apoptose 
when  the  TRAIL  is  tethered  to  a  cell  membrane  (Carlo-Stella  et  al.,  2006; 
Muhlenbeck et al., 2000; Wajant et al., 2001).  In addition, the demonstration of 
TRAIL protein in the supernatant of the MSCFLT cells, suggested that these cells 
would also be able to have a paracrine effect.  
 
 
3.2.3  Control of TRAIL expression with doxycycline 
The above experiments demonstrated that, in the stable transduction model, the Tet-
on  system  was  very  specific;  only  cells  exposed  to  doxycycline  expressed  the 
transgene.  The sensitivity of the system and its speed of response to addition or 
subtraction of doxycycline were then investigated.  Flow cytometry showed <0.5% 
GFP expression before activation with doxycycline.  This increased to 66.5 ± 2.9% 
after one day of doxycycline exposure, with near maximal activation by day 2 (74.7 
± 2.5%).  On removal of the doxycycline stimulus, after the cells had been exposed 
for 5 days, the percentage of GFP positive cells remained high for 5-7 days, however 
the intensity of GFP dropped significantly by day 3 (Figure 3.8A,B).  On day 7 there 
was only 12.2 ± 1.0%) of weakly positive GFP cells.   
 
In  addition  to  GFP  expression,  the  timescale  of  the  transgene  activation  with 
doxycycline  was  also  investigated  by  measuring  TRAIL  protein  expression.  
Western  blots  demonstrated  TRAIL  protein  expression  in  MSCFLT  lysates  was 
maximal after 2 days of doxycycline stimulus, but very little protein remained 1 day 
after its removal (Figure 3.8C).  The apparent disparity in the speed at which the 
GFP and TRAIL proteins return to baseline levels following doxycycline removal 
could be explained either by differences in degradation of the two proteins, or by the 
increased sensitivity of flow cytometry in comparison to western blotting.  Chapter 3.  Results I      
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Figure 3.8  Timescale of full length TRAIL transgene activation with doxycycline.  
A)  Bar  chart  displaying  results  from  triplicate  flow  cytometry  experiments.    GFP  is 
expressed by full length TRAIL-transduced MSCs (MSCFLT) within 1 day of doxycycline 
(dox) exposure and remains for 3 days after dox removal.  B)  Representative flow cytometry 
plots demonstrating a reduction in intensity of GFP expression 3 days after dox removal 
despite similar numbers of GFP +ve cells.  C)  Western blots of MSCFLT lysates showing 
maximum expression of TRAIL after two days of doxycycline treatment (10 g protein loaded) 
and loss of expression one day after doxycycline removal (5 g protein loaded), with actin 
loading controls. Chapter 3.  Results I      
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3.3  Function of TRAIL in transduced cells 
 
Having  demonstrated  the  successful  transduction  of  MSCs  and  their  ability  to 
express  TRAIL  in  a  tetracycline-induced  system,  it  was  necessary  to  assess  the 
function of the expressed TRAIL.  Apoptotic function had been suggested in the 
viral titration with Hela cells.  As described in section 3.2.2.1, there was an increase 
in cell death, which was proportional to the amount of cells successfully transduced 
(Figure 3.5A).  This result was expected, as Hela cells are a cervical cancer cell line 
sensitive to TRAIL-mediated apoptosis, whereas the 293T cells (and MSCs) are not 
cancer cells and hence are expected to be resistant to the effects of TRAIL.  
 
 
3.3.1  Coculture experiments    
To demonstrate the ability of TRAIL-expressing MSCs to kill tumour cells, the two 
cell types were cocultured and death assessed with phase microscopy (Figure 3.9A) 
and Annexin V flow cytometry (Figure 3.9B).  Annexin V binds phosphatidylserine, 
which is translocated from the inner membrane to the cell surface soon after the 
induction of apoptosis.  PI and DAPI are nuclear binding dyes that are excluded from 
live,  viable  cells,  but  fluorescently  stain  the  nucleus  of  dead  cells.    Annexin  V
- 
/DAPI
- cells were judged to be live. Annexin V
+/DAPI
- cells were considered to be 
undergoing apoptosis. Annexin V
+/DAPI
+ cells were recorded as being dead.   
 
In preliminary coculture experiments both 1x10
5   and 4x10
5 total cells per 6-well 
plate were used and the following cell combinations were cocultured 1) cancer cells 
alone,  2)  cancer  cells  with  normal,  non-transduced  MSCs  and  doxycycline  (to 
control  for  the  addition  of  doxycycline),  3)  cancer  cells  with  MSCFLT  without 
doxycycline (to control for the MSCFLT), and 4) cancer cells with MSCFLT with 
doxycycline  (to  assess  the  effect  of  TRAIL  expression).    The  higher  density 
cocultures led to a large background death rate due to overconfluency and hence the 
lower  density  (1x10
5)  cells  were  used  for  further  experiments.    There  was  no 
increased death and apoptosis with either the addition of normal, non-transduced 
MSCs and doxycycline, or MSCFLT without doxycycline (Figure 3.9B).   Chapter 3.  Results I      
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Figure 3.9  TRAIL-expressing MSCs cause cancer cell apoptosis in vitro. 
A) Phase microscopy demonstrating an increase in cell death (rounded and floating cells) 
when  MSCFLT  cells  were  activated  by  doxycycline  (dox)  in  co-culture  with  Hela  and 
MDAMB231  cells.  Scale  bars  represent  40µm.  B)  Representative  flow  cytometry  plots 
demonstrating an increase in death and apoptosis when Hela cells were co-cultured with 
dox treated MSCFLTs compared to no dox (nd), untreated controls or dox-treated normal 
MSCs. (C) Flow cytometry results from triplicate apoptosis assays showing an increase in 
death  and  apoptosis  of  total  cells  in  cancer  cell  and  MSCFLT  co-cultures  after  dox 
treatment. ***p<0.001,  **p<0.01, *p<0.05. 
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Both  apoptosis  (Annexin  V+/PI-)  and  death  (Annexin  V+/PI+)  increased 
significantly when doxycycline was added to the cancer and MSCFLT cocultured 
cells.  This effect was observed with lung cancer (A549; apoptotic and dead cells 
increased from 3.1 ± 0.1% to 19.6 ± 0.8%; p=0.001, t test; with the addition of 
doxycycline), breast cancer (MDAMB231; 15.4 ± 1.7% to 37.7 ± 6.5%; p=0.001, t-
test), squamous cell cancer (H357; 12.5 ± 0.3% to 36.1 ± 3.5%; p=0.001, t-test) and 
cervical cancer (Hela; (6.7 ± 1.0% to 36.1 ± 3.5%; p=0.0001, t-test) cells.  There was 
a minimal increase in death and apoptosis of fibroblasts in coculture with MSCFLT 
cells (12.0 ± 0.5% to 17.5 ± 2.1%; p=0.01, t-test)(Figure 3.9C). 
 
The  supernatant  from  doxycycline-activated  MSCFLT  cells  contained  TRAIL 
protein on an ELISA, as described in 3.2.2.1.  When added to Hela cancer cells this 
supernatant caused 38.8 ± 1.2% death and apoptosis compared to the 13.0 ± 1.3% 
death and apoptosis with the use of the non-TRAIL containing supernatant from 
MSCFLT without doxycycline (p<0.0001, t-test; Figure 3.10). 
 
 
 
 
Figure 3.10  The supernatant of TRAIL-expressing MSCs contains functional TRAIL. 
Bar chart from triplicate flow cytometry experiments demonstrating a significant increase in 
apoptosis  and  death  of  Hela  cells  when  they  were  cultured  with  the  supernatant  from 
MSCFLT cells with doxycycline (dox) compared to without doxycycline (nd). ***p<0.0001. 
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3.3.2  Specific death of cancer cells 
The above experiments demonstrated an increase in cell death and apoptosis of the 
combination of cells in the coculture.  The apoptotic cells were likely to be the 
cancer cells from the single cell viral transduction data (section 3.2.2.1).  It was not 
possible to separate the cell types by size on flow cytometry so the experiments were 
repeated with prior labelling of the cancer cell populations with a fluorescent dye 
(DiI).    The  apoptosed  and  dead  cells  were  shown  to  come  specifically  from  the 
cancer  cell  population.    The  addition  of  doxycycline  increased  the  dead  and 
apoptotic Hela cells from 6.1 ± 0.7% to 50.7 ± 2.7% (p<0.0001, Anova), whereas 
there  was  no  significant  increase  in  apoptosis  and  death  in  the  GFP-positive 
MSCFLT cells with doxycycline (14.5 ± 6.1% to 8.3 ± 4.6%)(Figure 3.11). 
  
 
 
 
 
 
Figure 3.11  The cancer cells are specifically killed in coculture with TRAIL-expressing 
MSCs. 
A) Hela cancer cells were stained with DiI before coculture with MSCFLT and doxycycline 
(dox).  By gating on the separate cell populations, the flow cytometry plots demonstrate that 
>50% of the Hela cells undergo apoptosis or die, whereas the MSCFLTs remain viable.  B) 
Bar chart representing triplicate flow cytometry experiments demonstrating the increase in 
apoptosis and death of the Hela cells in coculture with the addition of dox compared to 
without dox (nd), in contrast to theMSCFLT cells.  ***p<0.001.  Chapter 3.  Results I      
  112 
3.3.3  Dose dependent effect  
For clinical applications, it would be unlikely to attain a 1:1 ratio of MSCFLT and 
cancer cells, so it is important to be able to demonstrate a killing effect at much 
lower concentrations of MSCFLT cells.  Coculture experiments were repeated with 
lower numbers of MSCFLT cells.  A significant increase in apoptosis and death of 
the cancer cells was achieved at all concentrations of MSCFLT used; p<0.001 at 
ratio MSCFLT:Hela cell of 1:16.  There was a cell ratio-dependent effect; the greater 
the  number  of  MSCFLT  cells,  the  greater  the  death  and  apoptosis  of  Hela  cells 
(Figure 3.12A).  The coculture experiments were performed by plating the cancer 
and MSCFLT cells for 24 hours before the addition of doxycycline and there was a 
further  time  period  before  TRAIL  was  expressed  on  the  MSCFLT  cell  surface.  
Consequently, this experiment underestimated the true killing capacity of MSCFLT 
cells,  as  the  seeding  ratios  did  not  account  for  the  increased  proliferation  of  the 
cancer cells in comparison with the MSCFLTs before the expression of TRAIL. 
 
 
3.3.4  Mechanism of MSCFLT-induced cancer cell death 
The previous experiments have demonstrated that the combination of doxycycline 
and MSCFLT cells can cause apoptosis and death of a range of cancer cells, but that 
either agent alone does not reproduce this.  MSCFLT cells had also been shown to 
express TRAIL protein when induced with doxycycline.  The next set of experiments 
set  out  to  demonstrate  that  MSCFLT  cells  kill  cancer  cells  by  induction  of  the 
extrinsic apoptotic pathway by TRAIL. 
 
 
3.3.4.1 Death of cancer cells by TRAIL expression 
A TRAIL antibody with some ability to neutralise the bioactivity of TRAIL was 
added to the MSCFLT and Hela cell cocultures.  The antibody was used at a dose to 
give maximal neutralising effect (250ng/ml)(Matthews & Neale, 1987).  The amount 
of  MSCFLT-induced  death  and  apoptosis  was  significantly  reduced  with  this 
antibody (38.0 ± 0.5% compared to 50.7 ± 3.8%; p<0.001, Anova), however not 
back to baseline (11.5 ± 1.5%) (Figure 3.12B). Chapter 3.  Results I      
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The doxycycline-induced MSCFLTs were potent inducers of death and apoptosis of 
Hela cells, producing a larger proportion of apoptotic and dead cells in comparison 
to  high  doses  (200ng/ml,  designed  to  give  maximal  effect)  of  a  commercially 
available recombinant soluble TRAIL (50.7% ± 3.8% compared to 27.5 ± 0.7%; 
p<0.001, Anova) (Figure 3.12B). 
 
 
3.3.4.2 Death of cancer cells by extrinsic apoptosis pathway 
The caspases are a family of closely related enzymes crucial to apoptosis (see section 
1.2).  zVADfmk is a cell permeable, pan-caspase inhibitor that inhibits apoptosis.  
Application of this compound to the 1:1 cocultured MSCFLTs and Hela cells caused 
a 51.6% reduction in death and apoptosis compared to a DMSO treated control of 
(26.5 ± 0.7% compared to 54.8 ± 3.0%; p=0.003, t-test) confirming the importance 
of caspases, and the apoptotic pathway in the cell death (Figure 3.12C). 
 
Upon receptor binding of the TRAIL ligand, the death domain in the cytoplasmic 
region of the TRAIL receptor recruits FADD and caspase 8, leading to apoptosis by 
the extrinsic pathway.  To confirm the mechanism of MSCFLT-induced cancer cell 
death is via the extrinsic pathway, Hela cancer cells were retrovirally transduced 
with a dominant negative FADD (dnFADD) construct or an empty vector (Janes & 
Watt, 2004).  The dnFADD consists of the death domain that binds to the TRAIL 
receptor, but not the domain responsible for caspase 8 recruitment.  Overexpression 
of dnFADD in these cancer cells should inhibit the recruitment of caspase 8 and the 
subsequent  formation  of  the  death  inducing  signal  complex,  a  prerequisite  for 
extrinsic apoptosis.  There was a significant reduction (16.4 ± 1.4% compared to 
42.9 ± 4.9%; p<0.018, t-test) in death and apoptosis of Hela cells transduced with 
dnFADD after coculture with doxycycline-activated MSCFLT cells (Figure 3.12C).  
This  data  provides  strong  evidence  that  MSCFLT  cells  induce  apoptosis  via  the 
extrinsic pathway.  Chapter 3.  Results I      
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Figure 3.12  TRAIL-expressing MSCs induce cancer cell apoptosis at low MSC to cancer 
cell ratios via the extrinsic apoptotic pathway. 
A-C) Bar charts representing triplicate flow cytometry apoptosis assays.  A) The death and 
apoptosis of Hela cells is increased in coculture with doxycycline (dox)-activated MSCFLT 
cells even at low 1:16 ratios, compared to no dox controls (nd).  (B) Induced cell death and 
apoptosis  is  higher  using  the  dox-activated  MSCFLTs  than  with  recombinant  TRAIL 
(rhTRL), and can be partially blocked with blocking antibody (Ab).  (C) Cell death and 
apoptosis  is  reduced  in  Hela  cells  expressing  dominant  negative  Fas-associated  death 
domain (dnFADD) in comparison with those transduced with an empty vector (empty) in 
addition to when zVADfmk (zVAD), a pan-caspase inhibitor, is used compared to the control 
(con). ***p<0.001,  **p<0.01,  *p<0.05. Chapter 3.  Results I      
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3.4  Summary  
 
 
This chapter has demonstrated 
 
•  MSCs can be permanently transduced with lentivirus constructs. 
 
•  MSCs can express full length TRAIL in a doxycycline-inducible manner. 
 
•  The doxycycline induced TRAIL expression is specific and sensitive. 
 
•  TRAIL-expressing MSCs are able to specifically cause cancer cell apoptosis 
and death in vitro. 
 
•  The MSCFLT-induced cancer cell apoptosis and death is retained even at low 
MSCFLT : cancer cell ratios 
 
•  The MSCFLT-induced cancer cell apoptosis and death is via the extrinsic 
apoptotic pathway. 
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CHAPTER 4.  RESULTS II – Homing of MSCs to 
cancer 
 
 
 
Having produced MSCFLT cells, armed with the ability to express TRAIL and kill 
cancer cells in vitro, the next step was to ensure that they could migrate to tumours 
both in vitro and in vivo.  This chapter addresses the second aim of the project; the 
specific  migrating  ability  of  the  MSCs,  and  develops  murine  cancer  models  to 
demonstrate tumour homing in vivo.  As much of this chapter describes work done 
in vivo, it begins with a description of the development of the tumour models.  
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4.1  Cancer Models 
 
For  this  project,  with  the  future  aim  of  translational  applicability,  human  cancer 
xenograft models, human MSCs, and human TRAIL constructs were used.  
 
For xenograft tumour models, immunocompromised mice were needed, so that the 
human cancer cells would not be rejected by the murine immune system.  Three 
different tumour models were developed; a subcutaneous tumour model to allow 
tumour visualisation during the experiments, a direct lung injection model for lung 
cancer,  and  a  metastatic  lung  cancer  model  produced  by  intravenous  cancer  cell 
delivery.    Both  A549  and  MDAMB231  breast  cells  were  used  for  the  xenograft 
models. 
 
 
4.1.1  Nude mice 
Nude mice were initially used for the xenograft models.  These mice have a deletion 
in the FOXN1 gene on chromosome 11 and the defect is autosomal recessive (Segre 
et al., 1995).  These mice have a rudimentary, dysfunctional thymus and are T-cell 
deficient.    They  do  however  have  normally  functioning  B-cells  and  NK  cells.  
Subcutaneous injection of A549 cells produced tumours in 6/8 nude mice after 8 
weeks, but the size of the tumour was small and inconsistent.  MDAMB231 cells 
produced 0/6 tumours after 12 weeks.  Direct lung injection of A549 cells produced 
small  areas  of  lung  tumours  in  10/12  mice,  however  again  the  model  was  not 
uniform or reproducible with some parenchymal, mediastinal, and pleural tumours.    
Intravenous injection of MDAMB231 cells produced small areas of tumours in the 
lung as early as eight days following injection.   
 
Due to the unsuccessful growth, long latency, and lack of reproducibility with some 
of the tumour models, NOD/SCID mice were then used for the xenograft models. Chapter 4.  Results II      
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4.1.2  NOD/SCID mice 
In these mice, the SCID (Severe Combined Immunodeficiency) mutation has been 
transferred onto the diabetes-susceptible NOD (Non-Obese Diabetic) background.  
Mice homozygous for this mutation have a block in lymphocyte development and 
have a lack of functioning B-cells and T-cells.  There are also abnormalities of the 
innate immunity with defective NK and macrophage function (Shultz et al., 1995).  
The increase in immunodeficiency in comparison to the nude mice should encourage 
faster and more reproducible tumour growth with the different models.   
  
Subcutaneously  injected  MDAMB231  cells  developed  into  reproducible 
subcutaneous tumours in 13/15 mice within 3 weeks, and this subcutaneous model 
was used for further experimentation (Figure 4.1A,B).  A549 cells were directly 
injected into the lungs of NOD/SCID mice.  Tumours were produced in 5/5 mice.  In 
two of these mice, a single lobe tumour was formed.  The remaining three mice had a 
predominantly  pleural  tumour  pattern  (Figure  4.1J-L).    In  view  of  the  lack  of 
consistent lung tumours in this model, it was not used for further experimentation   
For  the  metastatic  model,  either  MDAMB231  or  A549  cells  were  intravenously 
injected into NOD/SCID mice and the lungs were evaluated at 10, 20 and 30 days 
(n=3 per time point).  Metastatic tumours were found in the lungs at all time points 
in all of the mice.  This model was very reproducible (Figure 4.1C-I) and used for 
further experimentation. 
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Figure 4.1  Tumour models.  
A)  subcutaneous  (s/c)  tumour  model:    2x10
6  MDAMB231  s/c;  B)  H&E  histology.    C-I) 
metastatic  model  2x10
6  MDAMB231  (C-F)  or  A549  (G-I)  cells  iv.    C)  Macroscopic 
appearance of lungs, D-I) H&E histology of lungs day 10-30.  J-L) H&E histology of direct 
lung cancer model: 1x10
6 A549 cells injected directly into the lung with matrigel.  Results 
were inconsistent with both single lobe lung tumour produced (J) (normal lobe in same 
mouse (K)), and pleural-based tumours in other mice (L) with the same technique.  Scale 
bars represent 20µm. Chapter 4.  Results II      
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4.2  MSC migration to tumours 
 
4.2.1  In vitro 
Transwell  experiments  were  used  to  demonstrate  the  ability  of  MSCs  to  home 
towards tumours.  MSCs were placed in the top chamber and allowed to migrate 
through a membrane with 8µm pores towards different cell cultures or media in the 
bottom chamber.  The number of MSCs migrating through the membrane towards 
the cells was used as a measure of the ability of MSCs to home to a particular cell 
type (Figure 4.2A).  A549, MDAMB231, and Hela cancer cell cultures were used to 
attract the MSCs, with 293T cells and medium alone used as controls.  The results 
demonstrated  a  significantly  increased  migration  to  the  MDAMB231  cells,  with 
250.4 ± 0.8 cells per microscope field migrating across the membrane in 24 hours 
compared to 293T cells (98.6 ± 9.3) and medium (57.6 ± 7.6) (p<0.001, Anova).  
There was not a significantly increased migration towards the A549 and Hela cells in 
comparison  with  the  293T  cells  (Figure  4.2B).    In  setting  up  these  transwell 
migration studies, several variables were altered.  The time of migration was trialled 
at 6 and 24 hours and although the cell medium of both the upper and lower sections 
of the transwells was always the same for each experiment, the serum content was 
varied  to  contain  either  10%  or  0%,  as  there  was  a  lack  of  consistency  in  the 
literature (Nakamizo et al., 2005; Schmidt et al., 2006; Xin et al., 2007).  With no 
serum  in  the  upper  and  lower  transwell  sections,  migration  of  the  serum-starved 
MSCs was poor and inconsistent.  Furthermore, migration to chemotactic gradients 
in  vivo  will  also  occur  on  the  background  of  basal  growth  factors  in  serum.  
Consequently, for these experiments, 10% serum in both the upper and lower wells 
was used and migration occurred for 24 hours.   
 
There was no difference in the in vitro migrating ability towards cancer cells of 
transduced  MSCFLTs  (92.3  ±  0.5  cells/field),  or  MSCFLTs  activated  with 
doxycycline (82.2 ± 2.1) in comparison to normal non-transduced MSCs (98.4 ± 
10.8) (Figure 4.2C).  This suggests that both the transduction and the expression of 
TRAIL do not influence the tumour homing capabilities of the cell.    
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Figure 4.2  MSCs migrate to some cancer cells in vitro and transduction does not affect 
this migration 
A) Transwell migration studies with staining of MSCs that have migrated to the underside of 
the transwell. x4 mag scale bar represents 50µm, x20 mag represents 10µm.  B)  Increased 
number (per microscopic field) of MSCs migrating through the transwell membrane toward 
MDAMB231 cells, but not towards other (A549, Hela) cancer cell types compared to control 
293T  cells  or  medium  alone  (***p<0.001).    C)    No  difference  in  migration  towards 
MDAMB231 cells between MSCs and MSCFLT, with (dox) or without (nd) doxycycline. 
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4.2.2  In vivo 
4.2.2.1 Coinjection 
MSCs  and  MSCFLT  cells  were  DiI-labelled  and  coinjected  subcutaneously  with 
tumour  cells  appeared  to  be  able  to  incorporate  throughout  the  tumour  (Figure 
4.3A,B).  The pattern of incorporation was different when the MSCs were injected 
into established subcutaneous tumours at day 45.  In this model, MSC incorporation 
was found predominantly in the stroma surrounding the tumours (Figure 4.3C,D).  
 
 
 
 
 
 
Figure 4.3  Incorporation of MSCs into subcutaneous tumours when directly injected. 
A-B)  0.75x10
6  DiI-labelled  MSCs  (red)  were  coinjected  subcutaneously  with  2x10
6 
MDAMB231  cells.    A)  H&E  staining  of  tumours  harvested  at  day  42.  B)  Fluorescent 
microscopy  of  a  contiguous  section  with  DAPI  nuclear  counterstain,  demonstrating 
incorporation of MSCs throughout the tumour.  C-D) MSCs incorporate predominantly in 
the tumour stroma when injected at day 45 into established subcutaneous tumours. C) H&E 
staining D) fluorescent microscopy.  Scale bars represent 50µm. 
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4.2.2.2 Systemic introduction 
MSCs or MSCFLT cells labelled with DiI, were injected intravenously at day 10 into 
the A549 and MDAMB231 metastatic models.  At day 30, the mice were harvested 
and immunofluorescence showed the incorporation of DiI-labelled cells into the lung 
metastases  in  both  tumour  models,  but  the  incorporation  appeared  more  tumour-
targeted in the case of the MDAMB231 cells (Figure 4.4).  This was consistent with 
the in vitro transwell migration data suggesting an increased homing to MDAMB231 
cells.      On  the  basis  of  these  results,  the  MDAMB231  cells  were  used  for  the 
metastatic cancer model.  There was a negligible amount of DiI labelling seen in the 
lungs  of  MSC  treated  mice  without  lung  metastases.    Similarly,  DiI-stained 
fibroblasts  were  not  detected  in  the  tumours  or  indeed  the  lungs  10  days  after 
injection.  This  histological  data  shows  MSCs  preferentially  engraft  and  are 
maintained  in  the  in  vivo  tumour  environment  compared  to  surrounding  lung 
parenchyma while fibroblasts are not. 
  
There was also evidence of homing of intravenously delivered MSCFLT cells to 
subcutaneous  tumours.    MSCFLT  cells  were  delivered  at  day  10,  20,  and  30 
following subcutaneous breast cancer implantation, and shown to be present in the 
subcutaneous tumours when the mice were harvested at day 38 (Figure 4.5A,B). 
 
In addition to the lungs and subcutaneous tumours, the liver, spleen, kidneys, and 
heart were also harvested.  Only very small amounts of DiI-labelled cells were seen 
in the liver and spleen, and there was no incorporation into any of the other organs 
(figure 4.5C-F).  
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Figure 4.4  MSCs migrate to metastases in vivo. 
DiI-labelled  (red)  MSCs  or  MSCFLTs    injected  intravenously  at  day  10  and  shown  to 
localise to MDAMB231 (A) and A549 (B) lung metastases on fluorescent microscopy with 
DAPI nuclear counterstain, and H&E contiguous sections from day 30 harvested lungs.  The 
MSCFLT cells appear to target more specifically to the MDAMB231 metastases.  x10 mag 
scale bar represents 20 m and x4 mag scale bar represents 50 m. Chapter 4.  Results II      
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Figure 4.5  MSCs migrate to subcutaneous tumours, and have negligible incorporation 
into normal organs 
DiI-labelled (red) MSCFLT cells were injected intravenously at day 10, 20, 30 and shown to 
incorporate into MDAMB231 subcutaneous tumours.  A) H&E staining of sections from day 
38 harvested tumours and B) fluorescent microscopy of contiguous sections showing DiI 
incorporation (marked by arrow), with DAPI nuclear counterstain.  C-F) There is minimal 
DiI-labelled cells in the liver (C) and spleen (D)(marked by arrows) and none in the kidney 
(E) and heart (F).  Scale bars represent 20 m. Chapter 4.  Results II      
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4.2.3  Tumour cell lines produce multiple cytokines and chemokines 
Unlike leukocyte and haematopoietic stem cell migration, the specific chemokines, 
cytokines and growth factors that are instrumental in MSC migration have not yet 
been determined.  It is likely that multiple cytokines operate in combination, and that 
there is some redundancy.  In view of this, a cytokine array panel, with duplicate 
capture antibodies spotted on a nitrocellulose membrane, was used to simultaneously 
profile  the  relative  levels  of  multiple  cytokines  in  a  single  sample,  in  order  to 
highlight possible important candidates (Figure 4.6A).  In view of the strong in vitro 
migration of MSCs towards specifically MDAMB231 cancer cells, the chemokine 
production of this cell line was profiled in comparison to the other cancer cell lines 
and controls.  Consequently, the supernatant of confluent MDAMB231, 293T, A549, 
and  Hela  cells  (without  serum)  were  used  as  samples  for  the  cytokine  array.  
Densitometry  analysis  with  NIH  Image  J  program  software  was  performed  to 
convert the dot plots into values, and large differences (at least double) between the 
samples were plotted on a bar chart (Figure 4.6B).  The results demonstrated a large 
increase  in  the  factors  C5a,  granulocyte  macrophage  colony  stimulating  factor 
(GMCSF), IL-6 and IL-8 in the MDAMB231 supernatant compared to the other cell 
supernatants.  Other interesting results included the large concentration of serpin E1 
in  all  the  cancer  cell  supernatants,  the  large  amount  of  CXCL1  and  CCL5 
chemokines  in  the  A549  and  Hela  cells  respectively,  and  the  lack  of  significant 
CXCL12,  a  chemokine  important  in  haemopoietic  stem  cell  migration  and  a 
candidate for MSC migration, in any of the supernatants. 
 
 
4.2.4  Ex-vivo tumours produce multiple cytokines and chemokines 
The rationale of using MSCs to express TRAIL was for them to home to tumours for 
targeted therapy.  The in vitro data suggested that the MDAMB231 cell line had the 
greatest ability to attract the MSCs in a transwell experiment and analysis of the 
chemokines in the supernatant has suggested possible candidates for this increased 
migration.  In vitro, the A549 and Hela cell line caused the same MSC migration as 
the controls.  However, it is important to appreciate that the in vitro experiment is a 
poor recreation of the in vivo situation and should only be used as a guide.  The Chapter 4.  Results II      
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tumour stroma is extremely important, both for its affects on tumour behaviour, but 
also its contribution to bone marrow cell recruitment.  Publications have suggested 
that the tumour stroma is critical for the recruitment of bone marrow-derived stem 
cells (Sangai et al., 2005).  In vitro cell cultures are just collections of tumour cells 
without the supporting stroma and map of blood vessels necessary to recreate proper 
cell recruitment.  
 
In  view  of  this,  ex  vivo  lungs  with  multiple  MDAMB231  metastases  were 
homogenized and the chemokine array profile compared to normal mouse lungs.  
The  chemokine  profile  of  an  ex  vivo,  homogenized,  subcutaneous  MDAMB231 
tumour was also investigated.  The aim of this experiment was to ascertain whether 
any  of  the  chemokines  suggested  in  the  in  vitro  experiments  were  specifically 
produced by tumours in vivo, to give some clinical validity to the in vitro work.  As 
previously, densitometry analysis was performed to convert the dot plots into values, 
and large differences (at least double) between the lung and lung with breast cancer 
metastases were plotted on a bar chart (Figure 4.6C).  This showed an increased 
expression  in  the  lung  containing  metastases  of  soluble  intercellular  adhesion 
molecule-1 (sICAM- 1), IL-6, IL-8, macrophage migration inhibitory factor (MIF), 
CCL4,  and  serpin  E1,  with  CXCL12  and  IL-10  increasing  by  just  under  double 
compared to the lung without metastases.  The homogenized subcutaneous breast 
tumour contained very high levels of IL-6, IL-8, MIF, and serpin E1. 
 
On  the  basis  of  these  global  chemokine  arrays,  IL-6  and  IL-8  became  attractive 
candidates as important tumour-derived signals leading to MSC migration.  They 
were both increased predominantly in the MDAMB231 cell line, to which the MSC 
migrated most effectively in the in vitro transwell experiments.  They were also 
increased in ex vivo lung homogenates containing breast metastases in comparison 
to normal lung homogenates, and finally, they were present at high levels in ex vivo 
subcutaneous breast tumour homogenates, to which MSCs also homed.  Previous 
data had also suggested a potential role of these factors in MSC migration.  The IL-8 
receptors, CXCR1 and CXCR2, are critical in leukocyte migration (Luster et al., 
2005; Spaeth et al., 2008), and have been shown to be responsible for some in vitro 
MSC  migration  in  one  study  (Ringe  et  al.,  2007).    Similarly,  functional  IL-6 
receptors have been demonstrated on MSCs (Schmidt et al., 2006).  Furthermore, Chapter 4.  Results II      
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both  primary  breast  cancers  and  breast  cancer  cell  lines  produce  IL-6  and  IL-8 
(Dwyer et al., 2007; Gutova et al., 2008), and these cytokines have been implicated 
in the increased migration of MSCs seen after intensive exercise (Schmidt et al., 
2009). 
 
 
4.2.5  In vitro cytokine neutralisation 
The transwell migration of MSCs to MDAMB231 cells (section 4.2.1) was repeated 
with the use of neutralising antibodies to IL-6 and IL-8, at concentrations suggested 
by previous studies (Bastian et al., 1998; Okamoto et al., 2000).  Although at the 
lowest dose of IL-8 (0.1µg/ml) there was a statistically significant reduction in MSC 
migration  (p<0.05,  Anova)  this  was  not  repeated  at  higher  doses  and  there  was 
generally no reduction in MSC migration with the use of either inhibitor (Figure 
4.7A).  To ensure this result was not secondary to the insensitivity of the neutralising 
antibodies in the presence of serum, the experiment was repeated with serum-free 
medium  in  the  upper  and  lower  compartments  of  the  transwell.    With  these 
experimental  conditions,  as  previously  discussed,  migration  of  the  serum-starved 
MSCs  was  poor  and  inconsistent,  however  there  was  no  significant  reduction  in 
MSC  migration  toward  the  cancer  cells  with  the  addition  of  either  IL-6  or  IL-8 
neutralising antibodies (Figure 4.7B).  These results may suggest that IL-6 and IL-8 
are not important in MSC homing towards tumours; however they may also reflect 
the  likely  considerable  redundancy  in  the  system  with  multiple  chemokines 
producing similar effects. 
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Figure 4.6  Cancer cells produce multiple cytokines and chemokines in vitro and in vivo. 
Human  cytokine  array  panels  (A)  were  used  to  determine  possible  candidates  for  the 
increased MSC migration demonstrated in certain conditions.   B)  MDAMB231 cells in 
vitro produce increased C5a, GMCSF, IL-6,8,10 compared to the other cancer and control 
cell lines.  C)  Homogenized, ex vivo lung with multiple MDAMB231 metastases (met lung) 
produced more C5a, sICAM, IL-6,8,10, CXCL10, MIF, CCL4, serpinE1 and CXCL12 than 
normal control lungs (N lung).  Of these, homogenized, ex vivo, subcutaneous MDAMB231 
tumours (subcut ca) produced large amounts of IL6,8, MIF, and serpinE1.  Diagonal lines 
represent values in excess of the axes. Chapter 4.  Results II      
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Figure 4.7  MSC migration to cancer cells is not reduced by IL-6 or IL-8 inhibitors. 
A) With 10% serum in the upper and lower wells, transwell migration studies demonstrated 
a reduction in MSC migration to MDAMB231 cells at the lowest dose of IL-8 neutralising 
antibody  (Ab)(0.1µg/ml),  however  this  was  not  repeated  at  higher  doses  and  there  was 
generally  no  reduction  in  MSC  migration  with  the  use  of  either  inhibitor,  or  when  the 
experiment was repeated in serum free conditions (B), *p<0.05. Chapter 4.  Results II      
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4.2.6  Future migration work 
Much  of  this  work  focusing  on  the  identification  of  chemokines  and  cytokines 
important  in  the  MSC  migration  towards  tumour  tissue  is  preliminary  and  is  a 
proposed future project in the Janes’ laboratory.  Although no effect in blocking IL-6 
and IL-8 has been established in this thesis, future work may focus further on these 
possible candidates. Experiments will need to establish the presence of IL-6 and IL-8 
receptors  on  the  MSC,  and  then  use  a  combination  of  ligand  and  neutralising 
antibody experiments to demonstrate a specific functional effect, both in establishing 
and then blocking MSC migration in vitro and in vivo.  The use of receptor blockers, 
or silencing RNA to prevent the expression of receptors on the surface of MSCs may 
also be useful, however there is a lack of receptor specificity, the IL-8 receptors 
CXCR1  and  2  are  also  bound  by  CXCL6  and  CXCL1  and  7  respectively.    The 
contribution of other cytokines and chemokines to the homing of MSCs to tumours 
should also be assessed in further work.  Serpin E1 is also highlighted in the cytokine 
profile  arrays  as  a  molecule  produced  in  high  concentrations  by  tumour  tissue 
(Figure 4.6B,C).  This is a serine protease inhibitor, which functions predominantly 
as  an  inhibitor  of  fibrinolysis,  but  is  also  associated  with  tumour  invasiveness 
(Chazaud et al., 2002).  It may also augment MSC tumour-tropism (Gutova et al., 
2008), making it an attractive candidate for further research. Chapter 4.  Results II      
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4.3  Summary  
 
 
This chapter has demonstrated 
 
•  The development of a subcutaneous and lung metastatic cancer model which 
are reproducible 
 
•   MSCs  are  able  to  migrate  to  cancer  cells  in  vitro,  particularly  to 
MDAMB231 breast cancer cells.  
 
•  MSCs are able to specifically migrate to lung metastases and subcutaneous 
tumours in vivo.  
 
•  The mechanism of MSC homing to tumours is likely to be due to chemokine 
gradients.  IL-6 and IL-8 are produced by MDAMB231 cells in vitro, and as lung 
metastases  and  subcutaneous  tumours  in  vivo,  and  are  promising  candidates  for 
further study. 
 
•  Preliminary  experiments  neutralising  IL-6  and  IL-8  did  not  alter  MSC 
migration in vitro. Chapter 5.  Results III      
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CHAPTER 5.  RESULTS III – In vivo tumour effects 
of TRAIL-expressing MSCs  
 
   
 
Cancer cells have been shown to be susceptible to the MSCFLT cells in vitro, with 
an increase in death and apoptosis on coculture. This chapter focuses on combining 
the cancer cell killing and homing abilities of these engineered MSCs by using them 
as a cellular therapy in a variety of cancer models.  The aim was to demonstrate an 
effect in vivo and to determine whether the use of TRAIL-expressing MSCs could 
alter the clinical course of tumour growth. 
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5.1   Subcutaneous tumour model 
 
The advantage of the subcutaneous tumour model is that the cancer can be visualised 
throughout the experiment.  Longitudinal growth measurements can be taken during 
the course of the study, providing further information on the effects and timings of 
therapy.    Two  million  MDAMB231  cells  were  used  to  create  the  subcutaneous 
tumours  as  the  experiments  described  above  had  suggested  a  superior  MSC 
migration to this cell type.  The doxycycline-induced, MSCFLT cells were used as 
therapies, with the same cells without doxycycline used as controls for the effects of 
TRAIL.  Treatment of the subcutaneous tumours was either by coinjection of the 
cancer and MSCFLT cells, direct intratumoural injection of the MSCFLT cells or 
intravenous  MSCFLT  delivery.    The  coinjection  and  intratumoural  injection 
experiments were performed to investigate whether the TRAIL-expressing MSCs 
were able to cause cancer cell apoptosis and death in vivo, and whether this would 
alter the cancer growth.  The systemic MSCFLT treatment would take this a step 
further, also relying on the specific homing abilities.   
 
   
5.1.1  Coinjection 
As  a  proof  of  principle,  2x10
6  MDAMB231  cancer  cells  were  coinjected  with 
0.75x10
6  MSCFLT  cells  subcutaneously  into  NOD/SCID  mice.    The  mice  were 
equally split into three groups (n=3 per group), with the first group of mice receiving 
doxycycline (thus switching the construct on to produce TRAIL) in the drinking 
water from day 0.  The second group of mice received doxycycline at day 25, after 
the tumour had become established (0.25 ± 0.1cm
3), and the final group of mice 
received no doxycycline (Figure 5.1).  The results showed an early divergence in 
tumour growth between group 1 and the other two groups.  The group exposed to 
doxycycline from day 0 had significantly reduced tumour growth in comparison to 
the  other  groups.    This  remained  throughout  the  experiment  and  was  strongly 
significant at day 42 (0.03 ± 0.01cm
3 compared to 0.59 ± 0.18cm
3 in the mice that 
received no doxycycline) (p<0.001, 2-way Anova).  In the group where doxycycline 
was used at day 25, there was reduced tumour growth; however this did not reach Chapter 5.  Results III      
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statistical  significance  (Figure  5.1C).    The  same  patterns  were  observed  in 
comparing the tumour weights at the end of the experiment, with a significantly 
reduced tumour weight in the mice treated with MSCFLTs and doxycycline from 
day 0 compared to mice that received no doxycycline (0.07 ± 0.02g vs. 0.60 ± 0.07g) 
(p<0.01, Anova) (Figure 5.1D).  
 
This  proof  of  principle  experiment  was  repeated  with  much  larger  numbers.  
Activation of the TRAIL transgene at day 0 (n=10) again resulted in a significantly 
reduced tumour size compared to the mice that received no doxycyline (n=7) (0.12 ± 
0.12cm
3 vs. 0.66 ± 0.49cm
3)(p<0.001, 2-way Anova), however there was no change 
in  the  tumour  growth  when  TRAIL  was  activated  after  the  tumour  had  already 
become established at day 25 (n=7) (Figure 5.2A-B).   
 
Histological  analysis  of  the  sections  demonstrated  large  areas  of  necrosis  in  the 
tumours  of  the  mice  exposed  to  doxycycline.    There  was  also  evidence  of  DiI 
staining in these areas of necrosis, suggesting the involvement of the MSCFLT cells 
in the necrosis (Figure 5.2D).  Furthermore, TUNEL staining of excised tumours 
demonstrated  areas  of  apoptosis  co-localised  with  DiI-labelled  MSCFLT  cells 
(Figure 5.2E).   
 
The subcutaneous tumours were excised and digested to a single cell suspension. 
Confocal microscopy of the ex vivo DiI-labelled cells included cells of MSC type 
morphology  that  stained  with  an  anti-vimentin  antibody  (Figure  5.2F).    This 
suggested that the DiI staining seen in histological section was representative of the 
injected MSCFLT cells, and that they had kept, at least in part, their phenotype.  Chapter 5.  Results III      
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Figure 5.1  TRAIL-expressing MSCs reduce the growth of subcutaneous tumours.  
A) Subcutaneous tumours were produced by the coinjection of 2x10
6 MDAMB231 cells and 
0.75x10
6 MSCFLT cells, and the mice were treated with doxycycline (dox) at day 0 (grp1) or 
day 25 (grp3) or with no dox (nd).  B) Macroscopic appearance of the tumours.  C-D) Dox 
treatment from day 0 led to a reduced tumour size (C) and weight (D) compared to the nd 
group (grp2).  Although there was a trend to reduced tumour growth if TRAIL was activated 
at day 25, this was not significant.  *p<0.05, **p<0.01, ***p<0.001.  
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Figure 5.2  TRAIL-expressing MSCs reduce the growth of subcutaneous tumours.  
Subcutaneous tumours were produced by the coinjection of 2x10
6 MDAMB231 cells and 
0.75x10
6 MSCFLT cells, and the mice were treated with doxycycline (dox) at day 0 or day 
25 or with no dox (nd).  A) Dox treatment from day 0 led to a reduced tumour size compared 
to the nd group.  There was no reduction in tumour growth if TRAIL was activated at day 25.  
B) Macroscopic appearance of the tumours.  C) H&E immunohistochemistry showing large 
areas of necrosis within the tumours in mice treated with dox from day 0.  D) Contiguous 
fluorescent  microscopy  sections  showing  MSCFLTs  (DiI  -  red)  in  these  necrotic  areas 
(DAPI nuclear counterstain - blue). Scale bar represents 20 m.   E) TUNEL staining (green) 
demonstrated areas of tumour apoptosis localised with areas of MSCFLTs (DiI - red) within 
the tumours in mice treated with dox from day 0 (DAPI - blue).  Scale bar represents 20 m.  
F)  Ex  vivo  single  cell  digestion  and  culture  showed  DiI-positive  (red)  cells  with  MSC 
morphology that co-stained with vimentin (green) (DAPI - blue).  Scale bar represents 2 m.  
*p<0.05, **p<0.01, ***p<0.001. Chapter 5.  Results III      
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5.1.2  Intratumour Delivery 
TRAIL-expressing MSCs are therefore able to incorporate into early tumours and 
affect  cancer  growth.    A  further  experiment  was  performed  to  see  if  they  could 
incorporate into and affect the clinical course of established tumours.  
 
Two million MDAMB231 cells were injected subcutaneously into NOD/SCID mice.  
Subcutaneous tumours were allowed to grow until day 45 with an average size of 
0.28 ± 0.11cm
3.  The mice were then split into three groups; the tumours of group 
one were injected with 0.75x10
6 MSCFLT cells and exposed to doxycycline (n=4), 
group two were also injected with MSCFLT cells, but these mice were not exposed 
to doxycycline (n=4), and group three were injected with PBS intratumourly (n=5), 
and  exposed  to  doxycycline  (Figure  5.3A).    The  tumours  of  all  three  groups 
continued to grow following this treatment and there was no difference in subsequent 
growth over the next 12 days, or the final weight at day 57 (Figure 5.3B-D). 
 
 
5.1.3  Systemic Delivery 
The coinjection model had demonstrated an ability of the TRAIL-expressing MSCs 
to modulate tumour growth in vivo.  Intratumoural injection of MSCFLT cells would 
be a valid delivery route clinically for visualised tumours, however it would not be 
applicable in many clinical situations such as therapy for lung cancer metastases.  
Furthermore, intratumoural delivery does not utilise the homing property of the cells, 
one of the main reasons for their use.  For this, MSCFLT cells were intravenously 
injected  into  mice  to  treat  subcutaneous  tumours  (Figure  5.4).    Two  million
 
MDAMB231 cells were injected subcutaneously into NOD/SCID mice and the mice 
were treated at days 10, 20, and 30 with intravenous delivery of 0.5x10
6 MSCFLT 
cells with doxycycline (n=10), or MSCFLT without doxycycline (n=11), or PBS 
with doxycycline (n=9) (Figure 5.4A).  The mice were harvested at day 35, and 
despite the presence of DiI-labelled MSCs within the tumour mass (Figure 5.4B), 
there was no effect of the therapy on subcutaneous tumour growth or final weight 
(Figure 5.4C,D).  
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Figure 5.3  Intratumour delivery of TRAIL-expressing MSCs does not reduce the growth 
of established subcutaneous tumours.  
A) MDAMB231 subcutaneous tumours were treated at day 45 with intratumour delivery of 
TRAIL-transduced MSCs (MSCFLT) or phosphate-buffered saline control (no cells).  B) 
Macroscopic appearance of the tumours.  C-D) There was no effect on tumour growth (C) or 
weight (D) with the use of MSCFLT, with either doxycycline induced TRAIL activation (dox) 
or no doxycycline (nd). Chapter 5.  Results III      
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Figure 5.4  Systemic delivery of TRAIL-expressing MSCs does not reduce the growth of 
subcutaneous tumours.  
A) MDAMB231 subcutaneous tumours were treated at days 10, 20, 30 with intravenous 
delivery of MSCFLT cells or phosphate-buffered saline control (no cells).  B) Fluorescent 
microscopy demonstrating the DiI-labelled MSCFLTs (red) migrated to the subcutaneous 
tumour.  DAPI nuclear counterstain - blue.  Scale bar represents 20µm.  C-D) There was no 
effect on tumour growth (C) or weight (D) with the use of MSCFLT with either doxycycline 
induced TRAIL activation (dox) or no doxycycline (nd). Chapter 5.  Results III      
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5.2  Metastatic tumour model 
 
The  subcutaneous  models  demonstrated  the  ability  of  a  high  concentration  of 
MSCFLTs to affect the growth of primary tumours when at an early stage of tumour 
growth, with no effect on established tumours.  The advantage of the metastasis 
model would be to also utilise the specific tumour homing of the MSCFLT cells.  
The  metastatic  deposits  would  also  be  more  similar  to  the  early  tumours,  and 
whereas  primary  tumours  can  often  be  treated  with  surgery,  it  is  the  secondary 
cancer metastasis that leads to the majority of cancer death, therefore providing a 
very worthwhile target for the MSCFLT treatment. 
 
 
5.2.1  Systemic Delivery 
Two million intravenously injected MDAMB231 cells were used to produce lung 
metastases in NOD/SCID mice.  MSCFLT cells were then delivered intravenously at 
days 7, 14, 21 and 28 (Figure 5.5A).  The mice received MSCFLT and doxycycline, 
MSCFLTs alone, or PBS and doxycycline (n=8 per group).  They were harvested at 
day 35 and each lobe of every mouse was analysed histologically to determine the 
area and number of metastases.  Tumour metastases were found in all mice (8/8) 
without MSCFLT and all mice with MSCFLT without the use of doxycycline (8/8).  
In the MSCFLT plus doxycycline arm, three out of eight mice were tumour free 
(p=0.032, Chi
2) (Figure 5.5B).  In addition to the elimination of metastases with 
MSCFLT  plus  doxycycline,  the  lung  weight,  which  serves  as  a  correlate  for 
metastatic load, was also significantly reduced in the MSCFLT plus doxycycline 
group compared to the PBS-treated mice (0.22 ± 0.03g vs. 0.29 ±0.06g)(p<0.01, 
Anova).  Similar results were achieved when metastases numbers per lung area (0.04 
±0.05 vs. 0.27 ± 0.04)(p<0.001, Anova), or the total metastasis area per lung area 
(2.40 ± 2.66 vs. 14.29 ± 3.46)(p<0.001, Anova), were used as an endpoint (Figure 
5.5C-E).  Three mice had to be excluded from these latter analyses, as the lungs did 
not inflate during the fixation procedure.   
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Figure 5.5  TRAIL-expressing MSCs reduce the growth of lung metastases. 
A) 2 million MDAMB231 cells were injected intravenously at day 0 followed by intravenous 
treatment with phosphate-buffered saline (no cells) or MSCFLT cells at days 7, 14, 21 and 
28 with (dox) or without  (nd) doxycycline.  B) Representative histology of lung lobes in the 
three  experimental  groups.  Metastases  remained,  but  were  reduced,  after  injection  of 
MSCFLT  without  dox,  while  dox-induced  TRAIL  activation  of  MSCFLTs  eliminated 
metastases in 3 of 8 mice  (p=0.03).  C-E) Reduction in lung weight (C) and metastases area 
(D)  and  number  (E)  per  lung  area  with  the  use  of  MSCFLTs  both  with  and  without 
doxycycline treatment. There was a further significant reduction between dox-activated and 
nd MSCFLT.  ***p<0.001, **p<0.01, *p<0.05. Chapter 5.  Results III      
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MSCFLT cells delivered to control mice without doxycycline were unable to clear 
the metastases in any mice, but did have less metastases per area (p<0.001, Anova), a 
lower  total  metastasis  area  per  lung  area  (p<0.001,  Anova),  and  a  reduced  lung 
weight  (p<0.05,  Anova)  than  the  untreated  mice.    MSCFLT  plus  doxycycline 
treatment however produced a further significant reduction in metastases number 
(p<0.05, Anova) (Figure 5.5E).  
 
In a subsequent experiment, TRAIL and GFP were both shown to be expressed in 
vivo by the MSCFLT cells with immunohistochemistry when mice were harvested 
two days after treatment with MSCFLT and doxycycline (Figure 5.6A,B).  TRAIL 
mRNA derived from the lungs of these mice was also increased (Figure 5.6C). 
 
 
5.2.2  Early, prophylactic delivery 
The ability of TRAIL-expressing MSCs to reduce, and in some cases eliminate, the 
development of lung metastases is very exciting.  On the basis of these results and 
the  results  from  the  subcutaneous  experiments  suggesting  a  greater  tumour 
modulating  effect  at  early  tumour  timepoints,  the  next  experiment  attempted  to 
prevent  the  development  of  metastases  in  a  greater  percentage  of  mice  by 
administering the cellular therapy at earlier timepoints.  Two million MDAMB231 
cells were intravenously injected into NOD/SCID mice.  The mice received 0.5x10
6 
MSCFLT  and  doxycycline  (n=8),  0.5x10
6  MSCFLT  alone  (n=9),  or  PBS  and 
doxycycline (n=10) intravenously at days 0, 1, and 5.  Mice were harvested at day 35 
and analysed as above.  All mice developed lung metastases, with no differences in 
final lung weight, or metastasis number and area per lung area (Figure 5.7).        
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Figure 5.6  TRAIL and GFP can be detected in the lung metastases following intravenous 
delivery of TRAIL-expressing MSCs.  
Mice with MDAMB231 lung metastases were harvested 2 days after delivery of 0.5x10
6 DiI-
labelled,  MSCFLT  cells.    A)  Immunohistochemistry  demonstrating  cells  expressing  GFP 
(scale bar represents 5 m) and  B) TRAIL (scale bar represents 10 m) and contiguous 
immunofluorescence  sections  showing  these  cells  also  express  DiI  (red).    DAPI  nuclear 
counterstain – blue.  B) There was an increase in TRAIL mRNA from lung digests from mice 
treated  with  MSCFLT  and  doxycycline  (dox)  compared  to  mice  treated  with  MSCFLT 
without dox (nd).  *p<0.05. 
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5.3  Physiological metastatic tumour model 
 
Similar metastasis models created by the intravenous injection of cancer cells in 
immunocompromised mice have been used in several previous studies (Studeny et 
al., 2002; Studeny et al., 2004; Xin et al., 2007).  A more physiological metastasis 
model, whereby cancer cells detach from a primary tumour and migrate and seed 
metastases  was  also  developed  for  this  project  by  allowing  MDAMB231 
subcutaneous  tumours  to  grow  and  produce  lung  metastases.    Two  million 
MDAMB231 cells were injected subcutaneously into NOD/SCID mice and the mice 
were  treated  with  0.5x10
6  MSCFLT  and  doxycycline  (n=10),  0.5x10
6  MSCFLT 
alone (n=11), or PBS and doxycycline (n=9) intravenously at days 10, 20, and 30.  
Although there was no effect on the primary tumour growth (see 5.1.3), there was a 
reduction in the metastatic load with the MSCFLT therapy, consistent with the other 
metastatic  model.    Tumour  metastases  were  found  in  all  mice  (9/9)  without 
MSCFLT cells and 10/11 mice with MSCFLT cells without the use of doxycycline.  
In the MSCFLT plus doxycycline group, 3/10 mice were tumour free (p=0.138, Chi
2) 
(Figure 5.8B).  There was a significant reduction in metastases number per lung area 
(0.01 ± 0.01 vs. 0.03 ± 0.02) and total metastasis area per lung area (0.82± 0.95 vs. 
3.82 ± 1.38) (both p<0.05, Anova) in the MSCFLT and doxycycline group compared 
to the PBS-treated mice (Figure 5.8C,D).       
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Figure  5.7    Early  systemic  delivery  of  TRAIL-expressing  MSCs  does  not  prevent  the 
development of metastases.  
A) 2 million MDAMB231 cells were injected intravenously at day 0 followed by intravenous 
treatment with phosphate-buffered saline (no cells) or MSCFLT cells at days 0, 1, and 5 with 
(dox) or without (nd) doxycycline.  B-D) No reduction in lung weight (B) and metastases 
area (C) and number (D) per lung area with the use of MSCFLTs both with and without 
doxycycline treatment. Chapter 5.  Results III      
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Figure 5.8  TRAIL-expressing MSCs reduce the growth of physiological lung metastases. 
A)  2  million  MDAMB231  cells  were  injected  subcutaneously  at  day  0  and  treated 
intravenously with phosphate-buffered saline (no cells) or MSCFLT cells at days 10, 20, and 
30 with (dox) or without (nd) doxycycline.  B) Dox-induced TRAIL activation of MSCFLTs 
eliminated metastases in 3 of 10 mice  (p=0.14).  C-D) Reduction in metastases area (D) 
and number (E) per lung area with the use of dox-activated MSCFLT cells compared to the 
no cell-treated mice.  *p<0.05. 
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5.4  Summary  
 
 
This chapter has demonstrated 
 
•  MSCFLT  cells  significantly  reduce  the  growth  of  early  subcutaneous 
tumours when coinjected. 
 
•   MSCFLT cells do not alter the growth of established subcutaneous tumours 
when delivered by coinjection, intratumour injection, or intravenously. 
 
•  MSCFLT cells home to and reduce the development of lung metastases in 2 
different models, eliminating metastases in some subjects.   
 
•  MSCFLT  cells  cannot  prevent  metastases  before  they  have  developed.Chapter 6.  Results IV      
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CHAPTER 6.  RESULTS IV – Cancer stem cells and 
the side population  
   
 
 
6.1  Introduction 
 
6.1.1  Cancer Stem Cells 
Cancers are composed of a heterogeneous mix of cells with varying differentiation, 
proliferation and tumorigenic properties (Heppner, 1984).  Indeed, in vivo studies 
have demonstrated that within a cancer population, only a small percentage of cells 
are able to initiate tumour development (Al-Hajj et al., 2003; Lapidot et al., 1994).  
Many believe that the heterogeneous groups of cells includes a small population of 
cancer cells with stem cell properties, so called ‘cancer stem cells’, with the capacity 
to  self-renew  and  differentiate  asymmetrically  (Visvader  &  Lindeman,  2008).  
Conventional cancer treatments may eradicate the tumour bulk but spare populations 
of cancer stem cells, which are able to restore tumour tissue and lead to recurrence.  
This may explain why an initial tumour regression does not necessarily translate to 
an improved patient survival in many clinical trials for advanced cancers (Wicha et 
al., 2006).  Possible mechanisms for the resistance of cancer stem cells to treatments 
include  their  increased  ability  to  repair  damaged  DNA  (Bao  et  al.,  2006),  the 
activation of survival pathways (Hambardzumyan et al., 2008), and the increased 
expression of ATP binding cassette protein (ABC) transporters (Dean et al., 2005).  
The  identification  and  destruction  of  these  cells  may  therefore  improve  cancer 
treatment responses. 
 
 
6.1.2  Side Population 
Cell surface markers have been used in some cancers to produce a population of cells 
enriched with stem cell properties, for example CD133 in the identification of human Chapter 6.  Results IV      
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glioma (Singh et al., 2004) and colon cancer (Ricci-Vitiani et al., 2007) stem cells.  
However these markers appear specific to particular tumours, and no marker has 
identified cancer stem cells across tumour types.  Normal stem cell characteristics 
are  often  utilised  to  identify  this  population.    This  includes  the  ability  to  efflux 
nuclear dyes such as Hoechst 33342, which binds to DNA.  The efflux of Hoechst is 
due to ABC transporters, in particular ABCG2/BCRP1 (Zhou et al., 2001).  These 
Hoechst-effluxing cells were originally described in the bone marrow and termed 
‘side population’ due to their appearance on flow cytometry plots (Goodell et al., 
1996).    They  have  since  been  shown  in  a  variety  of  normal  tissues,  where  they 
possess stem-like properties (Wu & Alman, 2008).  These Hoechst-effluxing cells 
have also been identified in many cancers, including lung (Ho et al., 2007; Sung et 
al.,  2008),  breast  (Engelmann  et  al.,  2008),  oesophageal  (Huang  et  al.,  2009), 
hepatocellular (Kamohara et al., 2008), glioma (Harris et al., 2008), and renal (Addla 
et al., 2008) cancer cell lines, in addition to primary cancer cells (Barrett et al., 1995; 
Hirschmann-Jax et al., 2004; Szotek et al., 2006; Wu et al., 2007).   
 
The side population cells within cancers have many stem-like properties, including 
the ability to repopulate both the SP and non-SP cell compartments (Ho et al., 2007; 
Kondo et al., 2004; Zhang et al., 2009), an increased ability to form colonies (Zhang 
et al., 2009) and generate complex spheroids in 3D culture (Addla et al., 2008), a 
high telomerase activity (Ho et al., 2007), and increased quiescence (Ho et al., 2007).  
They have also been shown to express a number of stem-like genes (including OCT-
4, SOX-2, and BMI-1) (Huang et al., 2009; Zhang et al., 2009), ABC transporter 
genes  (including  ABCG2)  (Huang  et  al.,  2009;  Zhang  et  al.,  2009),  and  genes 
involved in the Wnt (Addla et al., 2008; Haraguchi et al., 2006; Huang et al., 2009), 
Notch (Addla et al., 2008; Huang et al., 2009), PI3K/Akt pathways, and  cell cycle 
regulation (Zhou et al., 2007).  Side population cells derived from both primary 
tumours (Wu et al., 2007) and cancer cell lines (Chiba et al., 2006; Ho et al., 2007) 
also have an increased ability to initiate tumours compared to the majority of the 
tumour cells, when xenografted into immunodeficient mice.  These features have led 
to  suggestions  that  these  cells  may  fill  the  role  of  the  putative  cancer  stem  cell 
(Giangreco  et  al.,  2007;  Hadnagy  et  al.,  2006),  although  other  groups  have  not 
demonstrated  such  stem  cell-like  behaviour  of  the  SP  cells  in  certain  cancers 
(Burkert et al., 2008; Lichtenauer et al., 2008). Chapter 6.  Results IV      
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In addition to the ability of these cells to repopulate tumours, they are also able to 
escape death by many chemotherapeutic agents, due in part to their increased ABC 
transporter expression (Chiba et al., 2006) which, in addition to effluxing Hoechst, is 
also able to efflux lipophilic chemotherapy agents such as doxorubicin (Doyle & 
Ross, 2003), and methotrexate (Chen et al., 2003).  Furthermore, chemotherapy and 
radiation treatments preferentially target rapidly proliferating cells in comparison to 
what  may  be  the  relatively  quiescent  cancer  stem  cells.  This  combination  of 
resistance and tumour initiation makes it likely that these side population cells are 
central to tumour growth and recurrence, and stresses the importance that future 
cancer therapeutics are able to target these cells.  I hypothesise that TRAIL therapy 
would target SP and non-SP cells equally. 
 
 
6.2    Results 
 
6.2.1  Squamous and lung cancer cell lines contain an ABC transporter side 
population 
Many  cancer  cell  lines  and  primary  cells  contain  a  side  population.  In  order  to 
determine whether squamous cell, lung and breast carcinomas might also contain a 
similar subpopulation of drug-resistant SP cells, confluent H357 (squamous), A549 
(lung)  and  MDAMB231  (breast)  cancer  cell  lines  were  incubated  with  Hoechst 
33342  dye  and  analysed  by  flow  cytometry.    A  characteristic  SP  fraction  was 
detected in the H357 and A549 cell lines, but not the MDAMB231 cells, which is 
consistent with a previous report (Engelmann et al., 2008).  The squamous and lung 
SPs  were  both  reserpine  sensitive,  indicating  their  dependence  on  ABC-type 
transporter activity (Figure 6.1).    
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Figure 6.1  Squamous cancer and lung cancer cell lines contain a side population.  
A-B) Representative flow cytometry plots demonstrating the H357 (A) and A549 (B) cancer 
cell  lines  contain  a  side  population  (SP)  of  cells  that  stain  poorly  with  Hoechst.    This 
population disappears with the ABC transporter inhibitor, reserpine.  The gates show the 
cells defined as SP and non-SP for the experiments. Chapter 6.  Results IV      
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6.2.2  The SP cells exhibit stem-like characteristics in vitro 
The ability to form expanding colonies of cells is a typical stem cell characteristic.  
The ability of both SP and non-SP H357 cells to form colonies was investigated and 
taken as an indicator of their individual proliferative capacity.  SP cells were shown 
to have an increased clonogenic potential compared to non-SP cells when 200 cells 
of  both  types  were  separately  plated  in  6-well  plates.    This  experiment  was 
performed by Laura Pritchard, a student in the laboratory (Appendix B, Figure 4).  
Similar results were suggested by my own experiments (section 6.2.5).  
 
 
6.2.3  The SP cells exhibit stem-like characteristics in vivo 
To test for in vivo tumorigenic potential, which is the feature most often taken to 
signify the presence of cancer stem cells, the tumour formation capacity of H357 SP 
and non-SP cells were compared.  Two million SP cells (n=6) or 2 million non-SP 
H357 cells (n=6) were subcutaneously injected into the flank of NOD/SCID mice 
and allowed to grow for 49 days. In accordance with previous attempts to grow 
H357 cells in an in vivo model (Janes & Watt, 2004; Jones et al., 1996), none of the 
non-SP cell grafts produced tumours (Figure 6.2A,B).  Interestingly, three of six SP 
sorted  and  engrafted  cell  populations  did  produce  subcutaneous  tumours  with  an 
average  volume  of  0.038cm
3  (Figure  6.2A,B).    Human  H357  squamous  cell 
carcinomas were confirmed by H&E, and active cell proliferation was demonstrated 
by staining for Ki67, a cell cycle protein expressed from G1 through to the end of the 
M  phase  of  the  cell  cycle  (Figure  6.2C,D).    To  my  knowledge,  this  is  the  first 
demonstration  of  an  H357  cell  population’s  ability  to  produce  tumours  in  vivo 
strongly suggesting that the SP contains a unique population of cancer stem-like cells. Chapter 6.  Results IV      
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Figure 6.2  The SP cells are tumorigenic in vivo.   
A,B)  Subcutaneous injection of 2x10
6 H357 side population (SP) cells led to tumours in 3/6 
NOD/SCID mice, compared to 0/6 tumours when 2x10
6 non-SP cells were used.  C) H&E 
staining confirmed a squamous cell carcinoma (scale bar represents 20µm) with D) high 
proliferation shown by Ki67 staining (scale bar represents 10µm). 
 
 
6.2.4  The SP cells are chemoresistant 
The  observation  that  H357-SP  cells  exhibited  elevated  Hoechst  33342  efflux, 
indicated that these cells may possess resistance to cytotoxic chemotherapeutic drugs, 
including mitoxantrone.  Colony forming assays were performed to assess SP and 
non-SP H357 cells for mitoxantrone sensitivity.  Two hundred cells were cultured in 
the  presence  of  0,  1  and  10ng/ml  mitoxantrone  for  3  days  followed  by  14  days 
culture in mitoxantrone-free media and the numbers of large colonies were compared.  
The SP subgroup of H357 cells was capable of maintaining significantly more large 
colonies than the non-SP cells in mitoxantrone (Figure 6.3A) (10ng/ml; 38.3 ± 4.5 
large colonies with the SP compared to 3.0 ± 1.0 with the non-SP cells; p<0.05, 2-
way  Anova).    This  raw  data  (Figure  6.3)  was  from  the  experiments  of  Laura 
Pritchard. (see also Appendix B, Figure 6), and I have adapted it for this project.  In 
addition, similar experiments to this have been repeated by myself (6.2.6).   Chapter 6.  Results IV      
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Figure 6.3  The SP cells have an increased resistance to mitoxantrone.   
A) 200 side population (SP) or non-SP H357 cells were plated for colony forming assays 
before the addition of 0, 1, or 10ng/ml of mitoxantrone (mitox).  The plates were stained with 
rhodanile  blue.    B)  Quantification  of  large  colony  numbers  from  (A)  demonstrates  an 
increased ability of SP cells to form large colonies in 10ng/ml mitoxantrone. * p<0.05.  
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6.2.5  The SP cells can be killed by TRAIL-expressing MSCs 
In the previous chapters, TRAIL-expressing MSCs have been shown to have the 
ability  to  cause  cancer  cell  death  and  a  decrease  in  tumour  and  metastasis 
development in vivo.  The cancer stem cell hypothesis suggests that the destruction 
of  the  cancer  stem  cell  candidates  is  also  crucial  for  a  cancer  therapy.    Having 
isolated a population enriched for possible cancer stem cells (SP) in both squamous 
and lung cancer cell lines, their susceptibility to the TRAIL-expressing MSC therapy 
was tested in coculture experiments.  SP and non-SP cells were freshly flow-sorted 
from DiI-stained H357 and A549 cells (Figure 6.1) and immediately cocultured with 
the MSCFLT cells.  The death and apoptosis of the cancer cells in coculture was 
assessed  by  Annexin  V  flow  cytometry  as  previously  described.      There  was  a 
significant increase in death and apoptosis of both the SP and non-SP subgroups of 
H357 cells with the use of doxycycline and activation of the TRAIL transgene (SP: 
13.4 ± 1.4% increased to 68.1 ± 5.5%, non-SP: 16.1 ± 1.4% increased to 60.9 ± 2.5%) 
(Figure 6.4) and A549 (SP: 2.7 ± 0.5% increased to 27.7 ± 1.9%, non-SP: 4.4 ± 1.5% 
increased  to  30.4  ±  1.6%)  (Figure  6.5)  (both  p<0.001,  Anova).    There  was  no 
difference between the SP and non-SP subgroups in their response to the TRAIL-
expressing MSCs in both cancer cell lines (Figure 6.4, 6.5). 
 
The susceptibility of the cancer cell subpopulations to TRAIL-expressing MSCs was 
further  assessed  with  colony  forming  assays.    Two  hundred  freshly  sorted,  DiI-
stained SP or non-SP H357 cells were added to a 6-well plate.  The following day, 
5x10
4 MSCFLT cells (treated with mitomycin C to prevent their further growth) 
were  added  to  the  plates  and  the  TRAIL  transgene  either  activated  or  not  with 
doxycycline.    As  had  previously  been  shown  (see  6.2.2),  colony  formation  was 
greater in the SP subgroup compared to the non-SP cells (60.0 ± 1.7 large colonies in 
the SP cells compared to 34.0 ± 7.8 large colonies in the non-SP cells)(p<0.001, 2-
way Anova).  Colony formation was significantly inhibited in both cell subgroups 
with the doxycycline-induced activation of the TRAIL transgene of the MSCs (SP: 
60 ± 1.7 large colonies reduced to 14.7 ± 4.2 large colonies with TRAIL expression, 
non-SP: 34.0 ± 7.8 large colonies reduced to 8.0 ±1.7 large colonies with TRAIL 
expression) (both p<0.001, 2-way Anova) (Figure 6.6). 
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Figure 6.4  TRAIL-expressing MSCs lead to death and apoptosis of H357 SP and non-SP 
cells.   
Freshly sorted DiI-labelled H357 side population (SP) and non-SP cells were cocultured 
with  MSCFLT  cells  with  (dox)  or  without  (nd)  doxycycline.  A-B)  Representative  flow 
cytometry plots demonstrating the percentage of apoptotic and dead non-SP (A) and SP (B) 
H357 cells.  C) Bar chart representing triplicate experiments demonstrating the increase in 
death and apoptosis with doxycycline–induced TRAIL expression in both the SP and non-SP 
subgroups.  *** p<0.001. Chapter 6.  Results IV      
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Figure 6.5  TRAIL-expressing MSCs lead to death and apoptosis of A549 SP and non-SP 
cells.   
Freshly sorted DiI-labelled A549 side population (SP) and non-SP cells were cocultured 
with  MSCFLT  cells  with  (dox)  or  without  (nd)  doxycycline.  A-B)  Representative  flow 
cytometry plots demonstrating the percentage of apoptotic and dead non-SP (A) and SP (B) 
A549 cells.  C) Bar chart representing triplicate experiments demonstrating the increase in 
death and apoptosis with doxycycline–induced TRAIL expression in both the SP and non-SP 
subgroups.  *** p<0.001. Chapter 6.  Results IV      
  159 
 
Figure 6.6  TRAIL-expressing MSCs reduce the clonigenic potential of H357 SP and non-
SP cells.   
A-B)  Two hundred DiI-labelled, side population (SP)(A) or non-SP (B) H357 cells were 
plated for colony forming assays before the addition of 5x10
4 MSCFLT cells.  C) Phase and 
D)  fluorescent  microscopy  demonstrate  the  GFP  from  the  doxycycline  (dox)-activated 
MSCFLTs  surrounding  the  DiI-labelled  H357  colonies.    E)  A  small  (<32  cell)  abortive 
colony and F) a large colony stained with rhodanile blue.  G)  Quantification of large 
colony numbers from (A,B) demonstrates a reduction in large colonies with dox–induced 
TRAIL expression in both SP and non-SP cells compared to the cocultures without dox (nd).  
Furthermore, SP cells produced more colonies than non-SP cells.  Scale bars represent 
25µm.  *** p<0.001.  Chapter 6.  Results IV      
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6.2.6  The  addition  of  TRAIL-expressing  MSCs  to  mitoxantrone  treatment 
causes additional cancer cell killing  
DiI-labelled, side population H357 cells were treated with 10ng/ml mitoxantrone for 
3 days followed by coculture with MSCFLT cells.  The Annexin V flow cytometry 
assay was used to determine the apoptotic and dead SP cancer cells.  There was a 
significant increase in dead and apoptotic cells with the addition of doxycycline and 
activation of the TRAIL transgene (56.3 ± 10.0% with doxycycline, compared to 
33.9  ±  2.4%  without  doxycyline)(p<0.01,  Anova)  (Figure  6.7).    This  suggests  a 
further cancer killing effect of the TRAIL-expressing MSCs above and beyond the 
mitoxantrone chemotherapy agent.  Indeed, when TRAIL was not expressed with 
doxycycline, the use of mitoxantrone alone did not significantly increase the dead 
and apoptotic cancer cells, consistent with a degree of mitoxantrone chemoresistance 
of the SP cells as discussed above (33.9 ± 2.4% with mitoxantrone compared to 
24.56 ± 4.2% without mitoxantrone)(p>0.05, Anova) (Figure 6.7).  
 
 
 
 
Figure  6.7    TRAIL-expressing  MSCs  produce  additional  SP  cancer  cell  killing  to 
mitoxantrone treatment.   
Side population (SP) H357 cells were exposed to mitoxantrone (Mitox) and then cocultured 
with  MSCFLT  cells.    Bar  chart  represents  triplicate  flow  cytometry  experiments  and 
demonstrates a further increase in death and apoptosis of the SP cells with the addition of 
doxycycline (Dox) and activation of MSCFLT TRAIL expression. *** p<0.001, ** p<0.01, 
ns non-significant. 
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6.3  Discussion  
 
There  are  some  limitations  with  the  present  evidence  suggesting  the  presence  of 
cancer stem cells in solid tumours.  The hypothesis is primarily supported by the 
significantly  increased  ability  of  selected  ‘stem-like’  cancer  cells  to  produce 
transplanted  tumours.    Furthermore,  in  vivo  radiation  experiments  have 
demonstrated that only a fraction of cancer cells may need to be killed to cure the 
tumour (Hendry et al., 1994).  However, the transplantation model may not best 
define the population of cancer cells that have the ability to regrow cancers in their 
original niche.  The transplants do not include the other stromal and non-malignant 
cells of the original tumour and hence provide a different environment in which to 
test tumour growth.  In addition it is possible that the ‘stemness’ of a cancer cell may 
be a dynamic process, with a population of cells with variable stem cell properties 
constantly changing over time (Hill, 2006).   
 
There are also issues with the identification of the putative cancer stem cell.  Surface 
markers  are  non-specific  to  the  cancer  cells  and  may  also  be  modified  by  the 
methods used to disaggregate cells from the tumour for selection.  Selection of cells 
by the Hoechst assay is toxic to cells and hence a comparison between the biological 
characteristics of the SP and non-SP cells is difficult.  Secondly, the dye efflux is a 
dynamic process and hence defining the side population is critically dependent on 
variables including the concentration of Hoechst and length of staining.  The SP cells 
are also unlikely to be a pure population of cancer stem cells.  Despite this, the 
technique is well recognised at producing an enriched source of stem-like cells and 
unlike  cell  surface  markers,  has  the  ability  to  sort  these  cells  from  different 
populations. 
 
One feature of the side population, or subgroup of cells enriched for stem cells, is 
their resistance to common oncological treatments.  These studies have demonstrated 
that  this  subpopulation  has  some  resistance  to  chemotherapy  agents  such  as 
mitoxantrone.  This subgroup of cells has also been shown to be more capable of 
tumour initiation in a subcutaneous model.  The combination of increased treatment 
resistance and ability to repopulate tumours suggest new treatments should be able to Chapter 6.  Results IV      
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target these cells effectively.  The in vitro coculture experiments with MSCFLT cells 
demonstrate that these TRAIL-expressing cells are able to kill SP and non-SP cells 
in both squamous and lung cell lines with equal efficacy.  This suggests that TRAIL-
expressing MSCs would be a useful potential agent for cancer treatment either alone, 
or potentially in combination with other radiotherapy and chemotherapy regimes.  
The benefits of a combination approach were also demonstrated in these studies, 
with  an  improved  SP  killing  using  a  combination  of  mitoxantrone  and  TRAIL-
expressing MSCs.  As has been mentioned previously, cancer recurrence is common 
post surgical removal (with curative intent) of the primary tumour.  This may be due 
to a few malignant cells, which remain dormant at distant sites until relapse.  These 
cells  are  usually  quiescent  but  have  the  ability  to  repopulate  tumours,  features 
making them candidates to be cancer stem cells.  As the TRAIL-expressing MSCs 
seem also able to destroy these cells, this may provide a further rationale for their use 
post primary tumour removal. Chapter 6.  Results IV      
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6.4  Summary  
 
 
This chapter has demonstrated 
 
•  Several  cancer  cell  lines  contain  a  side  population,  which  have  stem  cell 
characteristics. 
 
•  The cancer cell side population have enhanced colony forming ability and in 
vivo tumorigenic potential. 
 
•  The cancer cell side population have some chemoresistance.   
 
•  The cancer cell side population can be killed by the MSCFLT cells. Chapter 7.  Discussion      
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CHAPTER 7.  DISCUSSION 
 
 
   
7.1  Overview 
 
Cancer treatment has traditionally relied upon chemotherapy and radiotherapy, in 
addition to surgery.  Despite improvements in management, cancer is still one of the 
leading causes of death in the world.   Many cancers have developed resistance to 
present therapies.  In addition, chemotherapy and radiotherapy are generally poorly 
selective and cause damage and death of normal cells as well as the cancer cells, 
leading to treatment side effects including, in some cases, death.  
 
An improved cancer therapy would be able to specifically target cancer cells and 
have little effect on the normal tissues.  This thesis has developed this idea and 
moved away from traditional treatment approaches by combining two disparate areas 
of research.    The first is based on the observations that MSCs appear to home to, or 
at  least  engraft  preferentially  within,  tumours.    This  provides  a  perfect  delivery 
vehicle for a new cancer therapy, directing treatment specifically to the tumours.  
The second area of research focuses on the discovery of a new member of TNF 
family; TRAIL.  This transmembrane protein is able to cause tumour cell apoptosis 
and death without affecting normal cells, providing a specific therapy with minimal 
side  effects.    The  combination  of  these  two  approaches,  to  produce  a  TRAIL-
expressing MSC is consequently particularly attractive.  
 
In this project, mesenchymal stem cells have been engineered to express TRAIL 
under the sensitive control of the Tetracycline-on inducible system.  These cells were 
able to kill cancer cell lines in vitro via the extrinsic death pathway to a higher 
degree than recombinant protein.  In vivo, the TRAIL-expressing MSCs reduced the 
growth of early subcutaneous tumours, while in a systemically delivered metastasis 
model these cells reduced metastases but most significantly eliminated metastases in 
some mice.  Chapter 7.  Discussion      
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7.2  Mesenchymal Stem Cells 
 
Mesenchymal stem cells are isolated based on their combination of surface markers, 
adherence to plastic in culture, and differentiating ability.  The lack of a definitive 
marker  to  characterise  an  MSC  has  resulted  in  a  lack  of  uniformity,  with  many 
published studies using different definitions and characterisations of this cell type 
(Weiss et al., 2008).  Furthermore, although the majority of MSCs are isolated from 
the  bone  marrow,  other  sources  including  umbilical  cord  blood,  placenta,  and 
adipose tissue have also been identified and used (Lee et al., 2004; Li et al., 2007; 
Puissant et al., 2005).  The MSCs from these different sources have been shown to 
have varying gene expressions and lineage tendencies (Kern et al., 2006).  Culture 
conditions, expansion, and the MSC microenvironment have all been shown to alter 
the characteristics and behaviour of MSCs (Rombouts & Ploemacher, 2003; Stolzing 
& Scutt, 2006), and there is also the possibility of different subgroups of cells within 
the MSC compartment (Phinney, 2007).   This variability of cell type has made 
comparisons between studies difficult.  The lack of consensus has led to the recent 
development of a set of criteria to define an MSC, published by the International 
Society for Cellular Therapy (Dominici et al., 2006).  In view of these issues in the 
MSC  field,  the  MSCs  used  in  this  project  were  obtained  from  the  repository  at 
Tulane University.  These cells had been extensively characterised according to the 
necessary criteria, and importantly had been validated and used for many of the 
published studies (Spaeth et al., 2009; Stoff-Khalili et al., 2007).  These MSCs were 
further tested on receipt, demonstrating colony forming ability, and the ability to 
differentiate into multiple stromal lineages.  They had been extracted from the bone 
marrow of a single human female donor and were expanded for all the applications 
in this project.  All experiments were performed with as low a passage number as 
possible, typically between 4 and 8.  
 
In addition to the tumour-homing properties, MSCs are readily expandable, with up 
to 50 population doublings in 10 weeks (Giordano et al., 2007).  They are also easily 
transduced  with  integrating  vectors  due  to  their  high  levels  of  amphotrophic 
receptors  (Marx  et  al.,  1999).    Studies  with  both  retroviral  and  lentiviral  vector 
transfer have demonstrated long-term in vitro and in vivo expression of a range of Chapter 7.  Discussion      
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transgenes including human IL-3 over 17 passages (6 months) (Lee et al., 2001), 
Factor VIII (FVIII) over many months (Van Damme et al., 2006), and GFP over 20 
passages (Chan et al., 2005).  Transduced MSCs retained their stem cell properties 
and were able to differentiate into osteogenic, adipogenic, and chondrogenic lineages 
while expressing the transgene.  In addition, differentiated MSCs also maintained 
transgene expression after differentiation (Lee et al., 2001).  Viral transduction does 
not therefore appear to alter the characteristics and behaviour of the MSCs, and this 
was  similarly  found  in  this  project.    The  transduced  MSCs  retained  their 
differentiation profile, and migrated to cancer cells in vitro and in vivo with the same 
efficiency as the non-transduced MSCs.   
 
Mesenchymal stem cells are also widely acknowledged to be immunoprivileged and 
non-allogenic  and  xenograft  MSCs  can  be  used  without  the  use  of  prior 
immunomodulation.  In our models this was not important, as the mice were already 
immunocompromised,  however  this  has  great  clinical  implications,  where 
engineered  MSCs  could  be  used  in  patients  as  a  cell  therapy,  without  the 
considerations and complications surrounding immunomodulation prior to their use.  
This property could theoretically allow the development of an MSC bank, where 
cells  could  be  stored  and  used  ‘off  the  shelf’  for  patients.    Such  standardised 
preparations of MSCs are being used in many clinical trials including cardiac disease, 
GvHD, and Crohn’s disease, and the low immunogenicity has obviated the need for 
human leukocyte antigen (HLA) matching (Weiss et al., 2008).  In experimental 
xenograft transplantation models, rat MSCs have been shown to survive in a mouse 
model, however they have not been able to produce bone (Wang et al., 2007).  It is 
important to consider therefore, particularly with xenotransplantation, that the lack of 
immune recognition does not necessarily translate into a fully functional MSC. 
 
 
7.3  Viral transduction 
 
For the cell engineering, lentivirus constructs were produced for the transduction.  
Lentiviruses were used in view of potential significant advantages over other vector 
systems.  Adenoviral vector expression is transient as the vector does not integrate Chapter 7.  Discussion      
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into  the  host  genome.    Adenoviral  vectors  also  often  produce  a  significant  host 
immune  response  to  the  adenovirus.      Retroviral  vectors  have  the  advantage  of 
incorporating into the host DNA, providing long term gene expression, however they 
produce  the  possibility  of  incorporation  errors  such  as  host  gene  transactivation 
secondary to the potent viral enhancer element.  This is thought to be one of the 
factors leading to the development of leukaemia in immunocompromised patients 
treated with this gene therapy (Hacein-Bey-Abina et al., 2003).   Lentiviral vectors 
are  less  likely  to  cause  transactivation  of  host  genes  at  vector  integration.    The 
promoter  region  in  viral  long  terminal  repeat  (LTR)  sequences  can  be  modified 
extensively, inactivating it in the integrated vector genome.  Furthermore, lentiviral 
vectors  have  the  ability  to  stably  transduce  both  dividing  and  quiescent  cells 
(Kyriakou et al., 2006), which is another significant advantage when using stem cells 
that  are  often  quiescent  or  slow  growing.    The  use  of  lentiviral  vectors  has 
demonstrated more efficient MSC transduction and in vivo engraftement than the 
retroviral  vectors  with  GFP  and  FVIII  transgene  expression  (Van  Damme  et  al., 
2006).   Lentiviral vectors also provide more long lasting transgene expression, with 
one study demonstrating maintenance over 14 weeks in culture, with a concurrent 
decrease  in  transgene  expression  in  the  retroviral-transduced  cells  (Chan  et  al., 
2005).    In  addition  to  the  problems  with  longevity  of  transgene  expression,  our 
transient  transduction  experiments  showed  additional  problems  with  a  leaky  and 
unspecific tetracycline control of the transgene. 
 
Cell types were transduced successfully with the transgene, as documented by the 
GFP expression.  A multiplicity of infection of 10 was used to transduce the MSCs 
with the lentivirus, in accordance to previous reports (Aguilar et al., 2007; Chan et 
al., 2005).  At this MOI, the transduction efficiency of MSCs was greater than 80%.  
It was noted that this percentage of GFP-positive cells remained through several 
passages, in accordance with the existing long-term transgene data (Chan et al., 2005; 
Lee  et  al.,  2001;  Van  Damme  et  al.,  2006).    In  addition,  transgene  expression 
remained  even  with  repeated  activation  and  deactivation  with  doxycycline.    The 
stable transgene expression over many passages suggested that the MSCFLT cells 
had neither a survival advantage nor disadvantage when the TRAIL was expressed or 
silent,  or  in  comparison  to  the  non-transduced  MSCs,  again  consistent  with  the 
existing literature (Chan et al., 2005; Lee et al., 2001; Van Damme et al., 2006).  An Chapter 7.  Discussion      
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improved transduction efficiency of greater than 90% could be achieved by an MOI 
of  20,  without  any  excess  death  of  the  MSCs.    For  the  purposes  of  this  project 
however, a stable transduction efficiency of 80% was sufficient and allowed lower 
production amounts of the lentivirus.  With this in mind an MOI of 10 was used in 
further experiments. 
 
 
7.4  TRAIL transgene 
 
The successful transduction of cells and GFP expression also translated to TRAIL 
expression  as  demonstrated  by  the  western  blots  and  ELISA  data.    The  flow 
cytometry data was less convincing in demonstrating significant cell surface protein 
expression.  However this has also been found in other studies (Wenger et al., 2006), 
and may be due to lack of antibody sensitivity.  TRAIL is a type 2 transmembrane 
protein,  however  it  may  also  be  proteolytically  cleaved  to  produce  a  soluble 
molecule.  Previous studies using viral transduction of cells with full length TRAIL 
have demonstrated that the apoptosis-inducing effect in these studies is cell-based 
and not transferred to the medium.  The authors have inferred from this that soluble 
TRAIL is not released into the supernatant by the transduced cells (Kagawa et al., 
2001; Ucur et al., 2003).  Soluble proteins generally have better access to targets 
than  non-secreted  proteins  and  an  improved  anti-tumour  effect  has  been 
demonstrated in some in vitro and in vivo studies (Kim et al., 2006).  In view of this 
potentially  increased  anti-tumour  effect,  a  soluble  TRAIL  plasmid  for  lentiviral 
transduction was also produced.  This contained just the extracellular portion of the 
TRAIL molecule (amino acids 114-281).  In the transiently transduced 293T cells, 
both full length TRAIL protein (32kDa) and soluble TRAIL protein (21kDa) were 
demonstrated in the 293T cell lysates by western blot and ELISA.  However, no 
sTRAIL was demonstrated in the cell supernatant, suggesting that the soluble portion 
of  TRAIL  is  produced  but  not  released  into  the  supernatant  in  these  transiently 
transduced cells.  This is in agreement with studies suggesting that a secretion signal 
peptide is necessary to produce excretion of this molecule (Kim et al., 2006; Kim et 
al., 2004; Wu et al., 2001; Wu & Hui, 2004).  In contrast, there are two publications 
suggesting  that  simple  transduction  of  cells  with  the  extracellular  component  of Chapter 7.  Discussion      
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TRAIL is enough to produce a functional, soluble TRAIL (Ma et al., 2005; Shi et al., 
2005).  The stable transduction of MSCs with the soluble TRAIL transgene was 
similarly  only  partially  successful,  with  GFP  expression  but  no  evidence  of 
corresponding TRAIL protein expression.  Conversely, TRAIL protein expression 
was evident in both the cell lysates and the cell supernatants of MSCs transduced 
with the full length TRAIL transgene.  The production of TRAIL protein in the 
supernatant  by  the  full  length  TRAIL-transduced  MSCs  is  in  contrast  to  most 
(Kagawa et al., 2001; Ucur et al., 2003), but not all (Wei et al., 2001) of the literature 
demonstrating  no  anti-cancer  effect  of  the  supernatant  of  full  length  TRAIL-
transduced cells.  In addition to the literature suggesting an increased anti-tumour 
effect of soluble TRAIL, studies have also suggested the relative benefits of the 
membrane-bound  version.    Whereas  DR4  is  activated  by  soluble  or  membrane-
bound TRAIL, DR5 appears to require membrane-bound or cross-linked TRAIL for 
activation.    Furthermore,  some  cells  which  are  not  sensitive  to  soluble  TRAIL 
apoptose when the TRAIL is tethered to a cell membrane (Carlo-Stella et al., 2006; 
Muhlenbeck et al., 2000; Wajant et al., 2001).  In view of the potential advantages of 
membrane-bound TRAIL, the production of TRAIL protein in the supernatant by the 
full length TRAIL-transduced cells, and the lack of sTRAIL expression in the stably 
transduced MSCs, this project focused on the use of the full length TRAIL transgene.  
 
 
7.4.1  Tetracycline inducible 
The ability to turn on and off the transgene is especially useful in this model as it 
allows  for  tight  controls  in  experiments,  in  addition  to  the  ability  to  switch  on 
TRAIL at different stages of tumour growth, including both pre-tumourous states 
and after tumour establishment.  Far from being just a useful research tool, it can be 
envisaged that such a system could have clinical applications.  Possible imaging 
techniques may be used with labeled MSCs to allow in vivo tracking of these cells 
and  TRAIL  activated  only  when  the  cells  are  located  in  the  tumour  vicinity.  
Treatment  can  be  turned  on  specifically  to  be  coincident  to  chemotherapy  or 
radiotherapy  regimes,  with  the  expression  turned  off  between  these  courses.   
Furthermore, all the treatments can be turned off when no longer needed but have the 
potential to be reinstated simply with an antibiotic, in the case of relapse.  The in Chapter 7.  Discussion      
  170 
vitro  studies  have  shown  the  TRAIL  protein  to  be  expressed  within  one  day  of 
doxycycline  use,  and  to  lose  expression  one  to  two  days  after  the  doxycycline 
stimulus is removed.  The timescale of the GFP expression was slightly different 
with a similar activation in one day but a gradual loss of GFP over five to seven days 
following  doxycycline  removal.    The  differences  may  be  secondary  to  the 
differences in protein degradation or the relative sensitivities of the western and flow 
cytometry analyses. 
 
 
7.5   In vitro cell death 
 
The functionality of the MSCFLT cells was demonstrated by coculture experiments.  
By labelling the cancer cells, it was evident that the MSCs remained alive and killed 
the surrounding cancer cells.  Four different tumour cell lines, representing different 
organ cancers, showed sensitivity to the TRAIL expressed by MSCs.  In addition, 
cancer  cells  resistant  to  mitoxantrone  chemotherapy  were  also  sensitive  to  this 
approach.  In contrast, non-cancer cells appeared relatively unharmed.  There was no 
increase in death or apoptosis of 293T cells or the MSCs themselves with TRAIL, 
and although more fibroblasts appeared to die, the increase was minimal. 
 
For the coculture experiments, the cells were at near confluence overnight and then 
doxycycline was added for two days.  The cells were cocultured at confluence to 
allow  maximal  close  apposition  of  cell  types  to  enable  greatest  ligand  receptor 
interaction.  Two days were found to be sufficient to allow for TRAIL expression 
and the apoptosis of cells.  If the cells were left together for longer periods (five or 
seven days), there was increased cancer cell death, however there was also increased 
death  in  the  control  cells  due  to  overconfluence.    In  vivo  these  problems  of 
overconfluence do not occur.  Consequently, the MSCFLT cells will be apposed to 
the cancer cells for longer and may lead to a greater proportion of cancer cell death 
than  suggested  by  the  in  vitro  data.    The  supernatant  of  full  length  TRAIL-
transduced MSCs was also able to cause the apoptosis and death of cancer cells, 
suggesting that the MSCFLT cells would be able to cause death of a greater number 
of cancer cells than those immediately apposed. Chapter 7.  Discussion      
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The cancer cell death was dependent on the expression of TRAIL by the MSCs.  
Neither coculture of cancer cells with normal MSCs and doxycycline, nor MSCFLT 
cells without doxycycline led to increased death and apoptosis.  Other studies have 
shown different effects, with one demonstrating an increase in apoptosis of cancer 
cells  in  coculture  with  MSCs  (Lu  et  al.,  2008).    However,  as  described  in  the 
introduction, there is presently little consensus on the effects of MSCs themselves on 
cancer cells. 
   
Much of the in vitro work in this project used MSCFLT and cancer cells cocultured 
at a ratio of 1:1.  For clinical applications, there would not be a 1:1 ratio of MSCFLT 
and cancer cells, so it is important to be able to demonstrate an effect at much lower 
concentrations of MSCFLT cells.  The data showed that unsurprisingly there was a 
dose dependent effect; however even at initial cocultures of 1:16 (MSCFLT:cancer 
cell) the effect was strongly significant.  Cancer cells proliferated at a much faster 
rate than the MSCFLT cells.  When cocultured at a ratio of 1:1 without doxycycline, 
the ratio had reduced to 1:3.6 by the end of the coculturing experiment (2.5 days).   
Consequently, even though the original coculturing occurred at the stated ratios, this 
overestimated the proportion of MSCFLT cells by the time the TRAIL was active.  
Up to 40 % of the myofibroblasts of the tumour stroma have been found to be bone 
marrow-derived  in  some  studies  (Ishii  et  al.,  2003)  and  consequently  there  is 
potential for these in vivo findings to be translated into in vivo models.   
 
The use of zVADfmk and the dominant negative FADD construct illustrated the 
extrinsic apoptosis pathway as the mechanism of death in the in vitro studies.  The 
use of the dnFADD construct does not reduce the death completely to the level of the 
no-doxycycline state, which is most likely to be as a result of incomplete expression 
and efficiency of the dnFADD construct.  
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7.6  Migration 
 
MSCs  have  the  ability  to  preferentially  migrate  to  cancers.    This  project 
demonstrated this in vivo with the use of the lipid dye CM-DiI.  DiI labelling is 
technically very easy, causing a diffuse cytoplasmic staining which does not affect 
the  behaviour  and  culture  of  the  cells.    It  has  been  validated  as  a  technique  for 
labelling and tracking human cells transplanted into mice in a study whereby DiI-
stained cells were further characterised as human origin with the use of an in situ 
hybridisation  technique,  which  clearly  differentiated  between  human  and  mouse 
nuclei (Schormann et al., 2008).  The majority of DiI-labelled cells were found to be 
of  human  transplanted  origin,  with  a  small  number  of  labelled  cells  containing 
murine DNA, presumably having been taken up by the host cells from degenerated 
donor cells.  In this project, vimentin staining of ex vivo DiI cells was also used to 
demonstrate a mesenchymal morphology and staining pattern, as would be expected 
from the labelled donor MSCs. 
 
The precise mechanism behind the specific homing of MSCs to the multiple tumours 
in this project is difficult to pinpoint.  The most likely cause of preferential migration 
is the release of chemotactic gradients from the tumours.  MSCs have a large variety 
of chemokine and cytokine receptors on their cell surface, and respond functionally 
to the ligands in vitro.  Furthermore, manipulation of these receptors and ligands has 
been shown to alter the migration patterns in vivo.  Tumours are also known to 
produce a large array of chemokines and cytokines, which could serve as ligands for 
the  MSC  receptors  (Dwyer  et  al.,  2007).    Nevertheless,  although  migration 
mechanisms  have  been  well  characterized  for  haemopoietic  stem  cells,  with  the 
importance  of  the  ligand  CXCL12  and  its  receptor  CXCR4  highlighted,  the 
contributions of individual chemokines and cytokines in MSC migration have not 
been determined.  Previous studies that have attempted to determine the mechanism 
of MSC migration have focused on investigating the chemokine receptors present on 
the cell surface of MSCs and their functional importance in vitro.  Such an approach 
however has led to a lack of consensus between studies, with different receptors 
postulated (Honczarenko et al., 2006; Ponte et al., 2007; Ringe et al., 2007; Sordi et 
al.,  2005;  Von  Luttichau  et  al.,  2005).    The  differences  are  likely  to  be  due  to Chapter 7.  Discussion      
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experimental conditions, with variations in the MSCs and their microenvironments, 
altering  receptor  expression  and  activation.    In  this  project,  the  problem  was 
approached by investigating the chemokines produced by the tumours both in vitro 
and in vivo.  In vitro, the MSCs migrated preferentially to MDAMB231 cells and 
array panels were used to suggest the chemokines particularly produced by this cell 
line.  To improve the model, the chemokines produced by this cell line in vivo were 
then investigated by using the same array panels with homogenized, ex vivo tumours 
as the substrate.  Although this does add some validity to the in vivo work, it is 
important  to  realise  that  the  detected  differences  may  also  be  due  in  part  to  the 
presence of human cells within a mouse model, as opposed to a specific feature of 
the tumour.  With these limitations in mind, on the basis of these results, IL-6 and 
IL-8  were  highlighted  as  possible  candidates.    It  is  likely  however  that  there  is 
significant redundancy in the chemokine driven migration of MSCs and further work 
will be required to characterise the process in more detail. 
 
In  addition  to  the  chemotactic  gradient  produced  by  cancers,  other  possible 
explanations exist for the observation that the MSCs appeared to migrate to and 
localize within the lung metastases.  Metastases themselves preferentially home to 
particular sites within the body, and this explains the clinical observations of certain 
tumours producing distinct metastasis patterns; for example breast cancer typically 
produces lung, bone, liver, and lymph node metastases, whereas the lymph nodes 
and bones are the most frequent sites for secondary spread of colon cancer.  The 
importance of a chemokine mediated metastasis model was first suggested on the 
basis  that  CXCR4  and  CCR7  were  heavily  expressed  on  breast  tumours  but  not 
normal breast tissue and that the ligands, CXCL12 and CCL21, exhibited peak levels 
of expression in the lung, bone marrow, liver, and lymph nodes, the frequent sites of 
metastasis.  CXCL12, CCR7, and organ protein extracts promoted migration and 
invasion of the cancer cells in vitro and this could be reduced with the use of CXCR4 
neutralising antibodies, which also reduced breast cancer metastases in vivo (Muller 
et al., 2001).  This model has now been extended to the metastasis of a range of 
human cancers and expression of CXCR4 is correlated inversely with survival of 
several cancers including breast (Chu et al., 2008), lung (Reckamp et al., 2009), 
osteosarcoma (Laverdiere et al., 2005), and melanoma (Scala et al., 2005).   It is 
possible therefore that instead of responding to a chemotactic gradient produced by Chapter 7.  Discussion      
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the tumours, the MSCs are instead attracted down the same migratory paths as the 
metastatic cancer cells, towards the chemokines released by the sites of metastasis 
such as the lung.  The DiI-labelled MSCs were however largely seen within the 
tumours.  There is also the possibility that the systemically delivered MSCs lodge 
and  embolise  in  the  lung  vasculature  (Khakoo  et  al.,  2006;  Weiss  et  al.,  2008), 
producing the picture of apparent homing to the metastases.  
 
Against both of these possibilities, this project has demonstrated that intravenously 
delivered MSCs are able to migrate to subcutaneous tumours, as well as the lung 
metastases.  This, in addition to the in vitro data showing migration to cancer cells, 
would suggest that there is a specific homing to cancers and that this is likely to be 
driven by their production of cytokines and chemokines. 
 
 
7.7   In vivo models  
 
The in vivo tumour models in this project demonstrated that the TRAIL-expressing 
MSCs were able to kill cancer cells in vivo and have effects on cancer growth, 
progression, and metastasis.   
 
MSCFLT  cells  significantly  reduced  the  growth  of  subcutaneous  tumours,  when 
coinjected  with  MDAMB231  cells  and  activated  with  doxycycline.    If  the 
doxycycline  activation  and  TRAIL  expression  was  delayed  until  the  tumour  had 
become  established  at  day  25,  there  was  no  effect  on  reducing  its  size.    In  this 
experiment however the proportion of MSCFLT cells at day 25 would be low, as the 
MDAMB231 cells would have proliferated at a far greater rate than the MSCFLT 
cells.    With  this  in  mind,  more  clinically  relevant  models  were  produced,  with 
MSCFLT  cells  delivered  either  intratumourly  or  intravenously  in  mice  with 
established subcutaneous MDAMB231 tumours.  There was however also no effect 
on tumour size and growth with the doxycycline-activated MSCFLT in either of 
these models.  This suggested a role of MSCFLT in early cancer treatment, but did 
not rule out a potential use of these cells in established primary tumours, where, Chapter 7.  Discussion      
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although  not  affecting  primary  tumours  growth,  they  may  influence  survival  or 
metastatic spread. 
 
A  metastatic  lung  cancer  model  was  developed  by  the  intravenous  delivery  of 
MDAMB231 cells.  This was a very reproducible model and produced multiple lung 
metastases in all of the NOD/SCID mice (around 100) during the project.  Treatment 
of  these  mice  with  intravenous  doxycycline-activated  MSCFLT  cells  led  to  a 
significant reduction in metastasis number and size.  Furthermore, in a significant 
proportion of mice, no metastases developed at all.  There was a significant effect of 
metastasis reduction with the use of MSCFLT cells without doxycycline, suggesting 
that the MSCs themselves had some anti-cancer effect.  The expression of TRAIL by 
these  cells  however  led  to  a  significant  additional  effect  and  the  elimination  of 
metastases in some mice.  The antitumour effects of the MSCs alone have been 
described  previously  in  a  variety  of  cancer  models  with  different  mechanisms 
postulated to explain the effect including the stimulation of cancer cell cycle arrest 
(Lu et al., 2008), an increase in apoptosis (Sun et al., 2009), and the downregulation 
of several pro-survival and proliferating signaling pathways (Khakoo et al., 2006; 
Qiao et al., 2008a; Qiao et al., 2008b).  In contrast, other studies have demonstrated a 
protumorigenic  effect  of  MSCs,  with  an  increase  in  tumour  size  and  metastasis, 
which  have  also  been  ascribed  to  multiple  mechanisms  including 
immunosuppressive effect (Djouad et al., 2003) and the production of trophic factors 
(Karnoub et al., 2007; Kyriakou et al., 2006; Sasser et al., 2007).  
 
Although  the  intravenous  delivery  of  MDAMB231  cells  produced  a  very 
reproducible  lung  metastases  model,  this  does  not  accurately  recreate  the 
development  of  metastases,  whereby  cells  detach  from  the  primary  tumour  and 
migrate  and  seed  tumour  development  in  other  organs.  A  more  physiological 
metastatic  model  was  therefore  developed,  whereby  subcutaneous  tumours  were 
allowed to grow and the mice developed lung metastases directly from these primary 
tumours.    These  mice  were  treated  with  intravenous  MSCFLT  cells  and  similar 
effects of the reduction in metastases were observed.  This suggested that MSCFLT 
cells may have little or no effect on reducing the growth of established primary 
tumours outside the lung, but may still have a role in the prevention of metastases.  
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A final experiment looked at the possibility of preventing metastases with very early 
MSCFLT treatment.  This intravenous therapy was delivered at days 0, 1, and 5 after 
intravenous MDAMB231 cells, before metastases would have developed.  There was 
no effect of this treatment and all mice developed lung metastases.  This may suggest 
that small tumours or metastases, or tumour vasculature are necessary in order to 
produce sufficient chemokines and cytokines to attract the MSCFLT cells, which are 
unable to efficiently target multiple individual cells, as suggested by other authors 
(Djouad et al., 2003).    
 
Summarising the in vivo experiments, this thesis has demonstrated the ability of the 
MSCFLT cells to influence early tumour development and metastatic spread, which 
is in line with the proposed predominant physiological role of TRAIL; the immune 
surveillance against cancer cells.  
 
With the aim of future translational therapeutics, human cancer xenograft models, 
human MSCs and human TRAIL constructs were used in this project.   The use of 
human cancer cells necessitated immunocompromised mice to avoid rejection of the 
foreign cells.  NOD/SCID mice have greater levels of immunocompromise than nude 
mice, with additional B cell and NK cell deficiencies, and these mice provided more 
consistent and faster growing tumours than the nude mice.  It is important to note 
that no animal models are ideal representations of human disease.  Human TRAIL 
has  65%  homology  to  murine  TRAIL  (Wiley  et  al.,  1995),  and  there  are  also 
differences in the receptors in mice and humans.  In the mouse only one death-
inducing receptor with homology to DR5 has been discovered, in addition to two 
decoy receptors (mDcTrailr1, msDcTrailr2) (Lawrence et al., 2001).  The use of 
human TRAIL is more relevant to the death and apoptosis of human cancer cells, but 
the effects of human TRAIL on the normal murine cells may be different to the 
response of normal human cells, particularly with the known lack of a receptor with 
homology  to  DR4  in  mice.    This  may  underestimate  the  adverse  effects  of  the 
TRAIL therapy, however reassuringly these have been negligible both with the use 
of murine TRAIL in mice (Song et al., 2006) and in early human trials (Ashkenazi, 
2008;  Greco  et  al.,  2008;  Hotte  et  al.,  2008;  Johnstone  et  al.,  2008).    It  is  also 
important to note that the immunocompromised mice used in this project will have 
very little of their own host immune response to the tumours.  This could possibly be Chapter 7.  Discussion      
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seen  as  a  limitation  of  the  model  in  accurately  reflecting  the  clinical  situation, 
however many patients with cancers will also have degrees of immunocompromise 
secondary to traditional therapies.  
 
 
7.8  Translation 
 
The ultimate goal of this research is for the development of a cellular therapy for 
humans.  The directed anticancer treatment described in this thesis has significant 
potential for translation to clinical medicine.   
 
This thesis has demonstrated a role of MSCFLT cells in early cancer treatment and 
the elimination of metastases.  This effect on metastases is extremely important, as 
secondary spread is the main cause of mortality and morbidity in cancer patients.  
Many  patients  with  solid  organ  tumours  remain  at  significant  risk  of  future 
metastatic disease despite primary tumour resection and chemo- and radiotherapy.  
The recurrence rate following surgery of curative intent, despite tumour negative 
lymph nodes, is up to 40% in non-small cell lung cancer, 30% in colon cancer, 25% 
in breast cancer and 15-50% in prostate cancer (Riethdorf et al., 2008).  Identifying 
these  patients  at  significant  risk  of  future  metastatic  disease  is  now  becoming  a 
reality  with  the  use  of  highly  sensitive  and  specific  molecular  and  cytological 
techniques, which allow the detection of very small numbers of circulating tumour 
cells in the blood and bone marrow (Lang et al., 2007; Riethdorf et al., 2008).  The 
detection  of  these  cells,  presumably  resistant  to  the  hosts  endogenous  immune-
surveillance, are related to metastatic recurrence and poorer prognosis, and could be 
amenable to MSC directed TRAIL therapy.  Further work would be necessary to 
define  the  optimal  timing  of  therapy,  as  this  project  showed  an  inability  of  the 
MSCFLT cells to prevent the development of metastases when delivered too early, 
before the metastases had developed. 
 
The  most  likely  position  for  MSCFLT  therapy  in  cancer  treatment  would  be  in 
combination with present radiotherapy and chemotherapy agents.  The combination 
of TRAIL with these agents has shown significantly increased efficacy in vitro and Chapter 7.  Discussion      
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in vivo, and this is being utilised in clinical trials.  The MSC component of the 
therapy developed in this project may also benefit from combination treatment.  The 
homing of these cells to tumours has been shown to significantly increase with the 
use of radiation.  This has been demonstrated with irradiated glioma, breast and 
colon cancer xenograft models in addition to a syngeneic, murine, breast carcinoma 
model (Klopp et al., 2007; Zielske et al., 2008).  The latter study showed increased 
MSC  migration  to  cancer  cells  in  vitro  and  in  vivo  with  the  increased  tropism 
thought to be secondary to the increased inflammation and expression of cytokines 
from the irradiated tissue, in addition to the upregulation of chemokine receptors on 
the MSCs exposed to the irradiated tumour cells (Klopp et al., 2007). 
 
TRAIL-expressing MSC therapy is applicable to most cancers.  Many cancers are 
directly sensitive to the delivery of TRAIL, and resistant cells can be sensitised to 
TRAIL  by  combination  with  traditional  cancer  therapies  or  other  agents.  
Interestingly,  cancer  cells  resistant  to  TRAIL  as  part  of  a  primary  skin  tumour 
became  sensitive  on  detachment  in  the  initial  stages  of  metastasis,  by  the 
downregulation of the ERK signalling pathway (Grosse-Wilde et al., 2008).  Similar 
results have also been reported with breast (Goldberg et al., 2001) and ovarian (Lane 
et al., 2008) carcinoma cells, again highlighting the metastasis suppressor role of 
TRAIL.   
 
TRAIL causes cancer apoptosis and death by a different pathway to chemotherapy 
and radiotherapy and can also be used in treatment failure with resistant tumours.  
Importantly, this therapy appears able to kill potential cancer stem cells, which are 
often relatively quiescent and have other stem-like characteristics allowing survival 
and  cancer  relapse  in  the  face  of  traditional  anticancer  treatments.    TRAIL-
expressing MSCs appear to have very little host toxicity and are specifically directed 
to cancers throughout the body.     
 
One of the major hurdles in translating basic research into clinical treatments is the 
issue  of  safety.    It  is  promising  that  all  the  components  used  in  producing  the 
TRAIL-expressing MSC have already entered human clinical trials, with good initial 
safety and tolerability data.  TRAIL therapy, in the form of recombinant protein and 
monoclonal  antibodies  to  DR4  or  DR5,  has  been  used  in  Phase  2  clinical  trials Chapter 7.  Discussion      
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(Ashkenazi, 2008; Greco et al., 2008; Hotte et al., 2008; Johnstone et al., 2008).  
Exogenous MSCs have been delivered in clinical trials covering a variety of different 
applications including the promotion of haematopoietic recovery (Koc et al., 2000), 
GvHD  (Le  Blanc  et  al.,  2008),  osteogenesis  imperfecta  (Horwitz  et  al.,  2002), 
ischaemic cardiac disease (Hare & Chaparro, 2008), Crohn’s disease (Weiss et al., 
2008), and COPD (Iyer et al., 2009) and so far neither acute nor long term adverse 
effects  have  been  reported  following  their  infusion.    The  lentivirus  used  in  this 
project also has good initial safety data following a trial in HIV (Levine et al., 2006), 
and present studies utilising it in adrenal leukodystrophy and sickle cell anaemia are 
ongoing.Chapter 8.  Summary and Future Directions      
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CHAPTER 8.  SUMMARY AND FUTURE 
DIRECTIONS 
 
 
   
This  thesis  has  demonstrated  that  mesenchymal  stem  cells  can  be  engineered  to 
express TRAIL under the sensitive control of the Tetracycline-on inducible system.  
These cells were able to kill cancer cell lines in vitro via the extrinsic death pathway 
to a higher degree than recombinant protein.  In vivo, the TRAIL-expressing MSCs 
reduced the growth of early subcutaneous tumours, while in a systemically-delivered 
metastasis  model  they  reduced  metastases,  but  most  significantly  eliminated 
metastases  in  a  proportion  of  mice.    The  success  of  the  project  has  produced 
excitement that this therapy may have clinical application, and as such in depth, 
preclinical human safety studies are a natural progression. 
 
However,  there  are  still  many  unanswered  basic  science  questions  that  future 
laboratory  work  would  hopefully  address.    The  optimal  timing  of  delivery  and 
number of cells needed is unknown.  Early delivery of a greater number of MSCs 
improved the numbers of MSCs and the outcome of a cerebral ischaemia model 
(Chen et al., 2001; Omori et al., 2008).  A cell number plateau was reached in a rat 
model of brain injury, with no difference between the delivery of 1 or 3 million 
MSCs (Wu et al., 2008).  In each of these models however the lesion has a well-
defined  initiation,  which  is  not  apparent  with  cancer  development.    Future 
experiments  should  address  these  issues  to  give  some  appreciation  of  when 
MSCFLT cells should be delivered for the treatment of both primary tumours and 
their metastases.  It is also unclear whether repeated smaller treatments or solitary 
injections of large numbers of cells would produce the best response.  
 
In addition to optimising the delivery protocol, further experiments would focus on 
the mechanisms involved in MSC homing towards tumours.  The work performed in 
this thesis suggests the importance of chemokine and cytokine gradients produced by 
tumours, and the possible roles of IL-6 and IL-8.  Further experimentation would Chapter 8.  Summary and Future Directions      
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involve the identification of chemokine receptors present on the surface of the MSCs, 
and how these change with alterations to the MSC microenvironment, or culture 
conditions.    Specifically,  the  proximity  of  MSCs  to  cancer  cells,  the  culture 
confluence and passage number would be addressed.  The use of receptor blockers or 
silencing RNA to prevent the expression of receptors on the surface of MSCs may 
also be useful for in vitro and in vivo studies.  There is likely to be significant 
redundancy in the system and hence it is likely that combinations of ligands and 
antagonists will be required.  It would also be interesting to try and augment the 
migration  process.    This  has  been  suggested  by  low  dose  irradiation  of  primary 
tumours (Klopp et al., 2007; Zielske et al., 2008), however this approach would be 
less suited to multiple metastatic deposits.  Further transduction of MSCFLT cells to 
overexpress  chemokine  and  cytokine  receptors  may  increase  tumour  specific 
migration and improve the anticancer effects.  Future work could also assess the 
efficacy  of  MSC  homing  towards  tumours  in  different  locations  and  at  different 
stages of development.  Homing towards lung metastases may be more efficient than 
metastases in other locations such as the liver, as systemically delivered MSCs reach 
the lung vasculature at first pass.  The effects of the MSCFLT cells should therefore 
also be investigated in other metastatic models such as liver metastasis, and with 
different tumour sizes. The chemokine gradient theory would suggest that the most 
efficient  homing  would  occur  with  larger  more  established  tumours  producing 
increased concentrations of chemokines.  This may explain the lack of effect on 
preventing  metastases  when  MSCFLT  cells  were  delivered  very  early,  before 
metastases had developed.  This model could be repeated with the cancer cells and 
MSCFLT cells transduced to overexpress specific chemokine ligands and receptors 
respectively, to ascertain whether an increased attractive signal could improve the 
effects.  
 
A  development  that  would  help  with  the  further  investigations  into  optimising 
delivery and the migration of the MSCFLT cells is the ability to track the MSCs in 
vivo in real time, without sacrificing the mouse.  This would also have significant 
clinical applications, as the proximity of the MSCFLT cells to the tumours could be 
assessed before activating the TRAIL protein expression.  Other groups have used 
luciferase bioluminescence in mouse models for this function (Sasportas et al., 2009).  
However, this has both temporal and spatial detection limitations.  Novel imaging Chapter 8.  Summary and Future Directions      
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contrast agents have emerged that open up the possibility of visualizing stem cell 
transplants in vivo using magnetic resonance imaging (MRI) (Bulte & Kraitchman, 
2004).  In pilot work, carried out as part of this project, bio-compatible magnetic iron 
oxide (Fe3O4) superparamagnetic nanoparticles iron oxide nanoparticles have been 
introduced into MSCs to enable localized cellular-level sensing, while retaining full 
viability.  Future work would build on these initial observations to track the delivery 
of MSCFLT cells. 
 
The side population has been highlighted in this thesis as a candidate for a cancer 
stem cell.  These cells have been shown to have some chemoresistance and in vivo 
tumour initiating properties.  Future work would use these side population cells in 
further in vivo tumour models and look at the effects of chemotherapy, radiotherapy 
and  MSCFLT  individually,  and  in  combination,  to  try  and  recreate  the  clinical 
scenario  of  tumours  with  some  resistance  to  traditional  therapies. Chapter 9.  References      
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Abstract
Cancer is a leading cause of mortality throughout the world
and new treatments are urgently needed. Recent studies
suggest that bone marrow–derived mesenchymal stem cells
(MSC) home to and incorporate within tumor tissue. We
hypothesized that MSCs engineered to produce and deliver
tumor necrosis factor–related apoptosis-inducing ligand
(TRAIL), a transmembrane protein that causes selective
apoptosis of tumor cells, would home to and kill cancer cells
in a lung metastatic cancer model. Human MSCs were
transduced with TRAIL and the IRES-eGFP reporter gene
under the control of a tetracycline promoter using a lentiviral
vector. Transduced and activated MSCs caused lung (A549),
breast (MDAMB231), squamous (H357), and cervical (Hela)
cancer cell apoptosis and death in coculture experiments.
Subcutaneous xenograft experiments confirmed that directly
delivered TRAIL-expressing MSCs were able to significantly
reduce tumor growth [0.12 cm
3 (0.04-0.21) versus 0.66 cm
3
(0.21-1.11); P < 0.001]. We then found, using a pulmonary
metastasis model, systemically delivered MSCs localized to
lung metastases and the controlled local delivery of TRAIL
completely cleared the metastatic disease in 38% of mice
compared with 0% of controls (P < 0.05). This is the first study
to show a significant reduction in metastatic tumor burden
with frequent eradication of metastases using inducible
TRAIL-expressing MSCs. This has a wide potential therapeutic
role, which includes the treatment of both primary tumors
and their metastases, possibly as an adjuvant therapy in
clearing micrometastatic disease following primary tumor
resection. [Cancer Res 2009;69(10):4134–42]
Introduction
Cancer remains one of the biggest causes of mortality and
morbidity throughout the world (1). Present therapy focuses on
varying combinations of surgery, chemotherapy, and radiation
treatment. Despite healthcare improvements, metastatic disease
remains poorly responsive to conventional therapy and a new
modality of treatment is urgently needed.
Bone marrow–derived mesenchymal stem cells (MSC) are
stromal cells that reside within the adult bone marrow. They are
characteristically able to differentiate into bone, cartilage, and fat
and have roles in the differentiation of hematopoietic cells. Recent
studies have shown an ability of these cells to migrate to and
incorporate within the connective tissue stroma of tumors (2–7).
This property of MSCs can be used to direct targeting antitumor
agents to tumor cells and their micrometastases with improvement
in murine tumor models of glioma (4, 8), melanoma (6), and breast
(5) and colon (7) cancers.
Tumor necrosis factor–related apoptosis-inducing ligand
(TRAIL) is a type 2 transmembrane death ligand that causes
apoptosis of target cells through the extrinsic apoptosis pathway.
TRAIL is a member of the tumor necrosis factor superfamily,
which includes tumor necrosis factor and Fas ligand (9). The
expression of tumor necrosis factor and Fas ligand leads to the
damage of normal tissues in addition to their proapoptotic effect
on transformed cells (10, 11), limiting their clinical applications.
Conversely, TRAIL is able to selectively induce apoptosis in
transformed cells but not in most normal cells (9, 12, 13), making
it a promising candidate for tumor therapy. Intravenous delivery
of recombinant TRAIL has, however, met with problems including
a short pharmacokinetic half-life (12), necessitating frequent and
high doses to produce the desired effect. The use of MSCs as a
delivery vector promises to provide both targeted and prolonged
delivery of this death ligand.
In this study, we express TRAIL in MSCs using a lentivirus
conditionally activated by doxycycline. This system allows a mixed
cell and gene therapy approach for metastatic cancers that can be
activated and deactivated. We show that MSCs can be infected at
high efficiency using the lentivirus system and delivery of TRAIL
causes apoptosis of cancer cells through the extrinsic death
pathway. In vivo models confirm a predilection of engraftment of
MSCs within metastatic lung tumors with activation of TRAIL
resulting in a significant reduction in metastasis number and
complete clearance in 38% of mice.
Materials and Methods
Cell culture. Tissue culture reagents were purchased from Invitrogen
unless otherwise stated. All cells were obtained from Cancer Research UK,
London Research Institute, and cultured in DMEM and 10% fetal bovine
serum unless otherwise stated. Human adult MSCs were purchased from
Tulane University and cultured in a-MEM with 16% fetal bovine serum.
Adipogenic and osteogenic differentiation of MSCs was done as described
previously (14, 15).
TRAIL lentivirus construction and transfection of MSCs. A lentiviral
plasmid (pRRL-cPPT-hPGK-mcs-WPRE) into which the Tet-On system
elements had been introduced (ref. 16; a kind gift from O. Danos, University
College London) was used as a backbone for the incorporation of TRAIL
DNA. The existing reporter gene, MuSEAP, was excised using the MluI and
EcoRV restriction sites. The IRES-eGFP sequence (from pENTR1A) was
amplified and restriction sites were introduced by PCR and then inserted
into the plasmid in place of MuSEAP. Subsequently, human TRAIL (amino
acids 1-281; RZPD) was similarly amplified and restriction sites were
introduced by PCR and then cloned into the lentivirus plasmid, via MluI
Note: Supplementary data for this article are available at Cancer Research Online
(http://cancerres.aacrjournals.org/).
Requests for reprints: Sam M. Janes, Centre for Respiratory Research, Rayne
Institute, University College London, Rayne Building, 5 University Street, London
WC1E 6JJ, United Kingdom. Phone: 44-20-7679-6926; Fax: 44-20-7679-6973; E-mail:
s.janes@ucl.ac.uk.
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Research Articleand BstB1 restriction sites, next to the IRES-eGFP. The plasmid constructs
were confirmed by DNA sequence analysis (Cogenics).
The lentivirus was produced by transfecting 293T cells with 15 mL Opti-
Mem plus 10 mL of a solution made by mixing 3.6 mL polyethylenimine
(Sigma-Aldrich)and56.4mLOpti-Memto600AgTRAIL plasmid,450Agofthe
packaging construct pCMV-dR8.74, 150 Ag of a plasmid producing the VSV-G
envelope, pMD.G2, and 60 mL Opti-Mem (both pCMV-dR8.74 and pMD.G2
were a kind gift from A. Thrasher, University College London). The lentivirus
was concentrated by ultracentrifugation at 18,000 rpm (SW28 rotor, Optima
LE80K Ultracentrifuge, Beckman) at 4jC and stored at  80jC before use.
Human MSCs were transduced with a multiplicity of infection of 10 virus
particles for each cell and 4 Ag/mL polybrene (Sigma-Aldrich).
Human TRAIL expression was verified by ELISA (R&D Systems) as per
manufacturer’s instructions and by Western blot.
Western blots. Supernatants were centrifuged and cells were lysed in
radioimmunoprecipitation assay buffer (PBS, 1% Igepal Ca-630, 0.5%
sodium deoxycholate, 0.1% SDS; Sigma) supplemented with complete
protease inhibitor cocktail (Complete-mini; Roche Diagnostics). Samples
were denatured, resolved with a 10% SDS-polyacrylamide gel, and
transferred using a semidry transfer method (NovaBlot; Pharmacia LKB).
Blots were then incubated with anti-TRAIL (1 Ag/mL H257 rabbit
polyclonal antibody; ref. 17; Santa Cruz Biotechnology) or anti-actin
(0.24 Ag/mL; Sigma) antibodies and detected using enhanced chemilu-
minescence (GE Healthcare) as per manufacturer’s instructions.
Coculture experiments. Human MSCs permanently transduced with
the full-length TRAIL plasmid (MSCFLT) were plated with target cells. A
total of 100,000 cells were plated in each 6-well plate. The following day,
doxycycline or other active agents were added to the cocultures and left for
48 h. Staining of target cells was done with the fluorescent dye, DiI, as per
manufacturer’s instructions (Invitrogen).
Apoptosis and cell death was assessed by flow cytometry (FACSCalibur
or LSRII machines; Becton Dickinson). This was done on floating and
adherent cells from cocultures using Annexin V-647 antibody (Invitrogen)
and 5 Ag/mL propidium iodide (PI; Sigma). 4¶,6-Diamidino-2-phenylindole
(DAPI; 2 Ag/mL; Sigma) was used instead of PI when cancer cells were
stained with DiI. Annexin V
 /PI
  cells were judged to be nonapoptotic.
Annexin V
+/PI
  cells were considered to be apoptotic. Annexin V
+/PI
+ cells
were recorded as being dead.
The following compounds were used in coculture experiments: the pan-
caspase inhibitor zVADfmk (1 Ag/mL; Sigma), a soluble recombinant TRAIL
(200 ng/mL; R&D Systems), and a neutralizing TRAIL antibody (250 ng/mL;
R&D Systems).
Production of dominant-negative Fas-associated death domain
cancer cells. Phoenix packaging cells were transiently transfected with
Figure 1. MSC characterization,
transduction, and gene expression. A,
MSCs, differentiation to adipocytes
(Oil-Red-O) and osteoblasts (Alizarin Red
S; magnification,  4), and colony-forming
ability. B, representative flow cytometry
for GFP expression in MSCs transduced
with the TRAIL-GFP lentivirus (MSCFLTs)
and activated with doxycycline and
timescale of GFP expression with addition
or removal of doxycycline. C, TRAIL
ELISA of MSCFLTs. D, Western blots of
MSCFLTs showing maximum expression
of TRAIL after 2 d of doxycycline
treatment (10 Ag protein loaded) and loss
of expression 1 d after doxycycline
removal (5 Ag protein loaded) with actin
loading controls.
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(dnFADD)/GFP construct (18) or empty vector and the virus containing
supernatant was added to infect AM12 packaging cells as described
previously (19). The AM12 cell supernatant was added to Hela cells (30%
confluence) with 5 Ag/mL polybrene and the cells were selected with
1 Ag/mL puromycin (20).
Cell migration assay. An in vitro cell migration assay was done to
determine the tropism of MSCs for tumor cells according to previously
described methods (4, 7, 21). One hundred fifty thousand cancer cells
or 293T cells were plated in 800 AL medium on the bottom well of a
Transwell plate (8 Am pore membrane; Becton Dickinson) for
24 h before 40,000 MSCs in 300 AL of the same medium were added
to the top well. MSCs were allowed to migrate across the membrane
for 24 h at 37jC. The cells attached to the top side of the membrane
were removed, and the migrated cells on the bottom side were fixed,
stained using a Rapid Romanowsky staining kit (Raymond Lamb), and
counted (5 fields per well, triplicate wells) at  10 magnification
(Olympus BX40).
Xenograft cancer models. All animal studies were done in accordance
with British Home Office procedural and ethical guidelines. Six-week-old
NOD/SCID mice (Harlan) were kept in filter cages.
Subcutaneous tumors were obtained by the injection of 2 million
MDAMB231 cells in 200 AL PBS subcutaneously into the left flank with a 29
gauge needle. Tumors were measured every 3 to 5 days with calipers, and
the volume was calculated as 4/3pr
3, where r is the radius. Metastatic lung
tumors were produced by the intravenous delivery of 2 million MDAMB231
in 200 AL PBS into the lateral tail vein.
In vivo use of TRAIL-expressing MSCs. In the subcutaneous models,
MSCFLTs labeled with CM-DiI (Invitrogen) as per manufacturer’s
instructions were either delivered concurrently with the cancer cells;
2 million MDAMB231 with 0.75 million MSCFLT in 200 AL PBS, or after
tumors had become established; 1 million MSCFLTs were injected into
Figure 2. TRAIL-expressing MSCs
cause cancer cell apoptosis in vitro. A,
representative flow cytometry plots
showing an increase in death and
apoptosis when Hela cells were cocultured
with doxycycline (dox)-treated MSCFLTs
compared with no doxycycline (nd),
untreated controls, or doxycycline-treated
normal MSCs. B, phase-contrast
microscopy (magnification,  5) showing
an increase in cell death (rounded and
floating cells) when MSCFLTs were
activated by doxycycline in coculture with
Hela and MDAMB231 cells. C, flow
cytometry results from triplicate apoptosis
assays showing an increase in death and
apoptosis of total cells in cancer cells and
MSCFLT cocultures after doxycycline
treatment. D, flow cytometry of coculture
experiments showed DiI-positive cancer
cells were responsible for dead and
apoptotic populations. Triplicate
experiments. ***, P < 0.001; **, P < 0.01.
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MSCFLT cells were suspended in 200 AL PBS and injected into the lateral
tail vein at 7, 14, 21, and 28 days after the cancer models had been set up (5).
To activate the TRAIL constructs in the transduced MSCFLTs, mice were fed
water containing 2 mg/mL doxycycline and 3% sucrose, with controls fed
water with 3% sucrose only.
Mice were sacrificed by CO2 asphyxiation followed by exsanguination.
Subcutaneous tumors were removed and weighed before they were split for
digestion with 0.1% collagenase A (Roche Diagnostics) into a single-cell
suspension as per manufacturer’s protocol or fixed in 4% paraformaldehyde
for histology. The lungs were excised and weighed before they were
insufflated with a fixed 20 cm pressure of 4% paraformaldehyde and then
bathed in 4% paraformaldehyde for histology. In some lungs, the left lobe
was removed and snap frozen in liquid nitrogen before insufflation.
Immunohistochemistry. Fixed specimens were embedded in paraffin
and cut into 3 Am sections for H&E staining. GFP antibody (rabbit
polyclonal; Invitrogen) and TRAIL antibody (rabbit monoclonal; Santa Cruz
Biotechnology) were used as primary antibodies and detected with
biotinylated secondaries and diaminobenzidine (Vector Laboratories).
Fluorescent microscopy was used to detect DiI-positive cells with DAPI
counterstain and secondary fluorescent antibodies against primary
vimentin antibodies (sc7557; Santa Cruz Biotechnology). TUNEL staining
was done according to the manufacturer’s instructions (Roche Diagnostics).
Microscopy was done using light (Olympus BX40), fluorescent (Carl Zeiss,
Axioskop 2), or confocal (Bio-Rad MRC 1024) microscope.
Quantitative real-time reverse transcription-PCR. RNA was extracted
from the snap-frozen left lung with Trizol (Invitrogen) and treated with
DNase (Ambion). cDNA was synthesized using a reverse transcription-PCR
kit according to the manufacturer’s instructions (Roche Diagnostics). Real-
time PCR amplification was done with Light Thermocycler (Roche
Diagnostics) using SYBR Green quantitative PCR kit (Invitrogen) with
primers for human TRAIL and the control 18S.
Metastases quantification. The number and size of tumor nodules were
assessed in H&E sections using similar methodology to that described
previously (22). Photomicrographs of representative sections of the entire
lung were taken at  2 magnification. This created a complete picture of all
lobes of the lungs of the mice. Image analysis software (SimplePCI High-
Performance Imaging Software; Hamamatsu Photonics) was used to trace
around the metastatic deposits and the lung sections and then calculate
lung and metastasis area and number of metastases.
Statistics. Statistical analysis was done using GraphPad Prism version 4
(GraphPad Software). Multiple groups were analyzed by ANOVA or Kruskal-
Wallis tests. Single group data were assessed using Student’s t test. All
in vitro experiments were done in triplicate unless specified.
Results
Characterization and TRAIL transduction of MSCs. Fully
characterized MSCs were purchased from Tulane University and
were shown to differentiate into fat and bone in differentiation
assays and have the expected colony-forming efficiency F SD (48 F
2.83%; Fig. 1A). MSCs were stably transduced with our lentivirus
expressing TRAIL and GFP under the control of doxycycline at
different multiplicities of infection. A multiplicity of infection of
10 was used for further experiments producing 82.13 F 0.40%
successful transduction (GFP expression) at day 7 (Fig. 1B) while
limiting the number of dead cells 4.8 F 1.83%.
MSCFLTs were examined for TRAIL and GFP expression using
flow cytometry, Western blots, and ELISA. Flow cytometry showed
<0.5% GFP expression before activation with doxycycline, whereas,
48 h after doxycycline addition to the medium, this increased to
74.7 F 2.5% (Fig. 1B). Withdrawal of doxycycline, after the cells
had been exposed for 5 days, led to a fall in GFP expression with
12.2 F 1.0% of cells weakly positive at day 7 (Fig. 1B; Sup-
plementary Fig. S1).
ELISA and immunoblotting for TRAIL showed that it was only
produced when the transgene was activated by doxycycline (Fig. 1C
and D). Western blots showed TRAIL protein expression in
MSCFLT lysates was maximal after 2 days of doxycycline stimulus
(Fig. 1D), but very little TRAIL protein remained after the
doxycycline stimulus had been removed for 1 day, following a
preceding doxycycline stimulus of 5 days (Fig. 1D).
TRAIL-expressing MSCs cause tumor cell death in vitro.
MSCFLTs were cocultured with tumor cells, and apoptotic and
Figure 3. TRAIL-expressing MSC-induced apoptosis occurs at low
MSCFLT-to-cancer cell ratios via the extrinsic apoptotic pathway. A, flow
cytometry apoptosis assays showing an increase in death and apoptosis of Hela
cells when MSCFLTs activated with doxycycline were cocultured with Hela
cells even at low 1:16 ratios compared with untreated controls. B, induced cell
death and apoptosis is higher using MSCFLTs than with recombinant TRAIL
(rhTRL) and can be partially blocked with blocking antibody (Ab). C, cell death
and apoptosis is reduced when using Hela cells expressing dnFADD in
comparison with those transduced with an empty vector in addition to when
zVADfmk (zvad), a pan-caspase inhibitor, is used compared with the control
(con). ***, P < 0.001; **, P < 0.01; *, P < 0.05.
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This effect was observed with lung cancer (A549; apoptotic and
dead cells increased from 3.1 F 0.1% to 19.6 F 0.8%; P = 0.001,
t test; with the addition of doxycycline), breast cancer
(MDAMB231; 15.4 F 1.7-37.7 F 6.5%; P = 0.001, t test),
squamous cell cancer (H357; 12.5 F 0.3-34.5 F 1.0%; P =
0.001, t test), and cervical cancer (Hela; 6.7 F 1.0-36.1 F 3.5%;
P = 0.0001, t test) cells (Fig. 2A-C). These apoptosed and dead
cells were shown to come specifically from the cancer cell
population by labeling the cancer cell populations with the
fluorescent dye (DiI). Thus, 50.7 F 2.7% of the Hela cell
population were dead or apoptotic compared with only 8.3 F
4.6% of the MSCFLT population (P < 0.0001, t test; Fig. 2D).
Coculture experiments were repeated with decreasing numbers
of MSCFLTs. A significant increase in apoptosis and death of the
cancer cells was achieved at all concentrations of MSCFLT used
(P < 0.001 at ratio MSCFLT/Hela cells of 1:16, ANOVA). There was a
cell ratio-dependent effect (Fig. 3A). This experiment under-
estimates the true killing capacity of MSCFLT cells as the seeding
ratios do not account for any proliferation of cancer cells compared
with MSCFLTs before the addition of doxycycline.
TRAIL-expressing MSCs kill cancer cells by TRAIL induction
of the extrinsic apoptosis pathway. A TRAIL antibody with some
ability to neutralize the bioactivity of TRAIL was added to the
MSCFLTand Hela cell cocultures. The antibody was used at a dose
to give maximal neutralizing effect (250 ng/mL; ref. 23). The amount
of MSCFLT-induced death and apoptosis was significantly reduced
with this antibody (38.03 F 0.49% compared with 50.67 F 3.8%;
P < 0.001, ANOVA) but not back to baseline (11.48 F 1.49%; Fig. 3B).
We found that our doxycycline-induced MSCFLTs were potent
inducers of death and apoptosis of Hela cells, with a larger
proportion of apoptotic and dead cells in comparison with maximal
doses (200 ng/mL) of recombinant soluble TRAIL (50.67 F 3.8%
compared with 27.50 F 0.70%; P < 0.001, ANOVA; Fig. 3B).
The caspases are a family of closely related enzymes crucial to
apoptosis. zVADfmk is a cell permeable, pan-caspase inhibitor.
Application of this compound to the 1:1 cocultured MSCFLTs and
Hela cells caused a 51.6% reduction in death and apoptosis (26.5 F
0.7% compared with a DMSO-treated control 54.8 F 3.0%; P =
0.003, t test) confirming the importance of caspases in the
mechanism of TRAIL-induced cell death (Fig. 3C).
To confirm that the mechanism of MSCFLT-induced cancer cell
death is via the extrinsic pathway, Hela cancer cells were
retrovirally transduced with a dnFADD construct or an empty
vector (18). The dnFADD consists of the death domain that binds
to the TRAIL receptor but not the domain responsible for caspase-
8 recruitment and the triggering of apoptosis. We observed a
significant reduction (P = 0.018, t test) in death and apoptosis of
Hela cells transduced with dnFADD after coculture with activated
MSCFLT cells (Fig. 3C). This data present strong evidence that
MSCFLT cells induce apoptosis via the extrinsic pathway.
MSCs migrate toward some tumor cells. In vitro Transwell
experiments showed the ability of MSCs to home toward tumors.
A549, MDAMB231, and Hela cancer cell cultures were used to
attract MSCs, with benign fibroblast 293T cells and medium
alone used as controls. There was significantly increased
migration to the MDAMB231 cells; 250.4 F 0.8 cells per field
compared with 98.6 F 9.3 cells to 293T and 57.6 F 7.6 toward
the medium (P < 0.001, ANOVA). There was no significantly
increased migration toward the A549 (92.0 F 7.1) and Hela (81.0 F
2.1) cells (Fig. 4A).
To examine if MSCFLTs could be traced to metastatic tumors, we
used a lung metastasis model. Intravenously injected MDAMB231
cells produced lung metastases in all of 20 NOD/SCID mice. These
tumors were visible at day 10 post-injection and grew to large
metastases by day 30 (Fig. 4B). DiI-stained MSCFLTs were injected
at day 10 and shown histologically to preferentially localize to lung
Figure 4. MSCs migrate to some cancer cells in vitro and preferentially engraft
in vivo. A, Transwell migration studies showed an increased number (per
microscopic field) of MSCs migrating through the Transwell membrane toward
MDAMB231 cells but not toward other (A549 and Hela) cancer cell types
compared with control 293T cells or medium alone. ***, P < 0.001. B, H&E
showing representative lung metastases post–intravenous injection of
MDAMB231 cells into NOD/SCID mice at days 10, 20, and 30 and a macroscopic
picture at day 30. Bar, 20 Am. C, DiI-labeled MSCFLTs (red) injected
intravenously at day 10 and shown to localize to lung metastases on fluorescent
microscopy with DAPI nuclear counterstain with H&E contiguous sections from
day 30 harvested lungs (magnification,  10; bar, 20 Am and magnification,  4;
bar, 60 Am).
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the tumors or in the lungs 10 days after injection (data not shown).
These histologic data show that MSCFLTs preferentially engraft
and are maintained in the in vivo tumor environment compared
with surrounding lung parenchyma, whereas fibroblasts are not.
TRAIL-expressing MSCs reduce subcutaneous tumor growth
in mice. Two million MDAMB231 cells were coinjected with 0.75
million MSCFLT cells and the TRAIL transgene was activated with
the addition of doxycycline at day 0 or 25 or never, with tumors
harvested at day 42. A recent study has shown that coculture of
MSCs with MDAMB231 cells did not alter the tumor growth (24). In
our study with transduced MSCs, activation at day 0 resulted in a
significantly reduced tumor size (0.12 F 0.12 cm
3 versus 0.66 F
0.49 cm
3; P < 0.001, two-way ANOVA) and weight (0.07 F 0.06 g
versus 0.33 F 0.33 g; P < 0.05, Kruskal-Wallis); however, there
was no change in the tumor growth when TRAIL was activated
after the tumor had already become established at day 25 (Fig. 5A
and B). TUNEL staining of excised tumors showed areas of
apoptosis colocalized with DiI-labeled MSCFLT cells (Fig. 5C). The
subcutaneous tumors were excised and digested to a single-cell
suspension. Confocal microscopy of the ex vivo DiI-labeled cells
included cells of MSC-type morphology and showed vimentin
staining (Fig. 5D). A separate experiment injected transduced
MSCFLTs into established tumors. Similar to late activation of
coinjected cells, the late injection of MSCFLT cells into established
tumors and activation of TRAIL at this later stage was unable to
alter the growth of the tumors (Supplementary Fig. S2).
Systemic delivery of TRAIL-expressing MSCs reduces and
can eliminate lung metastases. Intravenously injected
MDAMB231 cells were used to produce lung metastases in NOD/
SCID mice. MSCFLTs were then used as an intravenous combined
cellular and gene therapy with delivery at days 7, 14, 21, and
28 (Fig. 6A). At day 35, tumor metastases were found in all mice
(8 of 8) without MSCFLT and all mice with MSCFLT without the
use of doxycycline (8 of 8). In the MSCFLT plus doxycycline arm,
3 of 8 mice were tumor-free (P = 0.032, m
2; Fig. 6B). In addition to
the elimination of metastases with MSCFLT plus doxycycline, the
lung weight (P < 0.01, ANOVA), which serves as a correlate for
metastases load, was also significantly reduced in all of these mice.
Similar results were achieved when metastases numbers per lung
area was used as an endpoint (P < 0.001, ANOVA; Fig. 6C). Three
mice had to be excluded from this latter analysis as the lungs did
not inflate during the fixation procedure. MSCFLTcells delivered to
control mice without doxycycline were unable to clear the
metastases in any mice but did have less metastases per area
(P < 0.001, ANOVA) and a lower lung weight (P < 0.05, ANOVA)
than the untreated mice. Doxycycline treatment, however, pro-
duced a further significant reduction (P < 0.05, ANOVA; Fig. 6B and
C). In a subsequent experiment, TRAIL and GFP were both shown
to be expressed in vivo by MSCFLT with immunohistochemistry
when mice were harvested 2 days after treatment with MSCFLT
and doxycycline (Fig. 6D; primary antibody controls showed no
staining; data not shown). TRAIL mRNA derived from the lungs of
these mice was also increased (Fig. 6D).
Discussion
The ability of TRAIL to lead to tumor apoptosis and death
without affecting normal cells makes it an extremely exciting
molecule for tumor therapy. Here, we have shown that MSCs can
be engineered to express TRAIL under the sensitive control of the
Tet-On inducible system. These cells were able to kill cancer cell
lines in vitro via the extrinsic death pathway to a higher degree
than recombinant protein. In vivo, we show that TRAIL-expressing
MSCs reduce the growth of early subcutaneous tumors, whereas,
in a systemically delivered metastasis model, these cells reduced
Figure 5. TRAIL-expressing MSCs reduce
the growth of subcutaneous tumors. A, doxycycline
treatment of subcutaneous tumors composed of
mixed MDAMB231 cells and MSCFLTcells from day
0 led to a decreased size and weight (*, P < 0.05; **,
P < 0.01; ***, P < 0.001) of the tumors compared
with untreated mice. There was no reduction in
tumor growth if TRAIL was activated at day 25.
B, macroscopic appearance of the tumors. C,
TUNEL staining (green) showed areas of tumor
apoptosis localized with areas of MSCFLTs (DiI,
red) within the tumors in mice treated with
doxycycline from day 0 (DAPI nuclear counterstain,
blue). Bar, 25 Am. D, ex vivo single-cell digestion
and culture showed DiI-positive (red) cells with MSC
morphology that costained with vimentin (green;
DAPI, blue). Bar, 3 Am.
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mice.
We used MSCs as vectors of delivery due to observations that
they appear to home to, or at least engraft preferentially, within
tumors. MSCs also make an attractive therapeutic tool as they are
widely acknowledged to be immunoprivileged. Theoretically, future
cell therapies using allogenic MSCs could be used in patients
without the use of prior immunomodulation (25). Alternatively,
with the ease of harvest, culture, and infection of MSCs, the use of
autologous cells may also be realistic.
It is important to consider the possible direct effects that MSCs
may have on disease. Some studies have suggested intrinsic anti-
neoplastic properties of these cells, with improvements in Kaposi’s
sarcoma (2) and subcutaneous breast tumor models (26). Various
mechanisms have been proposed for these effects, including
Akt inhibition (2), nuclear factor-nB down-regulation (27), and the
Wnt pathway (26). Conversely, MSCs have also been associated
with a tumor-promoting effect in certain models, including in-
creased growth and metastasis in colonic (28) and breast (24)
subcutaneous tumor models. In our subcutaneous tumor model,
we did not see an increase in lung metastases when the tumor cells
were coinjected with MSCs. Furthermore, MSCs in our lung
metastasis model appeared to have an antineoplastic effect.
To our knowledge, this is the first study that uses MSCs as a
vector for a lentiviral delivery of a gene therapy for cancer. We used
a lentivirus in view of their significant advantages over other vector
systems. Adenoviral vector expression is transient and often
produces a significant host immune response, whereas retroviruses
may cause incorporation errors. Lentiviral vectors are less likely to
cause insertional mutagenesis as the promoter can be modified
extensively. Furthermore, they have the ability to stably transduce
both dividing and quiescent cells (29), which is a further significant
advantage when using stem cells that are often quiescent or slow-
growing. Finally, our construct incorporates the Tet-On system
allowing us to both turn on and, through withdrawal of doxycycline,
off the protein expression, attractive in the view of possible
Figure 6. TRAIL-expressing MSCs
reduce the growth of lung metastases. A,
2 million MDAMB231 cells were injected
intravenously at day 0 followed by delivery
or no delivery of MSCFLT cells at days
7, 14, 21, and 28 with or without
doxycycline. B, representative histology
of lung lobes in the three experimental
groups. Metastases remained, but were
reduced, after injection of MSCFLT without
activation of the TRAIL construct, whereas
TRAIL activation of MSCFLTs eliminated
metastases in 3 of 8 mice (P = 0.03). C,
reduction in lung weight and metastases
(met) number per lung area with the
use of MSCFLTs both with and without
doxycycline treatment. There was a further
significant reduction between activated
MSCFLTs compared with inactivated.
***, P < 0.001; **, P < 0.01; *, P < 0.05.
D, immunohistochemistry showing
cells expressing GFP (bar,5Am) and
TRAIL (bar, 10 Am) and consecutive
immunofluorescence sections showing
these cells also express DiI. There is an
increase in TRAIL mRNA from lung digests
treated with MSCFLT and doxycycline.
*, P < 0.05.
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Clinically, treatment could be timed to chemotherapy or radiother-
apy regimes, with the expression turned off in between courses.
TRAIL is thought to operate physiologically in the immunosur-
veillance against tumors. Administration of a neutralizing anti-
TRAIL antibody or the use of TRAIL knockout mice showed the
increased susceptibility of TRAIL deficient mice to TRAIL-sensitive
tumors and metastases (30–32). TRAIL-expressing MSCs in this
study may act in a similar way, replacing the deficient immuno-
surveillance systems in the NOD/SCID mice leading to tumor cell
destruction and prevention of metastasis. The property of
metastasis prevention would be ideal as an adjuvant therapy in
the treatment of many patients with solid organ tumors, who
remain at significant risk of future metastatic disease despite
primary tumor resection and chemotherapy and radiotherapy.
Identifying these patients is now becoming a reality with the use of
highly sensitive and specific molecular and cytologic techniques,
which allow the detection of very small numbers of circulating
tumor cells in the blood and bone marrow (33, 34), which could be
amenable to MSC-directed TRAIL therapy.
The use of targeted TRAIL therapy could be widely applicable to
many different cancers. Despite some cancers being resistant to the
effects of TRAIL, an additive effect has been shown with the
concomitant use of TRAIL with other antineoplastic agents that act
at different positions in either intrinsic or extrinsic apoptotic
pathways. For example, the down-regulation of Bcl-2 (35) or the
DNA damage caused by chemotherapy can increase the effects of
TRAIL therapy in various in vivo models (36–39).
One of the limitations of our study is the model used for the
in vivo experiments. With the aim of future translational
therapeutics, we used human cancer xenograft models, human
MSCs, and human TRAIL constructs. It is important to consider
that human TRAIL has only 65% homology to murine TRAIL (9),
and there are also differences in the receptors in mice and humans.
In the mouse, only one death-inducing receptor with homology to
DR5 has been discovered in addition to two decoy receptors
(mDcTRAILR1 and msDcTRAILR2; ref. 40). Consequently, the
effects of TRAIL on the normal murine cells may be different to
the response of normal human cells.
In summary, we describe, for the first time to our knowledge,
the use of TRAIL-expressing MSCs for the reduction and, in some
cases, elimination of metastatic disease in a murine lung metastasis
model. We believe that this therapy may have an important future
therapeutic role in preventing metastatic recurrence in patients.
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versions. Nat Med 2001;7:383–5.Squamous cell cancers contain a side population of stem-like cells
that are made chemosensitive by ABC transporter blockade
MR Loebinger
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Cancers are a heterogeneous mix of cells, some of which exhibit cancer stem cell-like characteristics including ATP-dependent drug
efflux and elevated tumorigenic potential. To determine whether aerodigestive squamous cell carcinomas (SCCs) contain a
subpopulation of cancer stem cell-like cells, we performed Hoechst dye efflux assays using four independent cell lines. Results
revealed the presence of a rare, drug effluxing stem cell-like side population (SP) of cells within all cell lines tested (SCC-SP cells).
These cells resembled previously characterised epithelial stem cells, and SCC-SP cell abundance was positively correlated with overall
cellular density and individual cell quiescence. Serial SCC-SP fractionation and passaging increased their relative abundance within the
total cell population. Purified SCC-SP cells also exhibited increased clonogenic potential in secondary cultures and enhanced
tumorigenicity in vivo. Despite this, SCC-SP cells remained chemotherapeutically sensitive upon ATP-dependent transporter
inhibition. Overall, these findings suggest that the existence of ATP transporter-dependent cancer stem-like cells may be relatively
common, particularly within established tumours. Future chemotherapeutic strategies should therefore consider coupling
identification and targeting of this potential stem cell-like population with standard treatment methodologies.
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Stem cells are present in many tissues where they function to
maintain appropriate homeostasis and differentiation as well as
regulate tissue responses to injury and infection (Watt and Hogan,
2000; Janes et al, 2002). These cells are capable of self-renewal,
have a relatively undifferentiated phenotype, exhibit high pro-
liferative potential, and are multipotent (Griffiths et al, 2005). In
adult tissues, stem cells tend to divide infrequently and many
exhibit an intrinsic resistance to environmental toxins or
chemotherapeutic agents (Giangreco et al, 2002; Zhou et al,
2002; Hirschmann-Jax et al, 2004).
Traditionally, stem cell pollutant resistance has been identified
on the basis of efficient Hoechst 33342 dye efflux (Goodell et al,
1996). Drug-resistant stem cells, termed side population (SP) cells,
have been identified in a growing number of tissues including bone
marrow, pancreas, muscle, brain, and lung (Goodell et al, 1996;
Lechner et al, 2002; Giangreco et al, 2003; Summer et al, 2003;
Kondo et al, 2004; Oyama et al, 2007). This SP phenotype is
dependent on ATP-binding cassette (ABC) transporter activity, as
ATP inhibitors such as verapamil and reserpine block dye efflux
(Goodell et al, 1997; Zhou et al, 2001; Scharenberg et al, 2002). In
particular, the ABC transporter ABCG2/BCRP1 appears critical to
maintain this phenotype as Abcg2 knockout mice lack SP cells and
are particularly sensitive to chemotherapeutic agents such as
mitoxantrone (Zhou et al, 2002).
In addition to normal tissues, recent evidence suggests that
some cancers also contain a population of stem-like, pollutant-
resistant cells (Passegue et al, 2003). Cancer stem or stem-like cells,
which exhibit increased chemotherapeutic drug resistance, have
been found within acute myeloid leukaemia (Wulf et al, 2001; Reya
et al, 2003), breast, and brain solid tumours (Al-Hajj et al, 2003).
Recently, several cancer cell lines have been identified that contain
a subpopulation of chemotherapeutic-resistant, cancer SP cells
including the rat glioma line C6, human breast cancer line MCF-7,
rat neuroblastoma line B104, and the human adenocarcinoma cell
line HeLa (Kondo et al, 2004). Cancer SP cells have also been
identified in vivo within 65% of human neuroblastoma tumours
(Hirschmann-Jax et al, 2004). These repopulate both SP and non-
SP cell types, indicating their multipotent differentiation potential
(Hirschmann-Jax et al, 2004). They also express numerous ABC
transporter proteins, providing them with increased drug resis-
tance (Hirschmann-Jax et al, 2004). Finally, it appears that
following chemotherapy, cancer SP are uniquely capable of
producing drug-insensitive secondary tumours (Passegue et al,
2003). On the basis of these observations, cancer SP cells are
increasingly considered to be potential cancer stem cells (Hadnagy
et al, 2006; Giangreco et al, 2006).
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sAerodigestive squamous cell carcinomas (SCCs) frequently
exhibit chemotherapeutic resistance and increased metastatic
potential following unsuccessful cancer treatment. We, therefore,
wished to determine whether SCC cell lines contained SP cells, and,
if so, whether these displayed cancer stem cell characteristics. We
now describe the presence of an SCC-SP cell subset whose
abundance was positively correlated with increasing cell con-
fluence and quiescence. These cells exhibited characteristics of
cancer stem cells including increased growth, multipotent
differentiation, and a capacity for in vivo tumorigenesis.
MATERIALS AND METHODS
Tissue culture
H357, SCC4, SCC13, and SCC15 cell lines, derived from patients
with advanced SCCs, were cultured in complete FAD medium
(Sugiyama et al, 1993). The culture medium (FAD FCS HICE)
consisted of one part Ham’s F12 medium and three parts
Dulbecco’s modified Eagle’s medium, supplemented with 10%
fetal calf serum (FCS), 0.5mgml
 1 hydrocortisone, 5mgml
 1
insulin, 10
 10 M cholera toxin, and 10ngml
 1 epidermal growth
factor (HICE). The culture medium was changed every 2 days.
Fluorescence-activated cell sorting
Cells were harvested at 70% or full confluence, washed, and
resuspended at 1 10
6 cellsml
 1 in FAD medium and incubated at
371C for 10min. Cells were labelled with 5mM Hoechst 33342
(Sigma, St Louis, MI) for 15, 30, 45, 60, 75, 90, 105, 120, and
135min at 371C to determine the required incubation time. As the
size of the SP was found to be stable from 30min, all subsequent
staining was carried out for 45min at 371C. The cells were
counterstained with 5mgml
 1 propidium iodide (Sigma) to label
dead cells, which were excluded from the analysis. Fluorescence-
activated cell sorting (FACS) was performed using a MoFlo High-
Performance Cell Sorter (DakoCytomation, Denmark). For SP
analysis, at least 1 10
5 total events were collected, and all
subsequent analysis was performed using FlowJo software (Tree
Star Inc., Ashland, Oregon). For cell cycle status analysis following
Hoechst 33342 efflux, ethanol-fixed cells were stained with
50mgml
 1 propidium iodide in the presence of RNase A
(50mgml
 1) and analysed with a FACS-Calibur flow cytometer.
The Watson Pragmatic model was applied to determine cell cycle.
All flow cytometry experiments were repeated to confirm
consistency. A representative plot is shown for each profile.
Colony-forming assays
In all, 200 SP and non-SP H357 cells were seeded per six-well plate
and cultured for 14 days. Colonies were washed, fixed using 3%
paraformaldehyde (BDH), and stained with Rhodanile Blue
overnight. Colonies of two or more cells were counted using an
Olympus CK2 inverted phase-contrast light microscope. Abortive
colonies were defined as colonies that contained fewer than 32 cells
according to the system described by Jones and Watt (1993). A
large colony was defined as greater than 32 cells per colony. All
experiments were performed in triplicate. In mitoxantrone
dihydrochloride (Sigma) dose–response assays, 200 H357 cells
were plated per well of a six-well plate and cultured in the presence
of 0, 1, or 10ngml
 1 of mitoxantrone for 3 days. After a further 14
days, the cultures were fixed, stained, and counted. In mitoxan-
trone and verapamil assays, 300 H357 cells were plated per well of
a six-well plate, cultured in the presence of 0, 1, or 10ngml
 1 of
mitoxantrone±verapamil hydrochloride 100mM (Sigma) for 7
days, and, subsequently, grown for a further 7 days in the absence
of drugs.
Proliferation assay
A total of 1000 H357 cells were plated per well and cultured in
complete FAD medium. Cells were harvested at days 2, 4, and 8,
and cell number counted by haemocytometer. Each H357 cell
population and time point were analysed in triplicate.
Quantitative RT-PCR
cDNA synthesis (random hexamers Superscript II; Invitrogen,
Paisley, UK) and subsequent quantitative RT-PCR (QPCR) was
performed using 1mg of total RNA isolated from freshly sorted or
serially passaged H357 SP, non-SP, and parent cells as indicated in
text. Human gene-specific, predesigned, and inventoried probes
were purchased from Applied Biosystems, Foster City, CA,
TaqMan QPCR analysis was based on the DDCt relative mRNA
abundance method and normalised to b2-microglobulin expres-
sion. At least two samples per sort parameter were assayed using
an ABI7900 real-time PCR machine (Applied Biosystems).
Subcutaneous tumour model
Six-week-old, male NOD/SCID mice purchased from Harlan
(Bicester, UK) were used for the experiments. All mouse studies
were performed in accordance with British Home Office procedur-
al and ethical guidelines. Animals were housed in pathogen-free
conditions with filtered air, and autoclaved food and water was
available ad libitum. H357 SP(1) and G2(1) cells (both sorted and
passaged once to expand cell numbers) were suspended in sterile
PBS at a concentration of 1 10
7 cellsml
 1. A total of 200ml of the
suspension containing two million cells was injected subcuta-
neously in the left flank with a 29G needle. Tumours were
measured every 3–5 days with callipers, and the volume calculated
as 4/3pr
3, where r is the estimated radius.
Statistics
Student’s t-, Student–Newman–Keuls, and Mann–Whitney sta-
tistical tests were carried out using SigmaStat. Data are expressed
as means±s.e.m. Data not in normal distribution were log
transformed prior to statistical testing.
RESULTS
Squamous cell carcinomas contain an ABC transporter-
and cell density-dependent side population
Several tumours and tumour cell lines maintain a population of
chemotherapeutic and pollutant-resistant cells with characteristics
of stem-like SP cells (Hirschmann-Jax et al, 2004; Kondo et al,
2004). To determine whether SCCs might also contain a
subpopulation of drug-resistant SP cells, four 70% confluent SCC
cell lines were incubated in 5mM Hoechst 33342 dye and analysed
by FACS. Cell confluence was verified by cell cycle analysis
(Figures 1A–C). A characteristic SP fraction was detected in all
four cell lines examined and was stable after 30min dye incubation
as determined by time course analysis (15–135min, SP examined
every 15min; not shown). Overall, SCC-SP abundance varied
between each cell line examined from 0.076% (SCC15) to 0.47%
(H357) (Figures 1D–F and Table 1). All SCC-SP populations were
reserpine sensitive, indicating their dependence on ABC-type
transporter activity (Figures 1G–I).
We next wished to examine whether a cancer’s cellular density
or cell cycle status influenced SCC-SP cell abundance. We therefore
cultured H357 cells to 100% confluence prior to Hoechst dye
incubation (Figure 1J). On average, increased cellular density or
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sreduced proliferation increased the H357 SP cell population from
0.47±0.16 to 4.53±0.61%, or nearly 10-fold (n 4, Figures 1K
and L).
SCC-SP cells express epithelial stem cell markers
To ascertain whether SCC-SP cells exhibited an enhanced stem
cell-like phenotype, we isolated and serially propagated H357 SCC-
SP cells as indicated in Figure 2A. Using QPCR, we examined the
expression of known epithelial stem cell genes including chon-
droitin sulphate proteoglycan 4 (CSPG4/MCSP; Legg et al, 2003),
tumour suppressor of lung cancer 1 (TSLC1; Morris et al, 2004;
Tumbar et al, 2004), integrin b1 (ITGB1; Jones and Watt, 1993),
and keratin 15 (KRT15; Liu et al, 2003). Serially propagated SCC-
SP cells (SP(3)) expressed significantly more CSPG4/MCSP and
TSLC1 than parent H357 cells but did not express increased levels
of either KRT15 or ITGB1 (Figure 2B). In freshly isolated,
unpassaged SP(1) cells, only TSLC1 expression was significantly
enriched relative to parent cells (data not shown). Altogether, these
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Figure 1 Squamous cell carcinomas contain an SP that varies with cell confluency. Seventy percent confluent SCC4, SCC13, and H357 SCC cells were
stained with propidium iodide staining profiles, highlighting the relative percentage of S-phase cells as an indication of cell confluence (A–C, J). The cells
were incubated in Hoechst 33342 prior to analysis by flow cytometry (D–F). The SP was compared between subconfluent (70%) (F) and confluent (K) cell
populations with reserpine controls (G–I, L).
Table 1 Summary of average SCC SP cell abundance
Cell
line
Average % of
SP s.d.
Minimum/maximum % of
SP
No. of
replicates
H357 0.470 0.160 0.25/0.63 4
SCC4 0.385 0.177 NA 2
SCC13 0.270 0.028 NA 2
SCC15 0.076 0.063 NA 2
NA not applicable; SCC squamous cell carcinoma; SP side population. SP
analysis performed at 70% cell confluence.
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epithelial stem cells.
Serial SCC-SP cell propagation enhances SP cell abundance
We next wished to examine whether isolated and in vitro expanded
H357 SP cells were capable of repopulating secondary SP and non-
SP populations. Parent H357 cells were therefore labelled with
Hoechst 33342 dye and sorted into two populations termed SP(1)
and G2(1) based on their relative blue/red fluorescence intensity
(Figure 2C, schematic Figure 2A). The G2 grouping reflected each
cell’s relative position in the cell cycle (that is, G2 phase;
Figure 2C). Following in vitro expansion, G2 cells reproduced
both an SP and non-SP cell population in similar proportions to
those of the parent population (0.46%, Figure 2D). In contrast,
SP(1)-sorted cells produced greater numbers of drug-resistant SP
cells relative to both parent and G2 populations (2.98%;
Figure 2D).
On the basis of our observation that SCC-SP cell expansion leads
to an enrichment of drug-resistant cells, we wished to determine
whether further SP cell propagation might continue to increase SP
cell abundance. H357 SP(1) cells were therefore re-sorted into
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fractionated into an SP(3) population (see schematic, Figure 2A).
Under these conditions, the ABC-dependent drug-resistant SP
fraction increased dramatically within both SP(2)- and G2(2)-
sorted subpopulations compared to the original parent cells
(Figure 2E). Further SP(2) fractionation to SP(3) increased the
SP fraction to 25.6% of total cells, an increase of approximately 50-
fold from the original parental population (Figure 2E). These
percentages were confirmed with a repeat experiment (data not
shown).
SCC-SP cells express ABCG2 and ABCC1 type ABC
transporters
On the basis of the observation that SCC-SP purification enriched
the relative SP abundance in secondary cultures, we wished to
examine whether SP cells also contained elevated ABC transporter
expression relative to parent and non-SP cells. Results of QPCR
analysis revealed that both parent and freshly sorted SP(1) but not
G2 cells expressed ABCG2(BCRP1) and ABCC1(MRP1) transpor-
ters (Figure 3A). Expression levels were not significantly different
from those of independently isolated haematopoietic SP stem cells
(HSC (SP), Figure 3A). There was additionally no significant
difference in either ABCG2 and ABCC1 expression when serially
propagated SP(3) cells were compared with parent SCCs
(Figure 3B). We were unable to detect ABCB1/MDR1 expression
in any SCC cell lines examined. Overall, these results suggested
that ABC transporter mRNA expression does not directly
determine SP cell abundance.
SCC-SP cells exhibit stem cell-like characteristics in vitro
One of the principal characteristics of epithelial stem cells is
enhanced in vitro clonogenicity and growth. To examine whether
SCC-SP cells exhibit enhanced in vitro proliferation, 1000 parent,
SP(1), and SP(3) cells were cultured for 2, 4, and 8 days. Both SP
cell populations grew significantly more rapidly than parent cells
(Figure 4A). SP(3) cells also exhibited significantly faster growth
rate 8 days postplating than SP(1) cells, indicating a serial
enrichment in SCC-SP proliferative capacity (Figure 4A). The data
200
180
160
ABCG2/BCRP1
ABCG2
ABCC1
ABCC1/MRP1
140
120
100
80
R
e
l
a
t
i
v
e
 
m
R
N
A
 
a
b
u
n
d
a
n
c
e
R
e
l
a
t
i
v
e
 
m
R
N
A
 
a
b
u
n
d
a
n
c
e
60
40
20
0
120
100
80
60
40
20
0
Parental
Parental
G2 SP
SP3
HSC (SP)
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Figure 4 Side population cells have higher proliferation rates and greater
clonogenic ability. (A) 1000 parent H357, SP(1), and SP(3) cells were
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H357 cell populations. (C) Quantitation of large colony numbers from
clonogenicity assays shown in (B). Assays were set up in triplicate. Error
bars indicate s.e.m.
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triplicate.
We also examined the clonogenic potential of SCC-SP cells as an
indicator of their individual proliferative capacity. Parent, G2(1),
SP(1), and SP(3) H357 cells were plated in triplicate and cultured at
clonal density for 14 days (Figure 4B). Results revealed significant
increases in large colony formation uniquely within both SP(1) and
SP(3) populations but not G2 cell populations when compared
with parent cells (Figures 4B and C). These findings were especially
evident following serial SP cell propagation (SP(3); Figures 4B and
C).
SCC-SP cells exhibit stem cell-like characteristics in vivo
To test for in vivo tumorigenic potential, we compared the tumour
formation capacity of H357 SCC-SP and non-SP cells. We
subcutaneously injected two million SP(1) cells (n 6) or two
million G2(1) H357 cells (n 6) into the flank of NOD/SCID mice
and allowed these to grow for 49 days. In accordance with previous
attempts to grow H357 cells in an in vivo model (Jones et al, 1996;
Janes and Watt, 2004), none of the G2(1) cell grafts produced
tumours (Figures 5A and B). Interestingly, three out of six SCC-SP-
sorted and -engrafted cell populations did produce subcutaneous
tumours with an average volume of 0.038cm
3 (Figures 5A and B).
Human SCC cell contribution to tumours and active cell
proliferation were confirmed by H&E and Ki67 staining (Figures
5C and D). To our knowledge, this is the first demonstration of the
ability of an H357 cell population to produce tumours in vivo,
strongly suggesting that our SCC-SP contains a unique population
of cancer stem-like cells.
Stem-like SCC-SP cells are chemotherapeutic resistant but
sensitised by verapamil
Our observation that SCC-SP cells expressed both ABCG2 and
ABCC1 multidrug transporters and exhibited elevated Hoechst
33342 efflux indicated that these cells likely possessed resistance to
cytotoxic chemotherapeutic drugs including mitoxantrone. To
assess SCC-SP and parent cell mitoxantrone sensitivity, 200 cells
were cultured in the presence of 0, 1, and 10ngml
 1 mitoxantrone
for 3 days followed by 14 days culture in mitoxantrone-free media.
Results indicated that both SP(1) and SP(3) were significantly
more resistant to 10ngml
 1 mitoxantrone treatment and capable
of maintaining large colony formation in comparison with parent
cells (Figure 6A). All cells appeared resistant to 1ngml
 1
mitoxantrone in agreement with previous ABC transporter
expression data (Figure 3A).
To investigate whether the addition of ABC-dependent transport
inhibitors might block mitoxantrone resistance and restore
chemotherapeutic sensitivity, parent and SP(3) cells were cultured
at clonal density in the presence of 1ngml
 1 mitoxantrone alone
or in combination with verapamil for 7 days followed by 7 days in
the absence of both drugs. We found that both parent and SP(3)
cells that previously exhibited full resistance to 1ngml
 1
mitoxantrone were dramatically growth inhibited following
verapamil treatment (Figures 6B and C). These data suggest that
verapamil-dependent ABC transporter inhibition blocks efficient
SCC-SP mitoxantrone efflux, thereby restoring chemotherapeutic
drug sensitivity to this previously resistant and aggressive tumour
stem cell-like population.
DISCUSSION
The present study is the first to identify a Hoechst 33342 effluxing
cell SP in several SCC cell lines that exhibits properties consistent
with cancer stem or stem-like cells. The abundance of this SCC-SP
varied between different SCC cell lines, and appeared highly
dependent on both cellular density and proliferation status. As
expected, SCC-SP cells expressed several previously characterised
multidrug effluxing ABC-type transporters and were resistant to
the chemotherapeutic agent mitoxantrone. SCC-SP cells also
expressed elevated levels of the epithelial stem cell genes MCSP
and TSLC1 relative to parent H357 cells. Importantly, we
demonstrated that SCC-SP cells may be chemosensitised following
the inclusion of ABC transport inhibitors. This finding may
suggest novel approaches to cancer treatment, which could include
the specific targeting of cancer stem cells.
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Figure 5 Squamous cell carcinomas containing SP cells are tumorigenic in vivo.( A, B) Three out of six NOD/SCID mice grew subcutaneous tumours
following injection of two million SCC-SP(1) cells compared with no SCC G2(1) cell-derived tumours (n 6). (C) H&E confirmed SCC and (D) Ki67
staining demonstrated high cell proliferation.
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confluence dependent has not been previously described. This
observation may partially explain differences reported between
several laboratories studying SP cells and highlights the impor-
tance of considering cell confluence when examining SP cells in
vitro. It is also possible that these cellular density effects might
contribute to the relative ‘stemness’ of cancer cells contained
within an in vivo tumour microenvironment. For example,
infrequently proliferating cells within well-established tumours
might be able to divert increased resources towards maintaining
this chemoresistant or stem cell-like phenotype.
Previous studies of cancers in vitro and primary tumours in vivo
have shown that SP cells are uniquely capable of generating both
SP and non-SP cell fractions. This data have been used to suggest
that SP cells are multipotent ‘cancer stem cells’ (Hirschmann-Jax
et al, 2004; Kondo et al, 2004). In the current study, we find that
serial SCC-SP cell propagation selects for cells that generate an
increased SP cell abundance while maintaining multipotent
differentiation. This is in contrast to non-SP (G2) cell populations,
which could only produce secondary cultures similar to the
original parental H357 cell line. We therefore believe that our SCC-
SP cells uniquely represent a cancer stem or stem-like cell
population.
In addition to stem cell-like properties in SCC-SP cells including
multipotent differentiation and high in vitro/in vivo growth
capacity, we have also now shown that SCC-SP stem cell-like cells
are rendered chemosensitive using simple ABC transport inhibi-
tors including verapamil and reserpine. This finding is significant,
as it has recently been observed that many cancers maintain
subpopulations of stem-like cells, which are chemotherapy
insensitive and uniquely maintain tumour regrowth capabilities
(Bonnet and Dick, 1997; Al-Hajj et al, 2003; Passegue et al, 2003;
Hirschmann-Jax et al, 2004; Singh et al, 2004; Patrawala et al,
2006). Thus, it is increasingly important that cancer treatments
target and eradicate putative cancer stem cells to halt clinical
tumour recurrence. Intriguingly, early combinatorial therapy
experiments demonstrated an effective synergistic therapeutic
effect using verapamil plus mitoxantrone administration in the
treatment of ovarian cancer (Tsuruo et al, 1985; Hendrick et al,
1991). Whether or not this in vivo chemosensitisation occurred via
similar mechanisms to those described in our current study is not
known, although clearly these findings highlight the need for more
research into this potentially combined therapy.
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